Promoting transferability: Insights from economic evaluations of public health interventions to tackle malaria in central Senegal by Pitt, C
LSHTM Research Online
Pitt, C; (2020) Promoting transferability: Insights from economic evaluations of public health inter-
ventions to tackle malaria in central Senegal. PhD (research paper style) thesis, London School of




Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.






Promoting transferability:  
Insights from economic evaluations of  
public health interventions to tackle malaria in central Senegal  
 
 
CATHERINE KROWN PITT 
 
 
Thesis submitted in accordance with the requirements for the 
degree of  
Doctor of Philosophy  
 





Department of Global Health & Development 
 
Faculty of Public Health & Policy 
 
LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE 
 
 
Funded by the Economic and Social Research Council 
Page 2 of 216 
Abstract  
Health economic evaluation seeks to guide priority setting by generating evidence on the 
relative efficiency of alternative policy choices. Yet, the volume and quality of economic 
evaluations are insufficient to inform the vast array of policy choices, especially in low- and 
lower-middle-income countries. This thesis aims to inform policy choices regarding strategies 
to tackle malaria and to improve methods to transfer economic evaluation evidence across 
contexts. 
A bibliometric analysis of the applied economic evaluation literature frames the thesis. Two 
economic evaluations were conducted sequentially alongside two cluster-randomized 
controlled trials in approximately the same population of over 500,000 people in four districts 
of central Senegal. The first evaluation explored the financial and economic costs of equipping 
community health workers to deliver seasonal malaria chemoprevention (SMC) door-to-door 
to children under 10 years of age. It revealed substantial economies of scale, with the largest 
primary healthcare facility catchment areas (by population) incurring the lowest average costs 
per child treated. The second evaluation assessed the costs and cost-effectiveness of several 
multi-component, geographically targeted, malaria strategies in a low transmission context. 
Building on the analysis of SMC, the data collected in the second trial was used to develop and 
populate a simple, transparent, flexible, and intuitive cost model, which projects how the costs 
of four interventions may be expected to vary outside the study setting, in other contexts, and 
with certain changes to the interventions themselves, as well as with input prices and 
epidemiology. 
Drawing on the two economic evaluations and a critical review of wide-ranging literatures 
relevant to transferability, the thesis concludes by proposing guidance for the design and 
conduct of economic evaluations alongside trials or pilots in ways that promote transferability. 
In particular, it recommends efforts from the outset of the evaluation to identify and narrow 
the “transferability gap” between planned implementation within the trial or pilot and the 
intended decision contexts.    
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Achieving universal health coverage (UHC) globally will require explicit priority setting 
processes informed by evidence on policy choices relevant to each context. Health economic 
evaluation seeks to guide priority setting by generating evidence on the relative efficiency of 
alternative policy choices. It has been defined as “the comparative analysis of alternative 
courses of action in terms of both their costs and consequences.” (Drummond et al., 2008) The 
use of health economic evaluations in decision processes for public health systems became 
institutionalized in Canada, Australia, the United Kingdom (UK) and several other European 
countries in the 1990s (Hjelmgren et al., 2001, Briggs et al., 2006, Drummond and Banta, 
2009). In the last twenty years, the number of economic evaluations conducted globally each 
year has grown dramatically, as has the number of economic evaluations conducted in low- 
and middle-income countries (LMICs) (Neumann et al., 2018). More recently, efforts to 
institutionalize health technology assessment (HTA) in LMICs including Thailand (Tantivess et 
al., 2009), South Africa, China (Hofman and Tollman, 2010, Butt et al., 2019, MacQuilkan et al., 
2018), and Ghana (Hollingworth et al., 2020) as well as in decision-making processes at the 
World Health Organization (WHO) (Brunetti et al., 2013, Rehfuess et al., 2019), have begun to 
draw on this growing body of literature and to generate further demand for economic 
evaluation evidence (Li et al., 2016). This increased focus on the role of economic evaluation in 
LMICs has led to the development and growth of various international initiatives, including the 
International Decision Support Initiative (iDSI) and various iterations of the Disease Control 
Priorities Project. 
Yet, despite this increase in interest and in the numbers of economic evaluations produced, 
scarcity of economic evaluation evidence remains a challenge for decision-making in all 
contexts. At every level, policy makers face constant decisions about whether to maintain the 
status quo or to adopt a new course of action. Either choice risks substantial opportunity costs 
if the alternative turns out to be the more efficient choice. As LMICs have fewer resources for 
health interventions and higher burdens of ill health than high-income countries (HICs), the 
opportunity costs they face in terms of both resources and health forgone from inefficient 
policy choices are even greater. 
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To inform these myriad choices, decision-makers can only rarely draw on robust evidence from 
an empirical evaluation conducted to inform the exact decision problem they face in their own 
decision context. While they may sometimes commission empirical research, such investment 
is not feasible for every decision in every context and takes time. Instead, especially for new 
interventions, any potentially relevant evidence is often drawn from small-scale pilots or trials 
and/or larger-scale implementation in another context of interventions that may not precisely 
reflect the ones under consideration. Policy makers must then consider whether and to what 
extent such evidence is relevant to their particular decision problem.  
Judgments about the relevance of economic evaluation evidence are challenging because the 
cost, effectiveness, and cost-effectiveness of a given intervention may vary across contexts; 
however, both overly wide and overly narrow definitions of “relevant evidence” risk sub-
optimal policy choices (Drummond et al., 2009). The degree to which evidence regarding 
interventions in one context may be appropriately used to inform decisions regarding another 
context is known as “transferability”. Evidence may be considered not transferable to a given 
decision problem, fully transferable, or transferable with modifications to the analysis or 
interpretation  (Barbieri et al., 2010). As discussed further in Chapter 6, numerous, wide-
ranging literature streams have offered insights for how to improve the transferability of 
economic evaluations conducted alongside trials and pilots, but their solutions have remained 
piecemeal. 
More economic evaluation evidence is therefore needed regarding key health priorities and 
areas of investment in LMICs, but just producing a greater volume of economic evaluations 
cannot effectively inform the vast and constantly evolving array of health policy decisions 
across the diverse range of LMICs. In addition to expanding the empirical evidence base by 
evaluating more interventions in more LMIC contexts, research is also required to increase the 
usefulness of those evaluations by facilitating evidence transfer beyond the specific evaluation 
context.  
Prioritizing subjects and contexts for economic evaluation research in LMICs is challenging 
because so many countries lack relevant evidence to guide their priority-setting decisions 
across so many areas of health (Neumann et al., 2016, Pratt et al., 2018, Woods et al., 2018). 
However, there is consensus that malaria control is a priority in many settings. It remains one 
of the leading causes of death in low- and lower-middle-income countries (LLMICs), especially 
in children and in Sub-Saharan Africa (GBD Collaborative Network, 2018), and imposes a 
substantial economic burden on households, health systems, and countries (Gallup and Sachs, 
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2001, Alonso et al., 2019, Arrow et al., 2004, Azemar and Desbordes, 2009, Fink et al., 2013, 
Holding and Snow, 2001, Klejnstrup et al., 2018, Onwujekwe et al., 2013, Ameme et al., 2014, 
Larsen et al., 2017). This burden, in turn, hinders the improvements in living conditions which 
could reduce malaria’s spread and impact (Degarege et al., 2019). The literature on the costs 
and cost-effectiveness of malaria interventions is relatively large compared with other health 
issues in LLMICs (except HIV), and has generally found that the main malaria interventions are 
amongst the “best buys” (Tediosi et al., 2017, White et al., 2011). The economic evidence base 
remains small, however, relative to the diversity of countries and contexts with ongoing risk of 
malaria, the wide range of new interventions and possible combinations of interventions now 
available or emerging, and the global resources invested in tackling malaria (WHO, 2019d).   
The epidemiology of malaria has shifted in recent years, with some countries eliminating 
malaria, others recording dramatic declines in malaria incidence, and a remainder continuing 
to face a very high and (in some cases) increasing disease burden (WHO, 2019d). Some of the 
global declines in malaria incidence and deaths have been achieved through substantial global 
investment in expanding coverage of proven preventive interventions, notably insecticide-
treated bed nets, and in expanding access to prompt treatment with artemisinin combination 
therapies (ACTs) (WHO, 2019d). New products and strategies are at various stages in the 
development process and aim to “maintain the gains” and to achieve further progress both in 
countries and regions approaching malaria elimination and in those still facing a high burden. 
Yet, donor funding for malaria has plateaued, its future is uncertain, and LLMICs, by definition, 
have especially scarce domestic resources. The push towards UHC may also call into question 
the global and national prioritization of malaria over the last fifteen years in favour of other 
health priorities. Evidence on the efficiency of new strategies to tackle malaria is therefore 
urgently needed to inform decisions regarding their adoption.  
Senegal’s entire population of nearly 16m is considered at risk of malaria; WHO estimated 
there were 884,000 cases (618,000 to 1,163,000) and 4,480 malaria deaths (4,260 to 4,780) in 
2018 (WHO, 2019d). As with other Sahelian countries, malaria transmission is highly seasonal, 
which affects the types of malaria interventions that may be appropriate. Seasonal malaria 
chemoprevention (SMC) emerged more than a decade ago as a highly efficacious strategy in 
such highly seasonal settings, reducing malaria incidence by up to 75% in children who 
received it in clinical trials (Wilson, 2011). Informed in part by economic evidence produced 
within this thesis, SMC has been scaled up in Senegal and across 11 other countries (WHO, 
2019d). As described in Chapter 4, the epidemiological context in central Senegal has changed 
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in the last 20 years from a relatively high transmission setting to one with overall low, but 
locally heterogenous transmission in which elimination was considered potentially feasible if 
additional interventions were implemented. This shifting epidemiological and policy context 
created new evidence gaps, necessitating evidence to inform decision-making on the 
implementation of geographically targeted interventions in malaria “hotspots”.  
While more politically stable than many neighbouring countries in West Africa, Senegal’s 
income group classification has switched several times in recent decades between lower-
middle-income (1987-1993, 2009-14, 2018) and low-income (1994-2008, 2015-17) status 
(World Bank, 2020a). In 2018, gross national income averaged $1,410 per capita (Atlas 
method) (World Bank, 2020b). As of 2011, the most recent year for which estimates are 
available, 38% of the population lived on less than $1.90 per day (2011 purchasing power 
parity) and 88% lived on less than $5.50 per day (World Bank, 2020b). Despite rapid 
urbanization, more than half (53%) of Senegal’s population still lived in rural areas in 2018, and 
57% of the rural population lived in poverty (based on the national threshold in 2010), 
compared with 33% of the urban population (World Bank, 2020b). The WHO estimated that 
international donors provided nearly all financing for Senegal’s malaria programme up to 2015, 
and ten times more than the domestic government in 2018, when a combined total of $52m in 
expenditure was reported (WHO, 2019d). However, as WHO’s malaria financing estimates 
include only direct expenditure on malaria-specific programmes and commodities, they 
exclude the substantial contributions of health workers’ time and existing health infrastructure 
to malaria control, and so underestimate both total and domestically-financed expenditure on 
malaria control. 
The priority-setting space regarding malaria interventions in Senegal is therefore complex and 
evolving. Choices must be made domestically within Senegal and other countries about the 
relative prioritization of health in general, of malaria in particular, of specific malaria 
interventions, and regarding how to allocate resources across different areas of the country 
with heterogeneous needs. Analogous choices must also be made in the donor agencies that 
provide most of LLMICs’ malaria funding, and these choices include prioritization across 
recipient countries with very different health needs and economic circumstances. 
Furthermore, WHO plays an important role in issuing policy guidance through formal 
processes based on reviews of available evidence and is therefore a significant, additional 
decision-maker. Economic evidence on the relative efficiency of new malaria intervention 
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strategies is therefore needed to inform these decision-makers both in Senegal and elsewhere 
so as to contribute to improving health.      
 
1.2. Aim and objectives 
 
This thesis aims to provide evidence to inform policy choices regarding strategies to tackle 
malaria and to improve methods to facilitate transfer of (economic) evaluation evidence more 
generally.   
The specific objectives are: 
1) To examine the size, scope, and distribution (geography, disease burden, authorship)  
of the recent, applied, economic evaluation literature; 
2) To analyse the costs of delivering seasonal malaria chemoprevention (SMC) to children 
under 10 on a large scale in central Senegal;  
3) To assess the costs and cost-effectiveness of various combinations of intensive malaria 
interventions geographically targeted at a local level using data from a trial in central 
Senegal;  
4) To develop and apply methods for the analysis of cost data in ways that promote 
evidence transfer, and develop general guidance on designing economic evaluations 
for transferability.  
 
1.3. Structure  
 
The thesis is composed of seven chapters. In this chapter, Chapter 1, I briefly introduce the 
thesis as a whole. I provide a short background to the thesis; present its aims, objectives, and 
structure; detail my specific contributions to each element of the research included within the 
thesis; and summarize ethical considerations and funding for the thesis. 
Chapter 2 responds to the first objective of the thesis. It examines the size, scope, and 
distribution of the recent economic evaluation literature, with an emphasis on those issues 
and challenges most salient for LLMICs. It identifies the need for more and better-quality 
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evidence on key health priorities in LLMICs and for greater focus on improving the methods for 
transferring economic evaluation findings across contexts.  
Chapters 3, 4, and 5 present two economic evaluations conducted alongside cluster-
randomized controlled trials of public health interventions to tackle malaria in central Senegal. 
Chapter 3 provides background to and an overview of the two economic evaluations, which 
are presented in subsequent chapters. Chapter 4 responds to the second objective of the 
thesis in presenting an analysis of the costs of SMC. Chapter 5 responds to the third and fourth 
objectives of the thesis in presenting a cost and cost-effectiveness analysis of geographically 
targeted strategies in malaria hotspots. Both economic evaluations provide important 
evidence to inform malaria policy, while demonstrating how data can be collected and 
analysed alongside a trial in ways that explicitly promote the transfer of findings to real-world 
settings and across geographies.  
Chapter 6 completes the response to the fourth objective of the thesis. It presents a critical 
review of 10 wide-ranging literature streams, which offer insights for understanding how to 
improve the transferability of economic evaluations conducted alongside trials and pilots. 
Drawing on this literature and my experience conducting economic evaluations, I propose a 
practical “designing for transferability” guide. This guide proposes some initial methodological 
guidance on how to make economic evaluations conducted alongside trials and pilots more 
transferable in future. 
Chapter 7 concludes the thesis. It summarizes the thesis’ empirical and methodological 
contributions to knowledge and discusses the strengths and limitations of the thesis as a 
whole.      
 
1.4. Contributions of the candidate 
 
This thesis brings together research from three projects. Three articles are included in full 
within the thesis, one from each of the three projects. These are articles for which I conceived 
the idea, collected and analysed the data, wrote the initial draft, and implemented revisions in 
response to feedback from co-authors, peer reviewers, my thesis supervisors, and attendees at 
conferences and workshops at which I presented the work. The first two of these articles have 
been published in Health Economics and Health Policy & Planning, respectively, while the third 
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will be submitted for publication in conjunction with a manuscript reporting the trial’s 
effectiveness results.  
The first project on which this thesis draws is a supplementary issue of Health Economics, 
entitled Economic evaluations in low- and middle-income settings: Methodological issues and 
challenges for priority setting. I initiated and led this supplementary issue, as highlighted in the 
editorial by Andrew Briggs and Rachel Nugent (2016). The foreword to the supplement (Pitt et 
al., 2016b), which I drafted with support from co-authors, outlines the supplement’s 12 
research articles, including the bibliometric analysis included in full in Chapter 2 (Pitt et al., 
2016a) and two further articles (Vassall et al., 2016b, Griffiths et al., 2016), which I co-
authored. In Chapter 2, I cite findings regarding variations in methods used in economic 
evaluations across low-, middle-, and high-income countries from the article I co-authored 
with Ulla Griffiths and Rosa Legood (Griffiths et al., 2016). In Chapter 6, I locate work on the 
integration of supply and demand constraints in economic evaluations in an article I co-
authored with Anna Vassall and colleagues (Vassall et al., 2016b) within literature streams 
which have addressed transferability and economic evaluations.   
The second project on which this thesis draws is an evaluation of SMC in Senegal. I joined at 
the start of the final implementation year, when I took over from Lesong Conteh, who 
continued to provide advisory support after taking up a new role at Imperial College London. I 
designed data collection tools; supervised data collection in collaboration with Mouhamed 
Ndiaye, a physician working as part of the trial team; supervised data entry and management; 
and conducted the economic evaluation. As part of this work, I drafted sections of a technical 
report on the economics of SMC for WHO’s Technical Expert Group, which subsequently 
recommended SMC for implementation. I conducted the analysis and wrote the economic 
evaluation of SMC (Pitt et al., 2017), which is presented in full in this thesis in Chapter 4. I also 
contributed substantially (as second author) through both analysis and writing to an article on 
the coverage, equity, and delivery of SMC (Ba et al., 2018), and contributed as a co-author on 
the trial’s main effectiveness paper (Cissé et al., 2016). 
The third project on which this thesis draws is an evaluation of geographically targeted 
strategies in malaria hotspots in Senegal. I contributed to the original grant proposal and the 
protocol for this trial, including drafting the economic evaluation component and contributing 
to the wider framing and communication of the study. I worked with a Senegalese research 
assistant in epidemiology, Fassia Tairou. She supervised data collection in the field with my 
guidance as part of her wider duties on the trial. I conceived and conducted the economic 
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analyses, including the development of a mechanistic cost model, which are presented in the 
article included in full in Chapter 5 of this thesis. I also contributed to the analysis and framing 
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2.1. Introduction to Chapter 2 
 
In this second part of the thesis, I systematically analyse the recent, applied economic 
evaluation literature and identify key gaps and challenges for this growing research field. My 
overall objective was to examine the size, scope, and distribution (geography, disease burden, 
authorship) of the recent, applied economic evaluation literature. Specific research questions 
were as follows:  
· What is the size and scope of published, full, applied economic evaluations globally? 
· How does the distribution of economic evaluations across health areas and country 
income groups relate to disease burden and resources for health?  
· Who is producing this research in terms of institutional and geographic affiliations and 
where is it being published, and how does this relate to where the countries are being 
done? 
· What are the implications for using economic evaluations to inform decision-making, 
especially in LLMICs?   
 
I present an article published in Health Economics, in which I report a bibliometric analysis of 
all cost-effectiveness, cost-utility, and cost-benefit analyses of health interventions published 
globally over a recent 28-month period. The bibliometric analysis evaluates what is studied, 
where, and by whom in economic evaluations, as well as where they are published and how to 
develop sensitive and specific search strategies. These analyses highlight, amongst other 
challenges, the dearth of economic evaluation evidence in LLMICs to which subsequent 
chapters of the thesis seek to respond.  
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ABSTRACT
We present a bibliometric analysis of recently published full economic evaluations of health interventions and reflect critically
on the implications of our findings for this growing field. We created a database drawing on 14 health, economic, and/or
general literature databases for articles published between 1 January 2012 and 3 May 2014 and identified 2844 economic
evaluations meeting our criteria. We present findings regarding the sensitivity, specificity, and added value of searches in
the different databases. We examine the distribution of publications between countries, regions, and health areas studied
and compare the relative volume of research with disease burden. We analyse authors’ country and institutional affiliations,
journals and journal type, language, and type of economic evaluation conducted. More than 1200 economic evaluations were
published annually, of which 4% addressed low-income countries, 4% lower-middle-income countries, 14% upper-middle-
income countries, and 83% high-income countries. Across country income levels, 53, 54, 86, and 100% of articles, respec-
tively, included an author based in a country within the income level studied. Biomedical journals published 74% of economic
evaluations. The volume of research across health areas correlates more closely with disease burden in high-income than in
low-income and middle-income countries. Our findings provide an empirical basis for further study on methods, research
prioritization, and capacity development in health economic evaluation.
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1. INTRODUCTION
In 2012, Wagstaff and Culyer published a high-profile bibliometric analysis that set out to characterise the
entirety of the health economics field, updating and extending prior work by Rubin and Chang (2003). Their
ambitious work examined publications across 42 years (1969–2010) and generated much discussed rankings
of the leading authors, institutions, and topics of health economics research over time. By restricting their
analyses to journals indexed in EconLit, however, they omitted the substantial body of health economics
research published in the medical literature, including many economic evaluations of health interventions. This
important and growing area of health economics examines the relative efficiency of alternative courses of
action in improving health (Drummond et al., 2005).
To address this gap, we present a bibliometric analysis of recently published, full health economic evalua-
tions (Drummond et al., 2005) and reflect critically on the implications of our findings. Bibliometric analysis is
defined as the quantitative study of written communication in forms such as journal articles and books
(Pritchard, 1969). It sets out to characterise a literature, rather than examine the findings of that literature, which
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is the approach of a systematic review. We stratify our analyses of the economic evaluation literature by the
income group classification of the countries studied (World Bank, 2015). This stratification ensures that
findings regarding low-income and middle-income countries (LMICs) receive due attention, given that they
are home to 84% of the world’s population and bear 89% of the global burden of disease (GBD) (World Health
Organization (WHO), 2014). In light of the growing interest in global health and priority setting, this contribu-
tion to the evidence base is also timely.
A previous bibliometric analysis of cost-effectiveness analyses (CEAs) was limited to studies reporting
outcomes as cost per quality-adjusted life-year (QALY) up to 2006 published in English in journals indexed
in Medline (Greenberg et al., 2010). As QALYs were infrequently used in LMICs up to 2006, this restriction
biased Greenberg et al.’s findings towards studies undertaken in HICs and omitted nearly half of full economic
evaluations (as we will show). Much has also changed since 2006, with a rapid expansion in the literature, in-
cluding in LMICs.
By 1984, just a handful of economic evaluations of health interventions had been conducted in LMICs
(Mills and Thomas, 1984) and even in 2000, Walker and Fox-Rushby (2000) were still able to review critically
the 107 economic evaluations of interventions to address communicable diseases in LMICs published between
1984 and 1997. In the past decade, however, the body of work has expanded such that it has been possible for
reviews to focus on specific disease areas, for example non-communicable diseases (Mulligan et al., 2006);
road traffic injuries (Waters et al., 2004); malaria (Goodman and Mills, 1999, White et al., 2011); various as-
pects of HIV/AIDS (Creese et al., 2002, Galarraga et al., 2009, Walensky et al., 2010, Johri and Ako-Arrey,
2011) and tuberculosis (Fitzpatrick and Floyd, 2012, Chavan et al., 2011); vaccination for Haemophilus
influenzae type b (Griffiths and Miners, 2009), seasonal (Ott et al., 2013) and pandemic influenza (Perez
Velasco et al., 2012); human papilloma virus (Natunen et al., 2013, Fesenfeld et al., 2013); cardiovascular dis-
eases (Suhrcke et al., 2012); surgery (Chao et al., 2014); and strategies to improve the demand and supply of
maternal and neonatal care (Mangham-Jefferies et al., 2014). Reviews of economic evaluations in LMICs have
also narrowed their focus by geography, for example to Meso-America (Valencia-Mendoza et al., 2011), Latin
America and the Caribbean (Augustovski et al., 2009), Thailand (Teerawattananon et al., 2007), Nigeria
(Gavaza et al., 2010), Tanzania (Mori and Robberstad, 2012), and Ghana (Odame, 2013). In adopting a more
constrained perspective, these reviews have allowed important insights into the economic evidence for specific
disease areas or geographies, but have not provided a wider perspective on the overall economic evaluation lit-
erature in LMICs, nor been able to compare this literature with the far larger body of economic evaluations in
high-income countries (HICs).
We aim to provide a recent snapshot of the state of the economic evaluation field. In the following sections,
we describe the methods for generating and analysing our data, present our results, and reflect on the state of the
field and the implications of our findings for research priority setting and capacity development.
2. METHODS
We began by developing a comprehensive database of peer-reviewed research articles reporting a primary, full
economic evaluation. Following Drummond et al. (2008), we defined ‘full economic evaluation’ as studies
which evaluate the efficiency of alternative interventions or courses of action by combining data on the costs
and effects on human health of the alternatives in CEA, cost-utility analysis (CUA), or cost-benefit analysis
(CBA). Further, we aimed to restrict our database to articles which went beyond simple reporting of some cost
and effect data, and instead included only articles which either (i) produced a summary measure of efficiency,
such as a ratio (e.g. incremental cost-effectiveness ratio), probability (e.g. that an intervention is cost-effective
given a defined threshold), difference (e.g. incremental net benefit), and/or graph, such as a cost-effectiveness
plane or cost-effectiveness acceptability curve as recommended in International Society for Pharmacoeconomics
and Outcomes Research guidelines (Ramsey et al., 2005), or (ii) which demonstrated strict dominance (i.e. that
one intervention is both more costly and less effective than the other). We defined ‘primary research’ to include
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the production of a novel estimate (i.e. to include modelling studies) and to exclude reviews which only cite pre-
viously published estimates.
Our analysis was restricted to articles published from 1 January 2012 to the date of our searches, 3 May
2014, comprising a period of 28 months. This restriction reflects both our aim to provide a recent snapshot
of a rapidly changing field and also practical considerations, since even this restricted timeframe required
screening, cleaning, and coding large volumes of data. In the following sections we describe the process of con-
structing the database and our analytical methods.
2.1. Data
Search strategies. Figure S1 illustrates our search strategy in a flow diagram adapted from the PRISMA
guidelines for systematic reviews.(Liberati et al., 2009) We identified 17 potential databases for our search
by consulting recent systematic reviews of economic evaluations and a health sciences librarian to identify
databases which seemed, prima facie, to be potentially useful or used by researchers.
Based on preliminary searches in all databases and a review of their content and functionality, we selected
14 databases for our final search: two health economics databases (the National Health Service Economic
Evaluations Database (NHS EED) and the Health Economic Evaluations Database (HEED)), one economics
database (EconLit), one general literature database (Scopus), two broad databases (the Science Citation Index
Extended (SCI), and the Social Science Citation Index, which were searched simultaneously), and eight health
sciences databases (Embase, Medline including in-process, Latin American Health Sciences Literature
(LILACS), Global Health, PsycInfo, Scielo, Biosis, and Cinahl). We excluded Google Scholar because Google
prohibits bulk downloading of citations; Pubmed because we were able to obtain the same set of articles
(Medline, Medline-in-process, and Pubmed-not-Medline) in our search using the Ovid SP interface, which
we also used to access EconLit, Embase, Global Health, and PsycInfo, and the Tufts Cost-Effectiveness
Analysis Registry because its coverage was limited to articles published in English which report outcomes
as QALYs and it charges substantial access fees.
Search strategies were optimised individually for each database, taking into account the scope of each
database and the features of its user interface. Careful checks were performed to ensure that the initial search
was as sensitive as possible and that any restrictions increased specificity without compromising sensitivity.
Each time we considered an additional restriction to increase the specificity of the search, such as excluding
all articles with the word ‘protocol’ in the title, we first reviewed the first 100 excluded records, and revised
the search strategy if any excluded records were found to meet our inclusion criteria. Full details of the final
search strategy employed in each database are provided in Table S1 and further discussion of the reasons for
not using controlled vocabulary indexing terms (e.g. MeSH terms) is available in Text S1.
Merging and screening. Search results were exported to Excel. We identified duplicate records to produce a set
of unique records linked to the bibliographic data in all of the databases in which they were found. By
comparing multiple databases and carefully reviewing data, we corrected many of the errors within the biblio-
graphic data. Titles and, if necessary, abstracts and in some cases full text were screened by one author (CP) to
determine whether they met our inclusion criteria. Although only English-language search terms were used, no
language restrictions were applied. Keyword searches of all text fields were used to facilitate identification of
articles for exclusion (using terms such as ‘review’ and ‘protocol’) and inclusion (using terms such as ‘domi-
nant’ and ‘cost-utility’).
We excluded articles which described themselves as CEA, CUA, or CBA but did not meet our inclusion
criteria. For example, self-proclaimed ‘cost-benefit analyses’ which only compared the costs of interventions
with cost savings resulting from reduced subsequent health care use were excluded as they did not measure
health benefits. Cost-minimization analyses were similarly excluded (Dakin and Wordsworth, 2013), as were
the many articles declaring an intervention ‘cost-effective’ which did not analyse both costs and effects.
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2.2. Analyses
All analyses are disaggregated by country income group and were conducted in Microsoft Excel.
Databases. For each of the 14 databases, we provide estimates of the sensitivity1 and specificity2 of our
search. Given the substantial overlap between databases and to allow us to identify the minimum number
of databases required to achieve a given overall sensitivity, we also assessed the added value of each
database firstly, by identifying the database yielding the greatest number of economic evaluations, and
secondly, by ranking the remaining databases in descending order according to the number of additional
economic evaluations they identified beyond those already identified by a more highly ranked database.
Geographical areas studied. Key term searches were developed to classify articles by country (or countries)
studied, which were then mapped onto World Bank income groups and regions (World Bank, 2015).3 All
potentially ambiguous country names were reviewed,4 as were all articles not classified by any search term
or classified as analysing multiple income groups. Articles which described themselves as studying a region
or set of countries (such as ‘malaria endemic countries’ (WHO Global Malaria Programme, 2014)) were
classified according to all the countries within that region. A single article could be classified as belonging
to multiple income levels or regions.
Health areas. We developed a classification of 25 health areas so as to allow comparability with the global
burden of disease (GBD) estimates (WHO, 2014), to be implementable with an electronic key term search,
and to permit meaningful analysis. In Table S2, we show how our 25 health areas map onto the GBD and onto
the WHO’s International Classification of Disease, version 10 (WHO, 2011). A set of up to 49 search terms was
developed for each of our health areas through an iterative process.
As with countries studied, a single article could be classified as belonging to multiple health areas. For
example, we counted economic evaluations of interventions for gestational diabetes as both ‘maternal and
newborn health’ and ‘diabetes’, and interventions to address HIV and tuberculosis co-infection (Pawlowski
et al., 2012) as addressing each disease. While this could be considered double-counting, we argue that
interventions addressing multiple areas do not contribute any less to each area than those interventions address-
ing only one disease. Further information is available in Text S2.
We then compared the distribution of health areas studied in economic evaluations to the GBD. Comparisons
are presented graphically with scatter plots comparing the volume of economic evaluations and burden of dis-
ease by (i) ranking and (ii) proportion of total, disaggregated by income group and in total, which allows us both
to assess the correlation and to identify health areas which are outliers meriting deeper exploration.
Languages and journals. Journals were classified as follows: (i) biomedical; (ii) health economics, services,
policy, and/or social sciences; or (iii) other (Table S3). We analysed the proportion of health economic
evaluations published in each journal type, the top 20 journals, and the concentration of economic evaluations
by income group and in total.
The language of the full text was also analysed. Where the full text was available in English and another
language, the article was categorised as English to permit analysis of what would be missed if only
1Sensitivity = (number of economic evaluations identified by our search of the given database) / (total number of economic evaluations
identified in our final economic evaluation database).
2Specificity = (number of economic evaluations identified by our search of the given database) / (total number of records identified by our
search of the given database).
3Macao, Hong Kong, and Taiwan, which are all classified as high-income countries by the World Bank, were analysed separately from the
mainland of the People’s Republic of China, an upper-middle-income country.
4Potentially ambiguous country names included for example, ‘Congo’, ‘Korea’, ‘Niger’, and ‘Guinea’, each of which is contained within
more than one country name; ‘China’, which is often used in reference to Taiwan, Hong Kong, and Macao; ‘Japan’, which appears within
the bibliographic data of studies of Japanese encephalitis; and ‘England’, which may refer to the United Kingdom, to New England in the
USA, or to studies published in the New England Journal of Medicine.
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English-language publications were considered. As there were many errors in the language data in the biblio-
graphic databases, these data were also compared with the journal name and country studied, and in some cases
the full text or journal website examined, to arrive at a final language classification.
Types of economic evaluation.We used key term searches to disaggregate studies by self-reported type: CBA,
CUA, and other CEAs. We further disaggregated cost-utility studies between those employing disability-
adjusted life-years (DALYs) and those employing QALYs. Search terms are listed in Table S4.
Institutional and geographical affiliations of authors. We analysed data on the institutional affiliation of all
authors to develop a comprehensive picture of the institutions and countries contributing to health economic
evaluations.
We identified the top 10 institutions within each income group by volume of economic evaluations produced.
As in previous work (Wagstaff and Culyer, 2012, Rubin and Chang, 2003), schools, colleges, and institutes were
aggregated with the university to which they belonged, with the exception of the highly federal Universities of
London, California, Texas, and other similar university systems, whose constituent members were analysed
separately.
We considered a number of possible approaches for analysing articles with more than one institutional
affiliation, including assigning a fractional value (and even weighted fractional values reflecting author order)
to each institution based on the number of authors or institutions represented on a given article (Aksnes et al.,
2012, Hagen, 2013, Retzer and Jurasinski, 2009). However, we rejected such approaches because using zero-
sum metrics, in general, establishes a perverse incentive against collaboration between institutions and against
the crediting of collaborators. We therefore assigned one point per institution per article, regardless of the
number of institutions or authors on a given article. This has the disadvantage of weighting the analysis towards
articles from multiple institutions, as these articles are counted multiple times in the analyses of institutional and




In total, our searches of the 14 databases identified 47 407 records (Figure S1). After duplicate removal, 15 057
unique records remained, and after screening, a total of 2844 unique, full economic evaluations were retained for
analysis.
3.2. Databases
Our search of Scopus identified the largest number of economic evaluations (n=2409), 85% of our total, followed
by NHS EED, which identified 80% of the articles we identified (Table S5). Together, these two databases iden-
tified 96% of articles, and adding the Medline search increased this to 98%. With each additional database, the
incremental gains were diminishingly small, and one database, Lilacs, failed to identify any additional articles be-
yond those identified by other databases. Econlit identified just 42 economic evaluations, 1% of the total. If we
exclude NHS EED from consideration as it ceased to update records fromMarch 2015 and exclude Wiley HEED
as it ceased to be available from the end of 2014, our searches of a combination of Scopus, Medline, and Global
Health would identify 91% of the economic evaluations, but a remaining 7% of economic evaluations in our da-
tabase were only identified by NHS EED andWiley HEED and not by our searches of other databases (Table S6).
If we restrict the analysis to articles studying LMICs and exclude NHS EED and Wiley HEED, our searches of
Scopus, Medline, and Global Health would together identify 93% of economic evaluations in LMIC settings,
while 4% were only identified in NHS EED and Wiley HEED (Table S7).
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3.3. Subjects studied
Geographical areas studied. At least one country, region, and income group studied was assigned to all
economic evaluations identified. Of these, 83% studied HICs, 14% upper-MICs, 4% lower-MICs and 4% LICs.
These sum to more than 100% because 2% of articles reported studies set in multiple countries in more than one
of the four income groups. As expected, most articles reported findings from Europe and Central Asia (44%)
and/or North America (34%) (Table I).
Table II and Figure 1 present the individual countries most frequently studied. The United States (USA) was
the subject of 813 studies, followed by the United Kingdom (UK) (n=478) and six further countries which were
each studied in at least 100 articles. While China, South Africa, and Brazil were studied in a relatively large num-
ber of articles, only 10 upper-MICs were studied in at least 20 articles each. Led by Uganda, India, Kenya, and
Zambia, all of the top 20 LICs and lower-MICs were studied in more than 20 economic evaluations, in part
because 61 of the 184 articles (33%) studying at least one LIC or lower MIC examined more than one country
Table I. Number of economic evaluations by income group and region of study
Income group(s) of countries studied
Region(s) studied Low Lower-middle Upper-middle High Multiplea Total % of total
East Asia and Pacific 22 43 165 229 25 405 14%
Europe and Central Asia 11 16 44 1210 20 1243 44%
Latin America and Caribbean 13 18 116 16 19 129 5%
Middle East and North Africa 14 20 43 27 20 62 2%
North America 1 1 1 960 1 960 34%
South Asia 27 49 20 15 25 56 2%
Sub-Saharan Africa 92 64 78 22 46 158 6%
Multiplea 27 35 31 85 38 102 4%
Total 104 121 391 2350 63 2844 100%
% of total 4% 4% 14% 83% 2% 100%
aArticles studying at least two countries of differing income levels or regions are categorised as ‘Multiple’.
Table II. Top 20 countries most frequently studied in economic evaluations by income group
High income Upper-middle-income Low and lower-middle-income
Rank Country N % Country N % Country N %
1 USA 813 35% China 116 30% Uganda 49 27%
2 UK 478 20% South Africa 71 18% Indiaa 41 22%
3 Netherlands 183 8% Brazil 56 14% Kenyaa 41 22%
4 Canada 162 7% Thailand 36 9% Zambia 39 21%
5 Spain 136 6% Iran 31 8% Malawi 35 19%
6 Germany 109 5% Colombiaa 28 7% Nigeriaa 34 18%
7 Australia 100 4% Mexicoa 28 7% Tanzaniaa 34 18%
8 Italy 98 4% Turkey 24 6% Zimbabwe 33 18%
9 Sweden 74 3% Botswanaa 23 6% Congo, Dem. Rep. 30 16%
10 France 57 2% Namibiaa 23 6% Ethiopia 29 16%
11 Japan 45 2% Angola 18 5% Lesothoa 28 15%
12 Belgium 42 2% Gabon 17 4% Mozambiquea 28 15%
13 Denmark 33 2% Mauritiusa 14 4% Rwandaa 28 15%
14 Korea, Rep.a 31 1% Perua 14 4% Vietnama 28 15%
15 Norwaya 31 1% Seychellesa 14 4% Ghana 27 15%
16 Greece 29 1% Bulgaria 13 3% Central African Republic 26 14%
17 Ireland 27 1% Argentinaa 12 3% Burundia 25 14%
18 Switzerlanda 24 1% Hungarya 12 3% Cameroona 25 14%
19 Finlanda 24 1% Maldives 11 3% Eritreaa 25 14%





391 100% Low- and lower-middle-income
countries
184 100%
aEqual ranking with country above and/or below.
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and 33 LIC and lower MIC articles (18%) studied more than 10 countries. In upper-MICs and HICs, only 14%
(n=54) and 7% (n=169) of studies, respectively, examined more than one country and 8% (n=32) and 1%
(n=27) examined more than 10 countries.
Health areas studied and the global burden of disease. At least one health area was assigned to 2829 (99.5%)
articles. The mean number of health areas per article was 1.4 and the maximum 7. Whereas 71% of articles
were assigned a single health area, 21% addressed two health areas and 8% addressed three or more. In LICs,
three health areas dominate: HIV/AIDS (30% of classified LIC articles), neonatal and maternal conditions
(16%), and malaria (15%) (Table III). In lower-MICs, HIV/AIDS again dominates (23%), but the remaining
health areas are more evenly distributed; malaria comes second (11%), and is followed by other infectious
diseases (8%) and mental health (8%); half of the latter focused on HIV treatment and prevention amongst
injection drug users. In upper-MICs, HIV/AIDS (12%) falls to second place, while cancer and other neoplasms
(19%) occupy the top spot with cardiovascular (11%) and respiratory diseases (10%) in third and fourth respec-
tively. As HICs are studied in 83% of economic evaluations, the disease areas addressed in economic evalua-
tions in HICs drive the distribution of all economic evaluations conducted worldwide, with cardiovascular
diseases (19% in HICs), cancer and other neoplasms (18%), mental health (10%), and musculoskeletal diseases
(10%), the leading areas of study in HICs and overall (Table III).
The distribution of articles across health areas corresponds substantially but by no means perfectly
with the global disease burden. The degree of correlation varies by income level, but also depends on
whether rankings or proportions are compared. By either metric, the health areas studied in HICs
correlate surprisingly well with disease burden and substantially better than economic evaluations in other
income groups, which feature more numerous and extreme outliers (Figure 2). The correlation between
the health focus of economic evaluations and disease burden is also substantially stronger in studies of
HICs than globally, because most economic evaluations (83%) address HICs and are well correlated with
HICs’ disease burden, whereas most of the GBD (89%) affects LMICs.
HIV/AIDS is studied in a greater proportion of economic evaluations at every income level than its share of
the disease burden; however, the gap is much smaller in HICs than in LICs and lower-MICs, where it is an
Figure 1. Number of economic evaluations set in each country. The intensity of shading reflects the number of economic evaluations
analyzing each country over the 28-month period from 1 January 2012 to 3 May 2014
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extreme outlier. Other such ‘winners’ across all income levels include ‘other infectious diseases’; ‘genitouri-
nary diseases, contraception, and fertility’; and ‘sexually transmitted diseases (excluding HIV)’. By contrast,
interventions to address wounds and injuries and, to a somewhat lesser extent, neurological conditions, appear
to be substantially under-researched relative to disease burden at every income level.
Figure 2. Economic evaluations versus burden of disease by income group. Results are presented in two ways: the lefthand column com-
pares the proportion of the total number of economic evaluations examining each of the 25 health area with the proportion of the total bur-
den of disease accounted for by each health area and the righthand column compares the ranking of the health areas by the volume of
economic evaluations and by burden of disease
C. PITT ET AL.16
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3.4. Journals and languages
Economic evaluations were published in a total of 967 different journals (Table S8). Five hundred fifty-nine
journals published only one economic evaluation each in the entire 28-month period we analysed and 165
journals published only two. Whereas 802 different journals published HIC articles, only 44 published
LIC articles. The proportion of articles published in the top 20 journals for each income group increased
Table III. Number of economic evaluations by health area and income group
Income group studied
Health area Low Lower-middle Upper-middle High World
Cancer and other neoplasms 7 8 73 416 492
Cardiovascular diseases 3 7 44 448 490
Mental health, cognition, and developmental and behavioural disorders
(including self-harm and substance disorders)
1 10 21 243 268
Musculoskeletal diseases (including back pain) 2 3 18 240 262
Respiratory diseases 6 8 39 188 228
Genitourinary diseases, contraception & fertility 4 4 18 180 203
Other infectious diseases (including encephalitis, hepatitis, other
parasitic and vector-borne diseases, and nematode infections)
6 10 38 111 159
Digestive disorders 3 3 21 127 152
Neonatal and maternal conditions 17 7 23 102 142
HIV/AIDS 31 27 46 61 136
Diabetes 1 3 22 102 125
Malnutrition (including obesity and exercise) 6 4 9 98 113
Wounds and injuries (including violence) 4 7 13 91 109
Endocrine, blood, and immune disorders (excluding diabetes or HIV) 0 1 12 86 99
Neurological conditions 1 3 16 81 98
Skin and oral conditions 0 3 5 67 75
Sense organ diseases 2 3 11 56 68
Tuberculosis 8 9 28 34 62
Sexually transmitted diseases (excluding HIV) 2 1 10 39 49
Diarrhoeal diseases 6 7 9 29 46
Communicable childhood diseases 2 5 9 24 40
Malaria 16 13 8 1 24
Congenital anomalies 0 1 2 20 23
Anaemia 0 1 1 9 11
Meningitis 2 2 3 3 9
TOTAL 104 120 390 2337 2829
A single economic evaluation may address more than one health area in countries of more than one income group. The totals exclude the 15
articles (0.5%) in our data set which could not be classified by health area.
Figure 3. Proportion of economic evaluations by journal type and income group. The classification of journals by type is provided in Web
appendix 6. Articles are disaggregated by the income group(s) of the country or countries studied
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steeply down the income groups: 29% of articles studying HICs were published in the top 20 journals
publishing HIC evaluations, while 38, 66, and 77% of articles studying upper-MICs, lower-MICs, and LICs,
respectively, were published in the top 20 journals publishing evaluations set in each of the respective
income groups.
Overall, 74% of articles were published in biomedical rather than health economics, systems, and policy
journals (22%) or other journal types (5%) (Figure 3). In HICs, 6 of the top 10 journals were health economics,
systems, or policy journals, compared with only 3 of the top 10 journals publishing articles about LICs and
lower-MICs (Table IV). The top outlet for economic evaluations across all income levels was PLoS ONE, an
open-access journal publishing ‘primary research from any scientific discipline’, which ranked amongst the
top three journals for all income groups. Vaccine ranked fourth overall (n=66) and in the top five for all income
groups. Yet overall, journals tended towards segregation by income group; 6 of the top 10 journals publishing
economic evaluations about HICs did not publish a single LIC or lower MIC study and two of the remaining
published only one each.
All articles addressing LICs and lower-MICs were published in English, while 4% of HIC articles (n=89)
were published in other languages, as was a striking 22% (n=87) of all articles addressing upper-MICs. In
upper-MICs, Chinese was the leading non-English language (n=48, 12%), followed by Spanish (23, 6%),
Portuguese (n=13, 3%), Turkish (n=2, 1%), and Farsi (n=1, 0%), while in HICs, Spanish was the language
of full-text for 46 articles (2%), followed by German (n=13, 1%), and 10 other languages.
3.5. Types of economic evaluation
Although the term is widely (mis)used in the literature, genuine cost-benefit analyses are very rare; we
excluded many articles from our database which described themselves as CBAs of health interventions
but did not value health or welfare outcomes. Of the 147 (5%) articles in our database which described
themselves as CBAs, some do not in fact place a monetary value on health outcomes and should probably
be described as CEAs or CUAs; however, for consistency and feasibility, our analysis of evaluation type is
based on key term searches, and therefore reflect the authors’ classification (Table S4). Cost-utility analyses
accounted for at least half of economic evaluations across all income levels, ranging from 50% (n=52) in
LICs to 62% (n=1448) in HICs. The proportion of CUAs employing DALYs decreases from 87%
(n=45) in LICs to 2% (n=35) in HICs, while the proportion employing QALYs increases from 13%
(n=7) in LICs to 35% (n=23) in lower-MICs, 68% (n=123) in upper-MICs, and 96% (n=1385) in HICs.
A very small proportion of studies described themselves as CUAs but did not contain any search terms for
DALYs or QALYs (Figure 4 and Table S9).
Figure 4. Proportion of economic evaluations by analytical type and income group studied. In this figure, ‘cost-effectiveness anal-
ysis’ refers to articles meeting our definition of a full economic evaluation but not containing any keywords to define it more
specifically as a cost-utility or cost-benefit analysis. Articles can be classified as both cost-utility and cost-benefit analyses if they
contain keywords for both. Articles are disaggregated by the income group(s) of the country or countries studied. CBA: cost-benefit
analysis, CEA: cost-effectiveness analysis, CUA: cost-utility analysis, DALY: disability-adjusted life-year, QALY: quality-adjusted
life-year
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3.6. Authors’ geographical and institutional affiliations
Author affiliation data were obtained for all articles. At least one author was affiliated with an institution in the
USA or the UK on 1145 (40%) and 619 (22%) of articles respectively (Table V). China-based authors
Table V. Most frequent countries of institutional affiliation of authors
High-income Upper-middle-income Low-income and lower-middle-income
Rank Country N Country N Country N
1 USA 1145 China 116 India 22
2 UK 619 Brazil 51 Uganda 20
3 Netherlands 267 South Africa 49 Kenya 13
4 Canada 238 Thailand 37 Vietnam 11
5 Australia 191 Colombia 32 Ghanaa 9
6 Germany 151 Mexico 26 Zambiaa 9
7 Spain 147 Iran 25 Nigeria 8
8 Switzerland 104 Turkey 18 Indonesiaa 5
9 France 103 Argentina 14 Burkina Fasoa 5
10 Italy 99 Malaysia 12 Bangladesha 4
11 Sweden 98 Peru 9 Pakistana 4
12 Belgium 78 Bulgariaa 7 Tanzaniaa 4
13 Japan 53 Serbiaa 7 Philippinesa 4
14 Denmark 45 Hungary 5 Egypta 4
15 Ireland 39 Venezuela 3 Ethiopiaa 2
16 Norway 32 Romaniaa 2 Malawia 2
17 Taiwan 28 Lebanona 2 Congo, Dem. Rep.a 2
18 Finland 27 Costa Ricaa 2 Benina 2
19 Korea, Rep.a 25 Jordana 2 Myanmara 2
20 Austriaa 25 Tunisiaa 2 Zimbabwea 2
21 Greece 23 Iraqa 1 Cameroona 2
22 Hong Kong 21 Botswanaa 1 Senegala 2
23 Singapore 21 Cubaa 1 Sri Lankaa 1
24 New Zealanda 19 Kazakhstana 1 Cambodiaa 1
25 Polanda 19 Panamaa 1 Nigera 1
26 Portugal 15 Jamaicaa 1 Afghanistana 1
27 Israel 12 Dominican Republica 1 Nepala 1
28 Russia 9 Rwandaa 1
29 Chile 8 Sierra Leonea 1
30 Czech Republic 7 Somaliaa 1
31 Sloveniaa 5 Syriaa 1
32 Qatara 5 Boliviaa 1
33 Croatiaa 2 Guyanaa 1
34 Saudi Arabiaa 2 Uzbekistana 1
35 Estoniaa 2 West Bank and Gazaa 1
36 Icelanda, Liechtensteina, Lithuaniaa, Macaoa,
Maltaa, Puerto Ricoa, Trinidad and Tobagoa
1
The table ranks countries of institutional affiliations of authors by the number of economic evaluations including at least one author
affiliated with that country. All countries affiliated with at least one author of at least one economic evaluation are listed.
aEqual ranking with country above and/or below.
Table VI. Income group studied versus income group of author affiliations
Income group of authors’ country affiliation(s)
Income group of countries studied Low Lower-middle Upper-middle High Total
Low 55 (53%) 7 (7%) 16 (15%) 98 (94%) 104 (100%)
Lower-middle 8 (7%) 65 (54%) 15 (12%) 99 (82%) 121 (100%)
Upper-middle 11 (3%) 11 (3%) 338 (86%) 175 (45%) 391 (100%)
High 4 (0%) 12 (1%) 51 (2%) 2345 (100%) 2350 (100%)
Total 59 (2%) 80 (3%) 394 (14%) 2601 (91%) 2844 (100%)
Row percentages are presented and reflect the proportion of articles addressing a given income level, which include authors affiliated with
institutions based in a country of the given income level.
C. PITT ET AL.20
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contributed to 4% (n=116) of all articles, making it the ninth largest contributor to economic evaluations, while
Brazil (51, 2%) and South Africa (49, 2%) also ranked within the top 20 country affiliations. With 22 articles
(1%), India was the highest ranking lower MIC and ranked 29th overall, just ahead of Hong Kong and
Singapore. Uganda was the largest contributor to economic evaluations amongst LICs with 20 articles (1%)
and ranked 32nd overall just ahead of New Zealand. In general, the lists of leading country affiliations of authors
within each income group strongly resemble the leading countries studied. Even for Uganda, however, the largest
LIC contributor, 30 of the 49 articles about the country did not include any Uganda-based authors; of these, 25
were studies set in at least 15 countries each, but 5 articles focused on 3 or fewer countries.
On 91% of articles, at least one author was based in a HIC (Table VI). All but 5 of the 2350 articles studying
HICs included at least one author based in a HIC and most articles studying upper-MICs included at least one
upper MIC-based author (n=338, 86%). By contrast, only 53 and 54% of articles studying LICs and
lower-MICs, respectively, included any author based in an institution in the respective income group. Authors
based in upper-MICs contributed to a relatively small proportion of articles analyzing LICs (n=16, 15%) or
lower-MICs (n=15, 12%), and in nearly half of these articles, upper-MICs were also studied. Authors based
in HIC institutions contributed to 94% (n=98) of articles analyzing LICs and 82% (n=99) analyzing lower-
MICs, compared with fewer than half of evaluations in upper-MICs (n=175, 45%). Of the 65 articles studying
LIC and lower-MIC which did not include an author from those income levels, 44 articles included at least one
author based in the USA (68%). At least one author listed a major pharmaceutical company amongst the insti-
tutional affiliations on 9% of articles (n=246) overall, varying from 9% (n=221) of articles studying HICs, to
12% (n=46) studying an upper-MIC, 7% (n=8) studying a lower-MIC and 4% (n=4) studying a LIC. English
is an official language in four of the top five HICs and LICs and lower-MICs contributing to economic evalu-
ations, compared with just one of the top five upper-MICs (Table VII).
Harvard University, including its affiliated hospitals, was by some distance the institution contributing to the
largest number of economic evaluations (n=152). The top institutions producing economic evaluations in LICs
and lower-MICs are notable for their low individual and collective output, as well as for including many
ministries of health or (semi-)autonomous research institutes (Table VII). The leading LIC or lower MIC insti-
tution, Makerere University, was listed amongst the author affiliations of 14 economic evaluations over the
2.3 years we studied. The WHO was listed amongst the author affiliations on 25 articles, while the World Bank
and United Nations’ Children’s Fund contributed to only four economic evaluations each.
4. DISCUSSION
Our analysis provides an evidence base from which to discuss the current state of the economic evaluation field
and has generated many questions which warrant further investigation. Some of these issues are examined in
other papers in this special issue. For example, Griffiths et al. (2016) compare the methods used in economic
evaluations in countries of differing income groups in a representative sample of articles from the database we
created, while other authors examine costing methods (Sweeney et al., 2016, Cunnama et al., 2016), outcome
metrics (Greco et al., 2016), and issues around capacity to produce and to use economic evaluations (Kaló
et al., 2016). Our analysis also offers insights to strengthen the process of prioritising, conducting, publishing,
and developing capacity for economic evaluation research. Here, we discuss the state of the field and the im-
plications of our findings for research priority setting and capacity development.
4.1. The state of health economic evaluation
We identified a large volume of economic evaluations—2844 over 28 months—including 1273 in 2013 alone.
The principal economics database, EconLit, contains 5483 publications with ‘Health’ JEL codes for 2012 and
2013, but captured just 1% of economic evaluations published in those years. A large majority of economic
evaluations were published in biomedical journals and even many of the journals we categorised as ‘health eco-
nomics, services, and policy’ are not indexed in EconLit. Adding the 2413 economic evaluations we identified
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for 2012 and 2013 to the EconLit health records would increase the volume of ‘health economics’ research by
44%. Further, these publications still do not include the many other health economic analyses of, for example
equity, demand, markets, and incentives, which are published in journals outside the economics literature as
defined by the EconLit database.
Despite important analytical differences and the lack of overlap between the body of literature addressed in our
analysis and Wagstaff and Culyer’s analysis of health economics within the EconLit database, our findings share
some commonalities. Both our analyses (along with Greenberg et al. (2010)) identified Harvard as the leading
institution and the USA as by far the most prolific contributor to health economic (evaluation) research, followed
by the UK, and then the Netherlands, Canada, and Australia. China and South Africa also rank highly in both our
analyses. Nonetheless, our findings also differ in important ways. As expected, our lists of leading journals share
very little in common, as economic evaluations are predominantly published in biomedical journals, which are
not indexed in EconLit. Some contributors, such as the World Bank and Taiwan, which ranked very highly in
Wagstaff and Culyer’s analysis, contribute far less to economic evaluations, while institutions with a stronger
focus on health (rather than only economics) tend to rank more highly in our analysis. There are also substantial
differences with respect to our estimates of the volume of research. Whereas Wagstaff and Culyer find that
‘economic evaluation . . .[shows] no clear trend’, our analysis has highlighted the substantial size of the applied
health economic evaluation literature relative to the health economics literature within EconLit and indicates
that with just 1% of the applied economic evaluation literature, the EconLit database is unlikely to provide a
representative indication of trends over time in the size or relative importance of health economic evaluation.
As previously highlighted (Wagstaff and Culyer, 2012), identifying health economic literature in the
biomedical databases was not straightforward. We found the use of economic vocabulary and article classifica-
tions in biomedical journals and databases to be so poor and inconsistent as to render simultaneously sensitive
and specific searching impossible (Text S1). The NHS EED database, while incomplete, was by far the most
sensitive and specific source of economic evaluations, which makes the decision to cease to update it from
March 2015 particularly lamentable. The ongoing work to add DALY-based cost-utility analyses to the existing
QALY-based Tufts Economic Evaluation Registry is a welcome development; however, it will still omit half of
economic evaluations conducted in LMICs and currently charges for access.
Our findings paint a picture of a research community that is simultaneously highly concentrated in a few
countries and institutions and highly fragmented. A very small number of journals publish economic
evaluations from both high-income and low-income settings and a large proportion of articles appear in
journals which only very rarely publish economic evaluations. The fact that so many biomedical journals
now publish economic evaluations (if only rarely) is a positive sign of the acceptance and integration of
economic evaluation within health research. It is also perhaps unsurprising, as economic evaluations are usually
oriented towards health sector decision makers. This fragmentation may, however, also explain some of the
problems of quality highlighted elsewhere (Griffiths et al., 2016), as biomedical journal editors may not only
lack specialist knowledge of economic evaluation methods but also lack familiarity with pools of suitably
qualified reviewers. In this way, the small number of journals publishing economic evaluations about LMICs
may present an opportunity to engage with the editors of these journals to help improve standards where
necessary, whereas the vast array of authors, institutions, and journals associated with economic evaluations
set in HICs presents a greater challenge. In any case, the lack of scholarly dialogue between those focusing
on countries of differing income levels seems likely to be detrimental to all.
We hope that recognition of the size, importance, and fundamental interdisciplinarity of health economic
evaluation will lead to an evolution in research culture within the field, and also, on a practical level, to
improvements in existing databases or creation of a new one that will better reflect and serve the needs of health
economics researchers. Of course, authors themselves, reviewers, and editors could already do far more to
facilitate the efficient identification of health economic evaluations. For example, an initial step could include
ensuring that all articles include the study design in their title, as is already required by Plos Medicine, and that
those that are not economic evaluations avoid economic terminology, such as ‘cost-effective’ in their titles,
abstracts, and keywords.
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4.2. Research priority setting
Our findings also raise a number of questions about the health and geographical areas that are and are not prioritised
for health economic evaluation. Burden of disease is not and should not be the sole determinant of the volume of
economic evaluation research. It seems difficult to argue, however, that the differences between the number of
economic evaluations conducted across LICs, MICs, and HICs are equitable or efficient. HICs account for 16%
of the world’s population, 11% of the GBD (WHO, 2014), and 83% of all economic evaluations conducted, while
LICs account for 12% of the world’s population, 19% of the GBD, and 4% of economic evaluations. There are 139
different LMICs (World Bank, 2015), which have very diverse epidemiological and economic characteristics, and
also, in many cases, weak(er) health systems with substantial and diverse constraints on the supply and demand for
health care; this diversity likely contributes to greater heterogeneity in the cost-effectiveness of interventions and
necessitates more, not less, research (Vassall et al., 2016). Further, the health benefits foregone by incorrect priority
setting decisions may be substantially higher in low-income settings than in high-income settings.
One of our most surprising findings is how well the health areas studied in HICs correlate with the burden of
disease in those settings. In LMICs, however, the picture is much more mixed, with many more economic eval-
uations conducted about health areas accounting for lower proportions of the burden of disease. There are sev-
eral reasons why such discrepancies may not be inequitable or inefficient. First, the GBD estimates themselves
are highly contested (Nord, 2013, Byass et al., 2013); intended to reflect only a very narrow definition of health,
the newest disability weights used in the GBD estimates exclude wider individual or social welfare conse-
quences (Salomon et al., 2012). In the case of HIV/AIDS, for example, the many and varied stakeholders could
therefore conclude that it is right that HIV should be studied more than health areas accounting for a larger bur-
den of disease because of its wider social and economic consequences or because its health consequences are
only lower than other diseases because of ongoing and expensive control efforts. Second, some health areas
may have a low value of additional information relative to the costs of generating the information, especially
if extensive research has already been conducted in that area. Third, so little may be understood about some
health problems at a clinical level that economic evaluation of interventions may be premature. Fourth, eco-
nomic evaluations may be conducted not to consider adding another more effective and more costly interven-
tion, but rather to consider divestment from costly interventions, and therefore economic evaluations in health
areas that contribute very little to the disease burden may be warranted. Finally, as economic evaluations are
conceptualised around a (package of) interventions, which may not map neatly onto specific conditions, cate-
gorization of economic evaluations by health areas also has some conceptual limitations, which could weaken
their correlation with disease burden; we found this to be particularly true for surgical procedures, pain manage-
ment and palliative care, and health systems and intersectoral interventions.
On the other hand, the four health areas accounting for the largest burden of disease in LICs are as follows:
(i) neonatal and maternal conditions; (ii) respiratory diseases; (iii) wounds and injuries; and (iv) diarrhoeal
diseases. While further biomedical advances, such as a point-of-care test for bacterial infections would help
(Zumla et al., 2014), the bulk of the impact of all four of these health areas needs to be addressed through health
systems, multi-sectoral, and/or social interventions such as prompt access to high-quality health facilities (Kerber
et al., 2007), road safety measures (WHO, 2013), and improved water and sanitation (Bartram et al., 2005). Such
solutions offer little potential for pharmaceutical company profits and instead require complex interventions. Re-
cent systematic reviews of economic evaluations of cardiovascular disease interventions in LMICs similarly found
that evaluations of pharmacological interventions dominated and a greater focus on evaluation of non-clinical
strategies were needed (Shroufi et al., 2013, Suhrcke et al., 2012). Financing such evaluations is unlikely to appeal
to private for-profit companies, and so domestic and international research funders, as well as researchers them-
selves, should concentrate on producing research in these areas, and thereby correct this market failure.
4.3. Capacity development
Several of our findings have important implications for thinking about how to increase capacity to produce and
to use high-quality and policy-relevant health economic evaluations. Large upper-MICs, especially China but
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also South Africa, Brazil, and Iran, produce substantial numbers of economic evaluations and far more than
many smaller HICs. This is in some ways unsurprising, as the costs of research are independent of the size of
a country’s population or economy and so the relative costs of research are lower in large economies. Capacity
development is important for all countries, but particularly challenging for LMICs and for small HICs as well
(Kaló et al., 2016). A large gap between the numbers of economic evaluations conducted and what is needed
for priority setting persists in all but a few countries (Geroy, 2012, Odame, 2013, Mori and Robberstad, 2012).
Our analysis has identified some clear institutional leaders in LMICs, but also highlighted that many
countries produce few, if any, economic evaluations. We propose the development of strong regional or
sub-regional networks, which bring together existing capacity in health economic evaluation and build on
centres of strength in health intervention research, even where substantial economic evaluation capacity
may not yet exist. A multi-stakeholder report on how to strengthen health economics more generally
in Africa highlighted the importance of international networks as well as local institutional support
(McIntyre et al., 2008). In addition to training and ongoing technical support, a well-funded regional
network could also offer scope for deeper collaboration in producing multi-country evaluations and assessing
transferability of findings across the region. Such a regional approach could be more efficient in generating
economic evidence and assessing its relevance to a wider range of settings more systematically.
The leading contributors to economic evaluations from LICs and lower-MICs tend to be research
institutions, often within or associated with ministries of health, rather than universities. Such embeddedness
should be an advantage in ensuring that research both reflects and informs a country’s health priorities. It also
means, however, that there may be no pre-existing link between those who conduct health economic evaluation
research and those who teach and train undergraduate and postgraduate students in these countries. This
marked difference from HICs and even upper-MICs may require new approaches to capacity development,
rather than replication of strategies that have achieved successes in upper-MICs and HICs.
At the same time, further work is needed to generate demand for economic evaluation both at national level,
through the institutionalization of priority setting (Odame, 2013, Mori and Robberstad, 2012), and globally,
through transparent priority-setting initiatives at global funding bodies and continuing efforts to strengthen
the role of economic evaluation in policy making at the WHO (Wiseman et al., 2016), whose policy recommen-
dations play a particularly large role in LICs and lower-MICs (WHO, 2012).
Finally, nearly half of economic evaluations studying LICs and lower-MICs do not include any authors from
LMIC institutions. Some of these were desk-based modelling studies; however, many involved data collection
in LMICs. Some may have included authors from LMICs affiliated with a HIC institution, for example as
doctoral students; however, such cases cannot explain the full magnitude of the discrepancy. It is unclear
whether this discrepancy reflects a lack of opportunities for participation from fellow researchers or funders,
lack of skills or incentives, or some combination of these and other factors, but the results are clearly inequi-
table (Chu et al., 2014). The situation also suggests a failure to recognise the wider potential of research
capacity development to improve health in LMICs and the more immediate impact that real partnership with
LMIC researchers and policy makers can have in ensuring that the research is policy-relevant and informs
policy decisions. Both funders and researchers in all countries must examine and address these inequities.
We hope that the findings of this analysis will be useful for those conducting (systematic) reviews of the
economic evaluation literature and that they will encourage and provide an empirical grounding for debate
on the current state and future directions for this growing field.
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2.3. Evidence gaps and challenges  
 
While the bibliometric analysis highlighted numerous research gaps and challenges, the most 
salient issue that emerged was the lack of economic evaluations on which to base priority-
setting decisions in LLMICs. This evidence gap is not unique to LLMICs, but data scarcity, the 
disproportionately high burden of disease, and scarcity of resources for health research and 
interventions make the challenge more acute (Pitt et al., 2016b). Nearly six years have passed 
since the period covered by the bibliometric analysis; however, it is unlikely that that an 
updated analysis would reach substantially different conclusions. To respond to the evidence 
gap, more economic evaluations are needed in LLMICs and these economic evaluations need 
to inform decision-making across a wide range of contexts.  
The bibliometric analysis indicated some of the most neglected countries and health areas 
within LLMICs. While malaria emerged as the second- and third-most-studied health area in 
economic evaluations in lower-middle-income and low-income countries, respectively, 
francophone Africa and West Africa emerged as regions in which economic evaluations were 
particularly scarce. This gap is especially problematic because malaria was estimated to be the 
leading cause of death in francophone Africa in 2017, the historical development of 
francophone countries’ health systems differed from that of anglophone countries, and 
malaria epidemiology in West Africa differs from other regions (El Bcheraoui et al., 2020, Boum 
and Mburu, 2020). In the following chapters, I respond to this research gap by presenting two 
new economic evaluations of malaria interventions in Senegal, which I conducted in ways that 
seek to maximize the transferability and thus usefulness of the evidence generated for other 
settings.  
The bibliometric analysis also demonstrated that a substantial proportion of economic 
evaluations in LLMICs already explicitly seek to guide decision-making across many countries. 
While vastly fewer economic evaluations addressed LLMICs (n=184) than UMICs (n=390) or 
especially HICs (n=2337), the numbers of economic evaluations examining more than 10 
countries were highest in LLMICs (n=33), followed by UMICs (n=32) and HICs (n=27). Yet, other 
research in the same Health Economics supplement raised important questions about the 
degree to which large, multi-country modelling studies – which most of these were – 
appropriately account for contextual variation, including health system constraints, which may 
lead to sub-optimal decision recommendations (Vassall et al., 2016a). In Chapter 6, I identify 
and respond to gaps in the methodological literature on transferability of economic 
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evaluations and offer guidance on how to conduct economic evaluations alongside trials and 
pilots in ways that allow them to inform decision-making across a range of contexts, especially 
in LLMICs, where economic evaluation evidence is so scarce. 
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In this third chapter, I respond to some of the key evidence gaps identified in Chapter 2 with 
two economic evaluations, both of which examine malaria interventions in central Senegal. 
These economic evaluations make important contributions to a scarce evidence base in an 
area of major public health importance and investment in many LLMICs. In recognition of the 
need to make potentially far-reaching policy decisions with relatively scarce evidence on these 
topics, I sought to facilitate evidence transfer and make the economic evaluations as 
informative as possible for a wide range of settings and decision-makers. To do this, I began by 
exploring cost variation in the first economic evaluation using econometric techniques 
(Sculpher et al., 2004, Drummond et al., 2005) and found that the scale of delivery at the level 
of the health post – rather than a wide range of other variables considered – accounted for 
most of the cost variation observed. In that first economic evaluation, I also developed a 
simple approach to disaggregating costs and thinking about how costs might be expected to 
vary outside the trial context. In the second evaluation, I extend and implement more fully this 
mechanistic approach to cost modelling and demonstrate the value of this approach in 
enhancing the transferability of economic evaluation findings from the trial to real-world 
settings, across geographies, and with changes to the interventions. Before presenting the 
economic evaluations in Chapters 4 and 5, I first summarize in this chapter the global burden 
of and investments in tackling malaria, the interventions evaluated and their contexts, and give 
a brief overview of the methods used in the two economic evaluations, with a focus on the 
links between them. 
 
3.2. Malaria epidemiology and burden  
 
Malaria remains one of the leading causes of death in LLMICs, especially in children and in Sub-
Saharan Africa (WHO, 2018a). In francophone Africa, malaria is the leading cause of death (El 
Chapter 3.   Introduction to the economic evaluations -  Page 48 of 216 
Bcheraoui et al., 2020). Usually presenting initially as a fever, it can result in permanent 
disability or death without prompt treatment. A parasitic infection transmitted by female 
anopheles mosquitoes, it disproportionately affects the poorest people in the poorest 
countries (Degarege et al., 2019, de Glanville et al., 2019, Barat et al., 2004). The WHO 
estimated that there were 228 (95% confidence interval, CI: 206 to 258) million malaria cases 
and 405,000 (384,000 to 452,000) deaths from malaria in 2018, of which 93% and 94%, 
respectively, occurred in the WHO Africa region (WHO, 2019d). Children under 5 accounted for 
67% of global malaria deaths in 2018 (WHO, 2019d), while malaria accounted for 6.9% of 
deaths in children under 5 in Africa in 2017 (WHO and MCEE, 2018). Globally, 84 countries 
experienced malaria cases in 2018, of which 43 were in the WHO African region (WHO, 2019d). 
Across Africa, malaria remained the fifth largest cause of death in all ages (WHO, 2018b) and in 
children under 5 (WHO and MCEE, 2018). 
Malaria imposes a substantial economic burden on households, health systems, and countries. 
Households in endemic areas bear the direct costs of any preventive tools they purchase and 
of seeking treatment when ill, as well as the indirect costs of lost income and productivity 
when a member of the household falls ill or dies. Public health services – often with donor 
support – bear the costs of publicly-provided preventive activities, such as bed net distribution 
or indoor residual spraying (IRS) campaigns, as well as the costs of providing treatment 
through public facilities with health service staff and other resources. Malaria has been shown 
to have negative effects on child development (Fink et al., 2013, Holding and Snow, 2001, 
Klejnstrup et al., 2018), the quality of the labour force (Arrow et al., 2004, Cole and Neumayer, 
2006), and foreign investment (Azemar and Desbordes, 2009), all of which are thought to 
contribute to reductions in overall economic growth – once estimated at 1% per year (Gallup 
and Sachs, 2001) – and in turn reduce the tax base for public services. 
The epidemiology of malaria has shifted in recent years, with some countries eliminating 
malaria, others recording dramatic declines in malaria incidence, and a remainder continuing 
to face a very high (and in some cases, growing) burden (WHO, 2019d). In Senegal, malaria 
incidence has decreased dramatically in the last twenty years and malaria now ranks as only 
the 10th most common cause of death nationally (GBD Collaborative Network, 2018, PNLP., 
2018). IHME estimates indicate a monotonic decline from 210 cases per 1,000 person-years at 
risk in 2000 to 116 in 2005, 99 in 2010, 64 in 2015, and 44 in 2017 (GBD Collaborative Network, 
2018). Throughout the country, as in countries across the Sahel, malaria is highly seasonal, 
with most cases occurring in a three- to four-month period beginning just after the start of the 
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annual rainy season, and peaking in October or November. As across West Africa, virtually all 
cases in Senegal are attributable to the plasmodium falciparum species of the parasite (WHO, 
2019d).  
Within Senegal, malaria transmission is also highly heterogeneous. The north and west of the 
country, including Dakar, are the driest parts of the country and have consistently had the 
lowest malaria incidence (PNLP, 2014) (Figure 1). The south of Senegal, which surrounds 
Gambia and borders Guinea-Bissau, Guinea, and Mali, is the poorest and most remote area of 
the country and has the highest rainfall and malaria incidence, which has seasonal peaks but is 
year-round. The centre of the country, where the two economic evaluations were conducted, 
averages slightly higher malaria incidence and prevalence than the north and west, but with 
substantial local-level variation, especially in recent years, when overall incidence and 
prevalence have been generally low. On various social, economic, and other health indicators, 
the population of the study districts tends to be somewhat worse off than those in the north 
and west, but better off than the south (ANSD and ICF, 2018). Malaria incidence and 
Figure 1 The four health districts involved in both economic evaluations: Mbour, Bambey, Fatick, and Niahkar 
The map presents Senegal with its 14 regions (in beige) and the four health districts (in bright colours) in which the 
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prevalence are lower, on average, in urban areas, while a wide range of socio-demographic 
variables indicate generally worse living conditions and health status in rural areas (ANSD and 
ICF, 2018).   
Both trials were undertaken in the four health districts of Niakhar, Fatick, Bambey, and 
Mbour.(Figure 1), where malaria has declined substantially in the last twenty years (Trape et 
al., 2012). In Niakhar, a demographic surveillance system (DSS) – the oldest in Africa – provides 
longterm data on morbidity and mortality and has facilitated the conduct of numerous clinical 
trials (Trape et al., 2012). In a previous clinical trial of the efficacy of SMC in Niakhar in 2002, 
children under 5 in the reference arm averaged 2.3 malaria episodes each during the 13 weeks 
of follow-up in the high transmission season (Cissé et al., 2006) (Figure 2). According to DSS 
estimates, the prevalence of malaria parasitaemia among children under 5 in Niakhar was 
estimated to have fallen from 31% in December 2003 to just 2% in December 2008. Malaria 
prevalence in children under 5 was similarly low at 5.1% (2.3% - 7.9%) in December 2008 
across the control areas of the SMC study – which included zones of Niakhar and the other 
three health districts (Cissé et al., 2016). In the Niakhar DSS, the rate of child deaths from 
malaria fell from 10.5 per 1000 person-years in 2000-3, to 7.6 in 2004-5, 6.6 in 2006-7, and 2.0 
in 2008-10, when the SMC effectiveness trial was conducted (Trape et al., 2012). Reasons for 
the dramatic 81% decline in child malaria mortality are thought to include the mass 
distribution of long-lasting insecticide-treated bed nets (LLINs), and the introduction of both 
rapid diagnostic tests (RDTs) and artemisinin combination therapies (ACTs), as well as climatic 
and other factors (Trape et al., 2012).   
 
3.3. Malaria financing 
 
To respond to the immense global burden of malaria, both endemic country governments and 
international donors have invested substantially in tackling malaria in recent years. In 2018, 
their contributions amounted to $0.9b and $1.8b, respectively (WHO, 2019d). While this 
combined $2.7b investment fell substantially short of the $5.0b estimated to be needed to 
meet global targets, the $1.8b donor contribution to malaria remained one of the largest areas 
of global health investment (OECD, 2019). In the decade to 2010, donor funding for malaria 
increased dramatically (WHO, 2011b, OECD, 2019), but both donor and domestic financing has 
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Like many of its neighbours, Senegal’s malaria programme is thus highly donor-dependent, 
which has important implications for policy making in Senegal and for understanding the global 
context in which resources for new malaria interventions are allocated. In Senegal in 2018, the 
National Malaria Control Programme reported expenditure of $4.9m from domestic 
government resources, and nearly ten times as much from donors, including the United States’ 
President’s Malaria Initiative (PMI, $24.0m), the Global Fund ($11.6m), and other bilateral 
donors ($11.6m) (WHO, 2019d). This ratio of (low) domestic government to (substantial) donor 
expenditure equalled the West African average. Over 2016-18, Senegal’s combined donor and 
domestic malaria funding ranked 11th of the 17 countries in West Africa, at $2.6 per person at 
risk (WHO, 2019d). More of Senegal’s donor funding for the health sector targeted malaria 
than any other health area over the period 2009-18 (OECD, 2020).  
 
3.4. Economic evaluations of malaria interventions 
 
To maximize the health impact of these investments, decision-makers must understand the 
relative efficiency of alternative intervention packages and prioritise interventions accordingly. 
In the period covered in the bibliometric analysis in Chapter 2 (Pitt et al., 2016a), malaria was 
the second most-frequently studied health area in cost-effectiveness analyses in lower-middle-
income countries (behind HIV), and the third most-studied health area in low-income countries 
(behind HIV and maternal and neonatal conditions). White and colleagues’ (2011) 
comprehensive review of both cost and cost-effectiveness studies of malaria interventions 
identified 55 and 43 studies, respectively (of which 33 overlapped). The studies evaluated 
distribution of insecticide-treated bed nets, IRS, intermittent preventive treatment of malaria 
in infants (IPTi) and in pregnancy (IPTp), seasonal malaria chemoprevention (SMC), diagnosis, 
and treatment of uncomplicated and complicated cases. An update of White and colleague’s 
review for the Disease Control Priorities project identified 83 cost and 64 cost-effectiveness 
studies up to 1 April 2015 (Levin and Brouwer, 2015, Brouwer et al., 2015). More recently, a 
systematic review of cost-effectiveness analyses of malaria interventions that used DALYs as 
the effectiveness metric identified 40 studies published between 1996 and 1 June 2016 (Gunda 
and Chimbari, 2017).  
These reviews found that “[all] of the major preventive interventions and ACT treatment were 
consistently cost-effective against a threshold of $150 per DALY averted” (White et al., 2011), 
and that “most interventions proved cost-effective” (Gunda and Chimbari, 2017). The DCP3 
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synthesis argued that “[the] cost of malaria control interventions is relatively low in all 
countries, but varies widely” and that “[most] of the studies available indicate rather low cost-
effectiveness ratios” (Tediosi et al., 2017). The reviews criticized the inconsistent 
methodological quality – as did a methodological review of transmission dynamic economic 
evaluations (Drake et al., 2016) – to which they attributed some of the variability in estimates. 
The malaria cost and cost-effectiveness literature is thus relatively large compared with 
economic evaluation literatures for other health areas in LLMICs (except HIV), but small 
relative to the diversity of countries and contexts with ongoing risk of malaria and the global 
resources invested in tackling malaria. Further, the growing resistance to insecticides (Hancock 
et al., 2020) and antimalarials (Uwimana et al., 2020), the wide range of new interventions and 
possible combinations of interventions now available or emerging (Kyrou et al., 2018, Tusting 
et al., 2017, Protopopoff et al., 2018, Rogier et al., 2019), and the plateau and uncertainty in 
future funding create new contexts and policy options requiring new economic evidence to 
inform decision-making. 
Within each of the two economic evaluations in this thesis, the most relevant economic 
evaluation literature is reviewed and used both to inform the analysis and to contextualize the 
findings. For both economic evaluations, the relevant empirical literature extends beyond 
malaria to include interventions for other health conditions involving similar delivery systems.    
 
3.5. Two malaria intervention trials in central Senegal  
 
The two economic evaluations presented in Chapters 4 and 5 were conducted alongside 
consecutive cluster-randomized, controlled trials (Figure 2Error! Reference source not found.). 
Both trials were designed to assess interventions involving door-to-door mass administration 
of malaria drugs by an existing cadre of community health workers (CHWs). The different 
strategies evaluated in the two trials reflected the area’s changing malaria epidemiology, as 
well as changes in the policy context. In 2002, an individually-randomized efficacy trial was 
conducted in 11 villages in central Senegal; it made the breakthrough finding that SMC (called 
“seasonal intermittent preventive treatment” at the time) led to an 86% (95% Confidence 
Interval: 80%, 90%) reduction in episodes of clinical malaria (Cissé et al., 2006). This dramatic 
result spurred further trials elsewhere in West Africa (Wilson, 2011) and efforts to understand 
the safety, feasibility, and effectiveness of large-scale, routine implementation of SMC. A large-
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scale effectiveness trial of SMC evaluated door-to-door administration of a full treatment 
course of antimalarial drugs to all children in the intervention areas (with a few small 
exceptions), regardless of parasite burden or symptoms, at monthly intervals for three 
months. The first economic evaluation included in this thesis (presented in Chapter 4) was 
conducted alongside the final year of this step-wedge trial in 2010, when SMC was delivered to 
approximately 180,000 children under 10. In 2012, WHO recommended SMC for children 
under 5 in areas of highly seasonal transmission in the Sahel (WHO, 2012), informed in part by 
evidence from the large-scale SMC trial and associated economic evaluation. The evaluation 
may also inform future deliberations of the WHO Malaria Policy Advisory Committee (WHO, 
2020b) on whether to recommend expansion of the age range for SMC, as it remains the only 
evaluation to date of SMC in children up to age 10.  
The second economic evaluation included in this thesis is presented in Chapter 5 (Error! 
Reference source not found.). The economic evaluation was conducted alongside a three-arm 
cluster-randomized trial which sought to assess the effectiveness of implementing IRS and 
either mass drug administration (MDA) or mass screening and treatment (MSAT) in higher 
incidence (or “hotspot”) villages in reducing malaria incidence compared to a reference 
strategy, which very closely resembled standard malaria control measures in the area. Unlike 
SMC, these interventions encompassed all age groups, but were targeted at hotspot villages 
within the study area. The intervention packages thus involved combinations of four different 
main interventions: classification of hotspot and non-hotspot villages; house-to-house visits to 
spray insecticide on the interior walls of all consenting households in hotspot villages; and 
either door-to-door delivery of MDA to people of all ages in the hotspot villages or door-to-
door delivery of mass screening (with a rapid diagnostic test) and treatment of those with 
positive test results by CHWs. The hotspot strategies were implemented in a population of 
approximately 444,000 people of whom approximately 239,000 lived in villages designated as 
hotspots in 2014 and were therefore targeted to receive IRS and either MDA or MSAT. The 
hypothesis was that implementing such a combination of chemotherapy and vector control in 
hotspot villages could reduce malaria incidence both in hotspot and non-hotspot villages, and 
in doing so, “virtually eliminate” malaria in the intervention arms, across both hotspot and 
non-hotspot villages.   
The decision to conduct the hotspot trial (Figure 2) and associated economic evaluation 
reflected changes in the local epidemiology and in the wider policy context. In the early 2000s, 
much of the malaria world was deeply sceptical about MDA for malaria, which for many 
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recalled the failures of the Global Malaria Eradication Programme of the 1950s and raised 
fears of resistance to antimalarials (WHO Evidence Review Group, 2015a, Cissé et al., 2006). 
However, with the intensification of the push to eliminate malaria by “shrinking the malaria 
map” (Feachem et al., 2010) – i.e. seeking to eliminate malaria first outside of and on the 
periphery of Africa – new, intensified control efforts were increasingly considered plausible 
global policy options. By 2015, WHO had convened an evidence review group on MDA, MSAT, 
and focal screening and treatment (FSAT) (WHO Evidence Review Group, 2015a). Evidence 
review groups are time-limited expert groups tasked with reviewing a specific area of work and 
providing “evidence-based information and options for recommendations” to the Malaria 
Policy Advisory Committee (WHO, 2020a), an “independent advisory group bringing together 
the world’s foremost experts on malaria . . . [to provide] strategic technical guidance to WHO 
Director-General” (WHO, 2020c). Both MSAT and MDA were thus receiving serious 
consideration for global policy. 
 
3.6. Methods overview 
 
The economic evaluation of SMC (Figure 2) was designed to respond to the WHO’s Global 
Malaria Program’s concerns at the time regarding the affordability of SMC, rather than its cost-
effectiveness. A dramatic drop in malaria incidence across the study area in 2009 had also led 
researchers to expect at the start of the third year of the trial, when the cost data collection 
was conducted, that the trial would be underpowered to detect an effect of SMC on malaria 
incidence, and that a cost-effectiveness analysis would not be meaningful or useful. I therefore 
led in-depth cost data collection and analysis aimed at understanding variation in the cost per 
course of SMC delivered. Guidelines on improving the transferability of economic evaluation 
evidence at the time recommended statistical analysis of heterogeneity within a trial as a 
means of improving transferability of findings outside of a trial (Sculpher et al., 2004, 
Drummond et al., 2005). Through careful collection and disaggregation of the costs of 
delivering SMC, I was able to generate a dataset of the costs of SMC delivery for each of the 46 
health posts implementing SMC. This dataset was large compared with other such datasets of 
costs by facility, but small compared with the number of variables that we hypothesized could 
explain the variation in costs across facilities. Using econometric approaches, as recommended 
(Sculpher et al., 2004, Drummond et al., 2005), I found that the size of the catchment area 
alone – i.e. the local scale of delivery – explained most of the variation in average costs across 
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this set of facilities. This finding led me to explore other approaches to understanding cost 
variation, which could exploit the in-depth understanding we had gained of cost drivers and 
how the intervention worked in practice. In this analysis of SMC, I began by simply 
disaggregating costs by administration round and by whether they could be expected to vary 
with the number of districts, health posts, CHWs, or children involved in the administration. In 
the following economic evaluation, described below, I developed this mechanistic approach to 
understanding and predicting cost variation more fully. 
The economic evaluation of geographically targeted strategies in malaria hotspots (Figure 2) 
built on and extended the analysis of SMC. Firstly, the cost data collection processes and tools 
from the SMC costing were re-used with minor adaptations for MDA, MSAT, IRS, and the 
identification of malaria hotspot villages. Secondly, I extended what was done in the SMC 
analysis by developing a mechanistic cost model, which I used to estimate how intervention 
costs would vary if the interventions were implemented in the entire study area or with 
changes to the interventions. The modelled costs were used in a cost-effectiveness analysis in 
which I modelled the incremental cost-effectiveness of 7 intervention packages relative to one 
another. Work on the economic evaluations of SMC and of the hotspot strategies informed the 
development of new guidance to promote the design and analysis of economic evaluations in 
ways that promote transferability, presented in Chapter 6. 
In both economic evaluations, I assess incremental costs – that is, the difference in costs 
between two clearly defined comparators – and carefully distinguish between financial and 
economic costs, as recommended by key guidelines (Vassall et al., 2017). Financial costs reflect 
payments, and are therefore important for assessing affordability or “budget impact”. While 
there are no strict thresholds for assessing affordability, comparing the financial costs of an 
intervention with the size of relevant budgets can give a useful indication of the extent of 
additional resource mobilisation that would be required or the proportion of existing activities 
that would need to be displaced to implement the intervention. Financial costs exclude 
donated resources, such as volunteers’ time, or the repurposing of existing resources – such as 
infrastructure or staff time – where no additional payments are made. They also reflect the 
time point at which a cost is incurred, which is important for interventions requiring 
substantial up-front payments. Economic costs reflect the full opportunity cost of all resources 
used, that is, their value in the next-best alternative use. Economic costs thus include the value 
of both paid-for and donated resources, making them the appropriate metric for assessing 
economic and allocative efficiency.  
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Recherche pour le Développement, Dakar, Senegal and 5Department of Infectious Disease Epidemiology, London
School of Hygiene & Tropical Medicine, London, UK
*Corresponding author. Department of Global Health & Development, London School of Hygiene & Tropical Medicine,
London, UK. E-mail: catherine.pitt@lshtm.ac.uk
Accepted on 18 June 2017
Abstract
Seasonal Malaria Chemoprevention (SMC) is recommended for children under 5 in the Sahel and
sub-Sahel. The burden in older children may justify extending the age range, as has been done ef-
fectively in Senegal. We examine costs of door-to-door SMC delivery to children up to 10years by
community health workers (CHWs). We analysed incremental financial and economic costs at dis-
trict level and below from a health service perspective. We examined project accounts and pro-
spectively collected data from 405 CHWs, 46 health posts, and 4 district headquarters by introduc-
ing questionnaires in advance and completing them after each monthly implementation round.
Affordability was explored by comparing financial costs of SMC to relevant existing health expend-
iture levels. Costs were disaggregated by administration month and by health service level. We
used linear regression models to identify factors associated with cost variation between health
posts. The financial cost to administer SMC to 180000 children over one malaria season, reaching
93% of children with all three intended courses of SMC was $234 549 (constant 2010 USD) or
$0.50 per monthly course administered. Excluding research–participation incentives, the financial
cost was $0.32 per resident (all ages) in the catchment area, which is 1.2% of Senegal’s general
government expenditure on health per capita. Economic costs were 18.7% higher than financial
costs at $278 922 or $0.59 per course administered and varied widely between health posts, from
$0.38 to $2.74 per course administered. Substantial economies of scale across health posts were
found, with the smallest health posts incurring highest average costs per monthly course adminis-
tered. SMC for children up to 10 is likely to be affordable, particularly where it averts substantial
curative care costs. Estimates of likely costs and cost-effectiveness of SMC in other contexts must
account for variation in average costs across delivery months and health posts.
Keywords: Seasonal malaria chemoprevention (SMC), intermittent preventive treatment, malaria, cost function, cost variation,
primary health care, community health workers, mass drug administration, campaigns, Sub-Saharan Africa
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In 2012, the World Health Organization (WHO) recommended
Seasonal Malaria Chemoprevention (SMC) for children under 5 liv-
ing in areas of the Sahel and sub-Sahel with highly seasonal malaria
transmission (World Health Organization 2012). Previously known
as intermittent preventive treatment of malaria in children (IPTc),
SMC consists of providing a treatment dose of an effective antimal-
arial on a monthly basis for three or four consecutive months of the
year in order to maintain therapeutic levels of antimalarial drugs
during the period of greatest malaria risk. SMC with sulfadoxine
pyrimethamine (SP) plus amodiaquine (AQ) is a highly efficacious
intervention, which clinical trials showed to reduce the incidence of
malaria by 75% or more amongst children under five who received
it in areas of highly seasonal transmission (Bojang et al. 2011; Dicko
et al. 2011; Konate et al. 2011; Sinclair et al. 2011; Wilson 2011).
A large-scale, stepped-wedge, cluster-randomized trial in Senegal
found that delivering SMC to children under 10 reduced malaria in-
cidence by 60% (95% CI 54–64) amongst children under 10 and by
26% (95% CI 18–33) in adults and children older than 10 who did
not receive SMC, through indirect effects (Cisse et al. 2016).
Preliminary findings regarding feasibility, safety, effectiveness and
costs from this large-scale study were requested and reviewed by
WHO’s Technical Expert Group on Preventive Chemotherapy in
2011 (World Health Organization/Global Malaria Program
Technical Expert Group on Preventive Chemotherapy 2011), which
subsequently recommended SMC.
Since the WHO recommendation, 12 countries have begun de-
livering SMC and 7 of these countries have been supported by a
$67 m grant from UNITAID to expand access to SMC (Malaria
Consortium 2016). While 11 of these countries provide SMC for
children up to 5 years of age in accordance with the WHO recom-
mendation, on the basis of the large-scale study findings, Senegal’s
policy since 2013 has been to provide SMC to children up to age 10.
Policy makers and programme managers in other Sahel countries are
considering whether to extend the recommended age range for SMC
to address the increasing proportion of the malaria burden falling on
older children.
As SMC requires repeated contacts with the health system out-
side the existing schedule of vaccinations and health campaigns, the
feasibility and cost of reaching children in rural areas on a large
scale have been important factors in deliberations on SMC (World
Health Organization/Global Malaria Program Technical Expert
Group on Preventive Chemotherapy 2011). Studies which examined
potential delivery strategies concluded that community health work-
ers (CHWs) need to play an important role in implementation
(Kweku et al. 2009; Bojang et al. 2011; Patouillard et al. 2011).
Economic evaluations were conducted alongside several SMC
studies to explore which drug combinations and delivery strategies
were most cost-effective (Conteh et al. 2010; Bojang et al. 2011;
Patouillard et al. 2011), but these were relatively small-scale trials,
which may overestimate both the costs and feasibility of implement-
ing SMC at scale. Nonvignon et al. (2016) also examined the cost-
effectiveness of SMC implementation with intensified household vis-
its. As all economic evaluations published to date have been con-
ducted amongst younger children, however, they do not directly
address questions about whether to extend the recommended age
range.
We provide an economic analysis of the costs of administering
three monthly courses of SMC in 2010 to a population of over
180000 children aged 3months to 10 years in central Senegal in the
context of the step-wedge trial previously described (Cisse et al.
2016). >93% of children in the target age range received all three
intended monthly courses of treatment (Ba et al. 2017); delivery was
highly equitable (Ba et al. 2017) and safe (N’Diaye et al. 2016) and
reduced the prevalence of molecular markers of resistance to SMC
drugs (Cisse et al. 2016). Extending the preliminary findings re-
viewed by WHO, we provide a comprehensive analysis of cost driv-
ers, the distribution of costs across the 3months of administration
and across health system levels, variation in costs between health
posts, and economies of scale. We aim to inform decisions on
whether to extend the recommended age range for SMC and draw
conclusions of wider relevance to the implementation of other large-
scale health campaigns and the organization of the health system.
Methods
Study setting and design
Details of the step-wedge study design (Cisse et al. 2016) and study
setting (Ba et al. 2017) are provided elsewhere. In brief, following
two seasons of piloting in a neighbouring district, 54 rural and semi-
urban public health post catchment areas in 4 districts (Bambey,
Mbour, Fatick and Niakhar) were randomized to start implement-
ing SMC in 2008 (9 catchment areas), 2009 (18 catchment areas) or
2010 (18 catchment areas). Cost data were collected in 2010, when
45 catchment areas (comprising 45 public health posts and 1 mis-
sion facility) implemented SMC.
Senegal was classified as a low-income country until 2011, and
was reclassified as such in 2017 (World Bank 2017). In the imple-
mentation area, 32% of the population was under 10 years old
(Cisse et al. 2016). The area’s rainy season runs from July to early
October and the climate is sudano-sahelian, leading to highly sea-
sonal transmission. While the malaria burden had been very high, it
had fallen by 2010, when malaria incidence in the study’s control
areas (confirmed by a rapid diagnostic test, RDT) was 4.3 cases per
Key Messages
• Our estimates of the costs of SMC are lower than previous studies, which may be attributed to the wider age range
(0–10 vs 0–5years), much larger overall scale of delivery, and more limited involvement of researchers in implementa-
tion in our study.
• We observed substantial economies of scale in the size of the catchment area of health posts; the average cost curve
was L-shaped, consistent with the limited existing empirical literature on provider costs.
• The financial costs of providing SMC for children under ten represent 12% of combined government and international
spending on malaria in Senegal and 1.2% of Senegal’s general government expenditure on health per capita, making
SMC potentially affordable especially if it were to avert substantial curative care costs.









































































thousand children under 5 and 10.0 cases per thousand children
aged 5–10 (Cisse et al. 2016). In 2014, malaria continued to account
for 5.0% of deaths in children under 5 and 3.4% of all deaths in
Senegal (PNLP 2015).
SMC delivery strategy
The existing CHW network, which already delivered a variety of
interventions including twice yearly Vitamin A and anthelminthic
tablets for children under 5 through door-to-door strategies, was
identified as most appropriate for SMC distribution. Under the
supervision of the head nurse at each health post, CHWs travelled
door-to-door on designated days in September, October, and
November to administer the first dose of loose, crushable AQ and
SP tablets each month to children aged 3–119months and to provide
AQ tablets for the child’s caregiver to administer using the house-
hold’s usual water supply on the subsequent 2 days. In 2010, imple-
mentation was organized primarily by the district health
management teams (DHMTs).
The head nurse at each health post trained CHWs over the
course of several hours on the day before administration in
September, but did not repeat this full training in October and
November. For CHWs who missed this initial training, informal,
on-the-job training was provided, as is standard practice for cam-
paigns. Each head nurse was responsible for organizing the hiring of
CHWs and deciding the number of days they were hired for and
their payment. Health posts received a lump sum to cover CHW in-
centive payments, based on the estimated number of CHWs needed
and the estimated number of days work it would take the CHWs to
cover the target population of the health post. Some nurses chose to
divide the lump sum by the number of CHWs associated with their
health post and pay CHWs a fixed amount, while others paid a daily
rate (Ba et al. 2017).
Perspective and hierarchical boundaries
Detailed data on resource use associated with delivery of SMC were
collected to estimate the incremental costs of implementing SMC at
scale in 2010. All 45 government health posts that delivered SMC in
2010 were included, as was one mission health post which managed
SMC delivery within a defined portion of the official catchment area
of one of the 45 government health posts.
The study takes a health service perspective. The opportunity
cost for households to participate in SMC is expected to be low as
SMC is delivered door-to-door (Conteh et al. 2010).
Both financial and economic costs are included. Incremental fi-
nancial costs reflect the additional funding needed to pay for the
intervention. Incremental economic costs reflect the full value of the
additional resources used to implement SMC, including those which
did not incur an incremental financial cost to the health service,
such as the time required of the district health team and health post
staff, and items paid for by CHWs or other organizations. The
economic value of individuals’ time was calculated as a fraction of
their salaries (including benefits) or, for CHWs, estimated earnings,
assuming 220 working days per year and an average 7.5-h
working day.
We focus on costs of implementation at the district level and
below. Costs incurred only at national level, such as those associated
with meetings amongst national-level representatives, are not
included because they only concerned research; implementation
questions were devolved to district managers. Nearly all the costs of
implementation from the district level and below were considered
recurrent, meaning that they would have to be repeated for each
year of implementation. The only capital costs (resources that last
over a year) associated with SMC implementation were those of the
research team vehicles, which were used in a few instances to sup-
port the distribution of SMC drugs and supervision. Straight line de-
preciation of the purchase price of vehicles was used with a 5-year
expected life of the vehicle (based on local usage) and an assumption
of 220 working days per year to estimate the daily economic value
of these vehicles, in addition to the financial costs of fuel.
Costs of research activities were generally excluded from the
analysis. In two cases, however, costs associated with research activ-
ities were very likely to have contributed directly to the success of
the administration and so they have been included and described in
detail. First, all costs of the demographic surveillance system (DSS)
set up to support the trial were excluded, however, some of the DSS
fieldworkers and supervisors provided supervisory support on the
administration days in September and October and transported
some of the drugs; the costs of their time and of drivers and vehicles
for these implementation activities have, therefore, been included
under supervision and supply chain, respectively. As it is standard
practice for districts and health posts to request the support of local
organizations such as NGOs or research institutes for health cam-
paigns, these costs are considered incremental economic costs, but
not incremental financial costs to the Ministry of Health. Second,
health staff at post, district, and regional levels received incentives
for participation in the research. These incentives were paid over
12months and were intended to support participation in research
activities such as morbidity surveillance. While it is not anticipated
that such incentives would be paid if SMC were implemented out-
side a research context, these incentives may have contributed to
more assiduous implementation of SMC, and so they are also pre-
sented as a separate cost category.
Data collection
Tools were developed to collect data on costs and resource use at
four levels: the project, the district, the health post, and the CHW.
At the district, health post, and CHW levels, questionnaires were de-
veloped, introduced to all district medical officers, head nurses, and
CHWs at the SMC planning meetings before administration began
in 2010, and refined to incorporate their feedback. Trained field-
workers collected data from all 4 districts and all 46 health posts fol-
lowing each round of administration in September, October, and
November. They also administered questionnaires to a systematic
sample of CHWs each month. In total, 405 CHW interviews were
conducted, reflecting 48% of the average of 822 CHWs who admin-
istered SMC each month, or 13% of the CHW-months of adminis-
tration. District and health post questionnaires and health post and
CHW questionnaires covered similar questions regarding resource
use, activities, and payments so that data could be triangulated. In
addition, several key informant interviews were conducted with
local field coordinators and CHWs to compare the per diems paid to
CHWs with what they could otherwise have earned on the SMC ad-
ministration days.
In November, three health posts in Bambey District combined
administration of SMC with administration of Vitamin A and
mebendazole. For these three posts, and in some cases for Bambey’s
district-level costs, the cost of delivering SMC alone in November
was estimated based on the costs incurred in these health posts in
October.









































































Data management and analysis
Questionnaire data were entered into an MS Access database.
Consistency checks were performed to ensure data validity and data
were exported to MS Excel for analysis. Data were carefully triangu-
lated between sources to maximize accuracy and avoid double-
counting. Costs are presented in United States Dollars (USD) based
on the average 2010 exchange rate with the West African Franc
(1 USD¼495 XOF(OANDA)).
Costs were summarized according to the categories presented in
Table 1. These categories were identified to ensure comparability
with previous studies of SMC (Conteh et al. 2010; Bojang et al.
2011) and to reflect the key cost centres. We present key cost drivers
and examine several aspects of the cost structure and cost variation.
To facilitate projections of how costs may vary if fewer or more
monthly rounds of SMC were implemented, we disaggregated costs
by the month in which they were incurred. To facilitate projections
of how costs may vary with different scales of delivery and in differ-
ent areas, we disaggregated costs by the health system level (district,
health post, CHW, child) with which they would be expected to
vary approximately linearly.
Costs are analysed with respect to several measures of output
described in detail elsewhere (Ba et al. 2017) (Table 2). Estimates of
the number of monthly courses administered were based on admin-
istrative data, which was triangulated from routine data in health
post reports and administration registers. Estimates of the number
of children in the target age range and all residents in the catchment
area were based on the DSS. The number of children receiving SMC
at least once and in all 3months was estimated by applying survey
Table 1. Description of cost categories
Cost category Description
SMC drugs Reflects the cost of SP and AQ tablets supplied by National Pharmacy of Senegal and Kinapharma (Accra, Ghana),
respectively and actually used or wasted during SMC administration, including the costs of importation to the
Port of Dakar
Drug transport/supply chain Reflects the cost of transporting drugs from Dakar to the districts (via a local storage site) by the research team, and
from the districts to the health posts by district and health post staff. Additional economic costs include the value
of time and of vehicles used by the research team, districts, and health posts
Drug administration (CHWs) Includes the cost of payments of per diems to and transport for CHWs to come to the health post, retrieve drugs
and registers, administer drugs to children, and return to the health post to return their reports and remaining
drugs on each day of the administration. Additional economic costs include transport costs paid by the CHW
and not reimbursed by the health facility
Supervision Reflects the cost of incentive payments to a head nurse, assistant, and in some cases trainee at each health post; to
each district health management team, region, and prefecture to supervise the implementation of SMC and to
manage any side effects or refusals; and the costs of any transport used for this supervision. Additional economic
costs include the value of time and transport for these health staff as well as the DSS supervisors and fieldworkers
for the days on which they helped districts to supervise the administration
Training of CHWs CHWs attended a single training day at their health post before administration in September. The payment of per
diems, as well as the costs of any food or supplies provided or used during the training and any transport paid for
by the health post or district are included as financial costs. Additional economic costs include the value of health
staff time
Training of head nurses Head nurses travelled to their district headquarters for a one-day training before administration in September.
Costs were incurred for the per diems paid to the head nurses, their transport, and the food and supplies pro-
vided. Additional economic costs include the value of participants’ time and of vehicles used
Meetings (evaluation & planning) Prior to the training, head nurses attended one or more evaluation and planning meetings at their district during
which they evaluated results of the SMC implementation in 2009 and outlined plans and budgets for implementa-
tion of SMC in 2010. Costs include per diems, transport, and any food or materials provided specifically for the
meetings. Meetings were held for head nurses at district level and for district managers in Dakar and at one of the
districts
Sensitization Both districts and health posts arranged activities such as travelling caravans, radio announcements, and commu-
nity meetings to promote awareness of SMC with regional or local authorities and within the community.
Additional economic costs include the value of participants’ time and vehicle use
Drugs for side effects The costs of the small stock of drugs and medical supplies with which to manage potential adverse events provided
to health posts were included regardless of the amount used, as these supplies would need to be provided in future
as a precaution. In addition, head posts were reimbursed the cost of treating children whose parents reported side
effects, in cases where the head nurse used medications other than those provided
Supplies Supplies used in the administration included hats, t-shirts, and polo shirts with SMC sensitization messages and the
MoH logo; registers of children and other monitoring tools; phone cards, etc. In addition, health posts also pur-
chased some supplies themselves, such as pencils and erasers, to complement those provided by the district.
Supplies purchased by CHWs are included as economic, rather than financial costs to the health service
Research participation incentives Regional medical officers, district medical officers and their deputies, district supervisors, and head nurses all
received quarterly incentive payments throughout the year to support research activities such as morbidity sur-
veillance. The entire value of these payments over 12months to the 3 regions, 4 districts, and 45 health posts that
implemented SMC in 2010 are included, as they are likely to have contributed to more assiduous implementation
of SMC in September, October, and November. It is not expected that this level of incentive payment would be
repeated outside a research context
This table provides a detailed description of the cost categories used in the analysis. Where economic costs are greater than financial costs, the source of add-
itional economic costs are mentioned explicitly.









































































estimates of the proportion of children receiving 0, 1, 2, or 3 courses
of SMC to the administrative estimate of the number of monthly
courses administered. The latter was a conservative approach yield-
ing lower estimates of the number of children receiving SMC (and
thus higher costs per course and per child) than applying survey esti-
mates to the target population estimated in the DSS.
Affordability was explored by assessing the annual financial cost
of SMC per person (all ages) resident in the catchment area as a pro-
portion of three relevant, existing expenditure levels. These were:
(1) average annual expenditure for malaria control and elimination
per person at risk in Senegal (which includes both domestic expend-
iture on malaria prevention and treatment and donor funding ear-
marked for malaria control) in 2013–2015 (WHO Global Malaria
Programme, 2016); (2) Senegal’s general government expenditure
on health per capita in 2014 (World Health Organization 2017) and
(3) Senegal’s total health expenditure per capita in 2014 (World
Health Organization 2017). The most recent expenditure levels
available are used to explore affordability relative to current fund-
ing, but are presented in constant 2010 USD to allow comparison
with our cost estimates.
We sought to identify factors associated with variation between
health posts in the average cost of SMC administration per course
administered. We analysed average economic costs including re-
search participation incentives with the district-level costs divided
equally among the health posts within each district. We hypothe-
sized that the following observed variables could be associated with
cost variation across health posts: the number of courses adminis-
tered (i.e. output or scale), coverage, geography of the catchment
area (minimum, average, and maximum distances from health post
to catchment villages; catchment area; number of catchment vil-
lages), and the number of years of experience (of the head nurse
and, separately, at the health post) of delivering SMC (0, 1, or 2).
Coverage estimates (the number of courses administered as a pro-
portion of the target) were based on administrative, rather than sur-
vey data, because survey-based coverage estimates were not
available for each health post (Ba et al. 2017). As our observations
(health posts) were nested within a small number of clusters (dis-
tricts), we fit a linear model with fixed effects at the district level
(Möhring 2012) to account for this clustering. We used STATA 14.
All independent variables were centred. Scatter plots of all pairwise
variable combinations were used to assess the linearity of relation-
ships; logarithmic transformations were performed on skewed data
and a quadratic term was added for any independent variables ex-
hibiting a curvilinear relationship with costs. Possible interactions
between the number of courses administered, coverage, and catch-
ment area were explored. We began with a full model containing all
independent variables and interaction terms and sequentially
removed the variable from the model with the highest P-value.
Variables were retained in the model if they contributed to the fit of
the model with P<0.05, if removal substantially altered coefficients
of other variables in the model, or if they were component variables
of retained interaction or quadratic terms. Once a parsimonious
model was reached, excluded variables were individually retested.
Standard regression diagnostics were performed (Chen et al. 2003).
Likelihood ratio tests were used to determine whether individual
variables and groups of variables improved model fit. We also de-
veloped a more parsimonious model based on a more stringent cri-
terion of P<0.0032, which corresponds with a Bayes factor of 20




The financial cost to administer SMC to a population of over
180000 children aged 3months to 10 years in four districts of
Senegal over one malaria season, reaching an estimated 93% (95%
CI 91–96) of children with all three monthly courses of SMC (Ba
et al. 2017) was $234549 (Table 3) or $0.50 per monthly course ad-
ministered (Table 2). The economic costs were 19% higher at
$278922 or $0.59 per course administered. When the value of in-
centives intended for research is removed, the financial and eco-
nomic costs fall by $43 424 to $0.41 and $0.50 per course
administered, respectively. This financial cost of $0.41 per course
administered excluding research participation incentives corres-
ponds to $1.22 per child receiving all three scheduled courses, $1.06
per child of target age in the catchment area, and $0.32 per resident
(all ages) in the catchment area (Table 2).
This cost per resident represented 1.2% of Senegal’s general gov-
ernment expenditure on health per capita, 0.6% of total health ex-
penditure per capita and 12% of combined government and
international spending on malaria in Senegal (Supplementary Table
S1 is available at HEAPOL online).
Table 2. Financial and economic cost of SMC per output










Monthly courses administereda 471,283 $0.41 $0.50 $0.50 $0.59
Children receiving SMC at least onceb 157,654 $1.21 $1.49 $1.49 $1.77
Children receiving SMC in all three monthsb
(i.e. "fully adherent")
156,311 $1.22 $1.50 $1.51 $1.78
Children of target age in the catchment areac 181,060 $1.06 $1.30 $1.30 $1.54
Residents (all ages) of the catchment areac 589,332 $0.32 $0.40 $0.40 $0.47
aBased on administrative data, which was triangulated from routine data in health post reports and administration registers (Ba et al. 2017).
bGenerated by applying survey estimates of the proportion of children receiving 0, 1, 2, or 3 courses of SMC to the estimate of the number of monthly courses
administered based on administrative data (Ba et al. 2017).
cBased on the DSS (Ba et al. 2017).










































































The main cost drivers were door-to-door drug administration (42%
of non-research financial costs) and SMC drugs (28% of non-
research financial costs, Table 3). Per diems paid to CHWs ac-
counted for most of the drug administration costs and 41% of total
non-research financial costs (Supplementary Table S2 is available at
HEAPOL online). AQ tablets alone accounted for 21% of non-
research financial costs, while SP tablets accounted for 7%.
Incentives paid to nurses and district staff for participation in the re-
search study increased the financial costs of the intervention by 23%
(from $191049 to $234462). While research incentives were in-
tended to support data collection rather than implementation and
are not normally provided for comparable distribution campaigns,
they may have contributed to the high coverage levels achieved, as
on average they represented a 7% increase in head nurses’ annual
salaries—or 15 days’ pay assuming 220 days worked per year—
and a>10% increase in the salaries of district and regional staff
(Supplementary Table S1 is available at HEAPOL online). Publicity
campaigns and other sensitization activities played an important
role in achieving high coverage (Ba et al. 2017), although they ac-
counted for only 1% of financial and economic costs.
Economic costs were $43945 greater than financial costs be-
cause they also included the value of the time MoH staff and others
spent in meetings, trainings, travel and supervision (74% of the add-
itional costs), as well as the economic value of vehicles used and the
cost of supplies paid for by CHWs while implementing the interven-
tion. Key informant interviews revealed that the payments made to
CHWs (median: $7.49 per day, range $5.05–16.16) were compar-
able to or greater than the daily rate of pay for agricultural labour,
similar to rates paid by non-governmental organizations (NGOs) for
health activities, and somewhat higher than health districts pay for
other mass campaigns. While the qualifications and opportunities
amongst CHWs varied, many were illiterate and unskilled and
others were secondary school students (Ba et al. 2017). In addition,
distribution tended to begin on weekends to ensure both that fami-
lies were at home and that CHWs would be available without taking
them away from other activities (Ba et al. 2017). The economic
value of CHW time spent implementing the intervention was there-
fore considered to be fully reflected in the financial costs of the pay-
ments made to them, and so no additional economic costs of CHW
time were calculated.
Time allocation
Most CHWs worked in pairs, delivering SMC to a mean of 46 chil-
dren per CHW per day at each health post (range 25–78)
(Supplementary Table S3 is available at HEAPOL online). Some
Table 3. Total financial and economic costs of SMC
Financial costs Economic costs
Total costs
US$ (2010)











TOTAL including research incentives $234 549 100.0 NA $278922 100.0 NA
TOTAL excluding research incentives $191 125 NA 100.0 $235 498 NA 100.0
SMC drugs (SPþAQ) $53 010 22.6 27.7 $53 010 19.0 22.5
Drug transport/supply chain $425 0.2 0.2 $3266 1.2 1.4
Drug administration (CHWs) $80 651 34.4 42.2 $80 651 28.9 34.2
Supervision $25 156 10.7 13.2 $57 563 20.6 24.4
Training of CHWs $6946 3.0 3.6 $8956 3.2 3.8
Training of head nurses $2283 1.0 1.2 $3813 1.4 1.6
Meetings (evaluation & planning) $2365 1.0 1.2 $3851 1.4 1.6
Sensitization $2519 1.1 1.3 $2962 1.1 1.3
Drugs for side effects $2491 1.1 1.3 $2491 0.9 1.1
Supplies $15 279 6.5 8.0 $18 935 6.8 8.0
Research participation incentives $43 424 18.5 NA $43424 15.6 NA
Table 4. Cost of activities by health system level and month of administration
Level Financial costs Economic costs
Sept (and earlier) Oct Nov Total costs Cost profile (%) Sept (and earlier) Oct Nov Total costs Cost profile (%)
District $7019 $4234 $5549 $16 801 8.8 $12 235 $7028 $7010 $26 274 11.2
Post $22 456 $7311 $8809 $38 576 20.2 $37 521 $14 987 $15 416 $67 924 29.1
CHW $6920 $16 $9 $6946 3.6 $6920 $16 $9 $6946 3.0
Child $43 939 $42 506 $42 356 $128 802 67.4 $45 351 $43 632 $43 475 $132 457 56.7
Total $80 334 $54 067 $56 723 $191 125 100.0 $102 027 $65 664 $65 910 $233 601 100.0
Cost profile (%) 42.0 28.3 29.7 100.0 43.7 28.1 28.2 100.0
Costs are attributed to the lowest level with which they would be expected to increase linearly. For example, if the number of CHW were doubled, but all else
held constant, the CHW-level costs would be expected to double while other levels would remain approximately constant. Similarly, adding an additional month
to the campaign would add 28–30% to total costs, assuming that this additional month’s campaign was conducted similarly to the October and November cam-
paigns, rather than the September campaign, which incurred additional start-up costs, especially for meetings and trainings. Research participation incentives are
excluded.









































































CHWs assisted with administrative duties in the health post for
some or all of the administration days and so administered few or
no courses directly; hence, for individual CHWs who administered
at least one course, the average number of courses administered per
day varied more widely, from 2 to 169. Health posts employed from
4 to 68 CHWs and delivery each month took from 2 to 6 days per
post. CHWs worked a mean of 7 h per day, but this varied from 1 to
12 h across CHWs and the average number of hours per day per
CHW also varied substantially between health posts, from an aver-
age of just 4 h per day in one health post to an average of 10 h per
day in another (Supplementary Table S3 is available at HEAPOL
online). CHW time spent on SMC was only moderately (22%)
higher in September (mean 665 cumulative CHW-hours per health
post) than in each subsequent month (543h) (Supplementary Table
S4 is available at HEAPOL online). Head nurses spent a median of
75 cumulative hours on SMC over the 3months (range 7–156),
more than two-thirds of which was spent on the September round
(Supplementary Table S4 is available at HEAPOL online).
Across the four districts, district medical officers spent a median
78h (range 12–116) on SMC, while their deputies spent substantially
less time (Supplementary Table S4 is available at HEAPOL online).
District supervisors spent a median 209h per district (range 42–376)
on SMC. Supervisors and fieldworkers from the DSS supported
supervision in September and October, spending the largest amount
of time in the district whose supervisors and senior officers spent the
least time on SMC. The additional time district and health post staff
spent in September relative to the two subsequent months was largely
spent in meetings and trainings at both the district and health post
level. Several separate meetings/trainings on SMC were held at the dis-
tricts involving head nurses in August and September; discussions of
SMC did not appear to be combined in other district meetings.
Cost structure
The first of the three monthly SMC rounds accounted for 42% of fi-
nancial costs (Table 4). Adding a fourth monthly SMC round would
be expected to increase total costs by 28–30%, assuming that the
additional month’s campaign were conducted similarly to the
October and November campaigns.
Two-thirds of financial costs (67%) were expected to vary with
the number of children, while 20% were expected to vary with the
number of health posts (Table 5). Only 9% of financial costs were
expected to vary with the number of districts, while <4% of costs
were expected to vary with the number of CHWs. Thus, for ex-
ample, if a new health post were created to serve half the catchment
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Figure 1. Total and average costs by health post with cost drivers. Health posts are ordered (left to right) in both graphs from largest to smallest total economic
costs, including research participation incentives. District-level costs have been divided evenly across the health posts within each district. As total costs
decrease, the average cost per course administered tends to increase, although there is some variation in this trend.









































































that the number of districts, CHWs and children in our analysis
would remain constant, but the number of health posts (and thus
the costs expected to vary with the number of health posts) would
increase by 2% (1/46). Holding all else constant, the addition of this
new health post could then be projected to increase the total finan-
cial costs of SMC implementation by 0.4%.
Cost variation and economies of scale across health
posts
The total economic cost varied substantially across the 46 health
posts, from $3223 to $15946 when district-level costs were appor-
tioned equally across health posts within each district and research
participation incentives were included (Figures 1 and 2). Costs
incurred only at the health post level and below varied from $1558
to $14 573. The average economic cost varied from $0.32 to $2.10
per course administered and from $0.30 to $1.38 when considering
only costs incurred at the health post level and below
(Supplementary Table S5 is available at HEAPOL online). The cost
of SMC tablets and the cost of per diems for CHWs were relatively
constant with respect to the number of courses administered (Figure
1). In contrast, the remaining significant cost centres, notably super-
vision, the additional economic value of health worker time, and the
research participation incentives, were relatively fixed with respect
to the number of health posts and thus account for most of the vari-
ation in average cost per course between health posts.
Average costs displayed a strong L-shape when plotted against the
number of courses administered (Figure 3). In this sample, there was
no evidence of a point at which health posts had such high levels of
output that they displayed diseconomies of scale. Average costs
increased steeply for health posts administering fewer than 8000
courses of SMC (10000 residents), while above 10000 courses
(12500 residents), average costs declined, but more gradually
(Figure 3). In exploring factors associated with this variation, we
found that using the more stringent, Bayesian criterion of P<0.0032
led to a parsimonious log–log model of average economic costs as a
quadratic function of the number of courses administered (including
fixed effects at the district level); this model described nearly all the
variation in the data (adjusted R2¼0.94). The more traditional, fre-
quentist threshold of P<0.05 led to a more complex model (adjusted
R2 ¼ 0.95), which also included variables for the interaction between
coverage and size of catchment area and between size of catchment
area and the logarithm of the number of courses, as well as the cover-
age and size of catchment area levels. While the likelihood ratio test
indicated that this set of additional variables improved model fit
(P¼0.020), the large number of variables relative to data points sug-
gests that the more complex model may be overspecified.
(Supplementary Table S6 are available atHEAPOL online)
Discussion
From an economic perspective, delivering SMC to children up to
10 years of age appears both affordable and sustainable, even within
the highly constrained budgets of West African health systems and
before accounting for savings from reductions in malaria cases. A
cost-effectiveness analysis would provide further information on the
Figure 2. Total economic cost vs the number of courses administered at each
health post. The figure illustrates the variation in the total costs incurred for
SMC administration between health posts. Costs incurred at the district level
are allocated equally across health posts in that district. Research participa-
tion incentives paid directly to head nurses and district health staff for trial
participation are included as they are likely to have led to more assiduous
implementation. The 46 health posts are presented with a different marker for
each of the 4 districts. Dashed line: mean total economic cost per health post
Figure 3. Economies of scale: average economic cost per course adminis-
tered vs the number of courses administered at each health post. The figure
illustrates the variation in the average economic cost per course of SMC
administered between health posts. The upper figure presents data on a
standard arithmetic scale and the lower figure illustrates the same data with
both the x-axis and y-axis presented on a logarithmic scale. Costs incurred at
the district level are allocated equally across health posts in that district.
Research participation incentives paid directly to head nurses and district
health staff for trial participation are included as they are likely to have led to
more assiduous implementation. The 46 health posts are presented with a
different marker for each of the 4 districts. Dashed line: mean economic cost
per course administered across the entire implementation area.









































































value-for-money of extending the recommended age range for SMC
from children under 5 to children under 10 and on decisions regard-
ing where to implement SMC. Two analyses of the cost-effectiveness
of SMC in children under 5 have been based on findings from small-
scale trials: one trial-based analysis used “cost per case averted” as
its outcome metric (Conteh et al. 2010), making its findings difficult
to compare across health conditions, while a later analysis employ-
ing a dynamic transmission model concluded that SMC in children
under 5 is likely to be cost-effective or highly cost-effective relative
to the arbitrary, but fairly conservative thresholds of $150 and $25
(1993 USD) per disability-adjusted life-year averted (Ross et al.
2011). A third analysis estimated the cost per case averted of SMC
for children under 5 for a strategy requiring CHWs to visit each
household on five consecutive days in each of four consecutive
months (Nonvignon 2016). The cost-effectiveness of SMC in chil-
dren under 10 is likely to be highly dependent on the coverage
achieved and the age-specific incidence of malaria, both of which
can be expected to vary significantly between countries, between re-
gions within a country, and over time. We have shown that costs
also vary substantially across health posts and across distribution
rounds; this variation must also be considered in estimating the
likely costs and cost-effectiveness of SMC in other settings. In disag-
gregating SMC costs by the health system level with which they are
expected to vary, we offer a preliminary step towards taking cost
variation into account in future estimates.
Our estimates are lower than those reported in previous analyses
of SMC, which may be attributed to our study’s extended age range,
far larger target population, delivery strategy involving only one
household visit per month, and more limited involvement of re-
searchers in implementation. Previous studies of SMC examined the
costs of delivery only to children up to 5 (or in one case 6) years of
age (Conteh et al. 2010). In our study, increasing the age range for
SMC from under-5s to under-10s virtually doubled the target popu-
lation, however, it only increased the target number of households
to visit by 13%, from 80 to 90% of all households in the area, and
high coverage was maintained in both groups (Ba et al. 2017).
However, the degree to which the lower costs we observed can be
attributed to the extended age range rather than the far larger over-
all target population or other factors remains uncertain. Since our
study, co-blister packs of dispersible SPþAQ have become available,
which may increase tablet costs while potentially reducing CHW
time on administration; these and any other changes to the distribu-
tion strategy would need to be accounted for in estimates of the
likely costs of SMC in other settings.
While we have focussed on the cost per monthly course of SMC
administered as our key outcome measure, other studies of the costs
of SMC have reported the cost per “fully adherent child,” defined as
a child receiving all three (or more) intended courses of treatment.
At $1.50 excluding research incentives (Table 2), the economic cost
per fully adherent child in our study was lower than reported esti-
mates from all other studies, and even somewhat lower than projec-
tions made of the likely costs of delivering SMC at scale. Inflating
costs to 2010 USD to allow some comparison (Bureau of Labor
Statistics 2013), the lowest previously reported cost per fully adher-
ent child of a three-course SMC regimen was $1.66 using CHWs to
deliver SP and AQ in Basse, Gambia (Bojang et al. 2011; Pitt et al.
2011). A study in trial conditions in Hohoe, Volta Region, Ghana
reported the cost per fully adherent child of delivering three bi-
monthly courses of SP alone through CHWs at $8.30, but projected
a cost of $1.74 if distribution were scaled up to the district level
(Conteh et al. 2010; Pitt et al. 2011). In a wide-ranging overview of
malaria control strategies, Goodman et al. (2000) estimated the cost
of seasonal fortnightly chemoprevention with dapsone and pyri-
methamine at $1.79 (90% range $1.40–2.20) using an existing
CHW network, but requiring parents to take their children to the
health centre. Estimates were substantially higher for the four-
course strategies studied in Jasikan, Volta Region, Ghana
(Patouillard et al. 2011; Pitt et al. 2011) and in Ghana’s Upper West
Region (Nonvignon 2016), and for the three- and six-course strat-
egies employing artesunate (AS) with AQ in Hohoe (Conteh et al.
2010; Pitt et al. 2011). The “fully adherent child” metric includes
the full cost of all the doses of SMC which were administered, but
not the benefits derived by children who were protected from mal-
aria with fewer than the intended number of courses of SMC. Given
the highly mobile nature of populations both in the study area and
in other areas where SMC is likely to be of benefit, children may
have missed doses because they were away from the area and there-
fore either not exposed to malaria or potentially able to receive
SMC elsewhere if it were more widely available (Ba et al. 2017).
Although the transferability of costs across contexts depends on
many factors (Vassall et al. 2016), our financial cost estimate of
$1.22 per fully adherent child ($1.50 including research participa-
tion incentives) is within the range of costs associated with deliver-
ing other malaria prevention interventions. A systematic review
reported a median financial cost per year of protection with ITNs at
$2.20 (range $0.88–9.54, constant 2009 USD), with IRS at $6.70
(range $2.22–12.85), with IPT in infants at $0.60 (range $0.48–
1.08), and with IPT in pregnant women at $2.06 (range $0.47–3.36)
(White et al. 2011). The financial cost of school-based IPT has
been reported at $1.20 (constant 2006 USD) per child per year
(Temperley et al. 2008) and school-based intermittent screening and
treatment has been reported to cost $6.61 per child per year (con-
stant 2010 USD) (Drake et al. 2011).
Our findings of substantial economies of scale represent an im-
portant contribution to a very limited evidence base on cost vari-
ation in health service delivery in low- and middle-income countries,
particularly at the primary health care and community level and out-
side the HIV field (Brooker et al. 2008; Fiedler et al. 2014; Siapka
et al. 2014). Consistent with previous studies of HIV prevention in
India (Guinness et al. 2007; Lépine et al. 2015; Lépine et al. 2016)
and of school-based albendazole distribution in Uganda (Brooker
et al. 2008), we found that average costs exhibited an L-shape, and
found no evidence in our sample of a point at which average costs
would begin to increase, generating the U-shape predicted in eco-
nomic theory. While our statistical analysis remains descriptive and
was limited by the small number of data points and possibly by the
trial context and other factors, the 46 health facilities we analysed
constitute a relatively large dataset in the context of health facility
costings. Our findings may be particularly relevant for other CHW
mass distribution campaigns, such as deworming tablets and vitamin
A, and for integrated community case management programmes, for
example. They also have wider implications for the organization of
the health system; many factors, such as accessibility, must be con-
sidered in deciding on the location and catchment size of health
facilities, however, our findings demonstrate the substantially higher
costs per person reached incurred by health posts with very small
catchment areas.
Although appropriate to our study, the incremental nature of
our analysis means that the existence of a functioning health system,
including a network of CHWs, is assumed. In contexts where, for
example, head nurses cannot easily call upon a group of CHWs for
distribution campaigns, where the head nurses themselves are ab-
sent, or where districts lack the capacity to coordinate training and
distribution of incentives, medicines, and materials, additional









































































resources would need to be invested to address or circumvent these
gaps. In this way, SMC could provide an opportunity to strengthen
health systems and especially CHW networks, but doing so would
involve greater costs than reported here.
Furthermore, we have not included the costs of pharmacovigi-
lance, ongoing programme evaluation, and national-level coordin-
ation, which are important aspects of SMC implementation and will
need to be included in programme budgets. As in all such analyses,
our data may also include errors or omissions, however, our exten-
sive triangulation and comparisons across health facilities allowed
us to correct discrepancies which might not have otherwise been de-
tected. Nonetheless, collecting data on health worker time use,
which accounted for most of the additional economic costs, is par-
ticularly challenging, and may have been subject to bias or
misreporting.
Finally, while we adhered to standard practice in calculating the
economic costs of health worker time based on their salaries, it is very
unlikely that any health worker’s salary represents their value to soci-
ety, especially where they are so exceedingly scarce. Valuable health
worker time should be used as efficiently as possible, taking into ac-
count the negative effects of nurses frequently absenting themselves
from health posts to attend meetings at district level and to supervise
CHWs in door-to-door campaigns. Strong national and district-level
leadership is therefore required to bring together national child health
and disease control teams to limit the total number of off-site training
and campaign days each year. Similarly, the availability and supply of
CHWs is not infinite. In our context, the value of incentive payments
to CHWs were higher than what many CHWs could otherwise have
earned, but that does not mean that they would necessarily continue
to be willing to implement many more additional campaigns each
year. Opportunities may exist to achieve economies of scope by com-
bining SMC with delivery of other interventions, such as mass distri-
bution of ITNs, health communication, or neglected tropical disease
programmes; however, careful consideration and discussion with all
levels of health workers will be required to ensure that additional
interventions are genuinely compatible and do not cause diseconomies
of scope by unduly increasing complexity.
Conclusion
Even in the context of a highly constrained health system, door-to-
door delivery of SMC by CHWs to children under ten is likely to be
affordable, especially if it averts substantial costs of curative care.
We identified substantial variation in the cost of delivering SMC to
children in Senegal, which contributes to a very limited evidence
base on variation in provider costs. Both cost variation and the com-
parability of local health system characteristics must be accounted
for in assessing the transferability of our findings to other settings.
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5.1.1. Abstract  
 
Introduction: In areas of generally very low malaria transmission, incidence tends to be 
patchy, with highly localised “hotspots”. We compared the costs and effects of geographically 
targeted strategies using dihydroartemisinin-piperaquine in hotspot villages for two rounds of 
either mass screening and treatment (MSAT) or mass drug administration (MDA), both with 
and without the addition of indoor residual spraying (IRS) with Actellic 300CS. 
Methods: We conducted an economic evaluation alongside a three-arm cluster-randomized 
controlled trial conducted over two years in a population of ~577,000 persons in rural, central 
Senegal, where malaria is highly seasonal. Prospective micro-costing was used to inform a 
model, which estimated costs of implementation across the entire study area (base case) and 
with different degrees and levels of targeting and number of implementation rounds (cost 
scenarios). Using a decision tree, we modelled the cost-effectiveness of seven alternative 
intervention strategies from a societal perspective over a lifetime horizon with a 3% discount 
rate, accounting for impacts in both hotspot and non-hotspot villages. We used probabilistic 
and deterministic sensitivity analysis and identified the cost-effectiveness frontier and 
expansion path.  
Results: Average economic costs per recipient per round were $1.99 for targeted IRS, $0.82 for 
targeted MSAT, and $1.57 for targeted MDA (constant 2018 United States Dollars). Per 10,000 
population (across hotspot and non-hotspot villages), total annual costs of targeted IRS 
($7,135) were highest, followed by MSAT ($5,368), MDA ($10,048), and hotspot identification 
($75). Compared to the reference strategy, which closely resembled standard practice, 
targeted MSAT alone cost an additional $9,839 (95% CI: $4,939 to $34,054) per disability-
adjusted life-year (DALY) averted; compared to targeted MSAT, targeted IRS+MSAT cost a 
further $10,221 ($5,597 to $32,423) per DALY averted; and compared to targeted IRS+MSAT, 
targeted IRS+MDA cost a further $36,203 ($13,084 to $121,785) per DALY averted. The 
remaining three strategies evaluated were dominated. Plausible changes in drug, test, and 
insecticide prices would alter the expansion path, as would inclusion of side effects of MSAT 
and MDA in analysis.  
Conclusions: In comparable contexts, the specific combinations of hotspot interventions 
evaluated in this trial are unlikely to lead to elimination in the near term and are not cost-
effective as disease control measures. Our cost model demonstrates economies of scale and 
diseconomies of targeting and can inform decisions regarding the deployment of IRS, MDA, 
and MSAT in different contexts.   
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5.1.2. Introduction 
 
In areas where malaria transmission is generally low, transmission also tends to be patchy, 
with highly localised “hotspots” and other areas with minimal or virtually no transmission. In 
such transmission contexts, malaria elimination is considered possible if standard malaria 
control activities are supplemented with additional, intensive interventions (WHO, 2017a). If 
no more than a few cases per week are reported at each health facility, the World Health 
Organization (WHO) recommends investigation of each malaria case and reactive 
interventions, such as indoor residual spraying (IRS), focal screening and treatment, or focal 
drug administration, in the immediate vicinity of the incident case (WHO, 2017a). In other 
areas, where malaria incidence is low but not low enough for reactive interventions to be 
feasible, WHO recommends ensuring universal coverage of core interventions (e.g. bed nets) 
and considering additional, intensive, population-wide control measures, such as mass drug 
administration (MDA), mass screening and treatment (MSAT), and/or intensified vector control 
to accelerate reductions in transmission (WHO, 2017a). Spatial and temporal clustering of 
cases means, however, that timely case investigations may not be feasible even in areas 
broadly classified as “very low transmission”, while population-wide intensive interventions in 
such settings may be inefficient and expose many people to unnecessary risks and discomfort. 
In these patchy, low transmission settings, geographical targeting at a local level (in localised 
“hotspots”) of MDA or MSAT, potentially in combination with IRS, may be an effective and 
efficient approach to reduce transmission.  
A WHO Evidence Review Group  identified only one randomized trial of a strategy in which 
MDA or MSAT were focused on malaria hotspots (WHO Evidence Review Group, 2015a, Newby 
et al., 2015, Bousema et al., 2016). Conducted in a low-transmission setting in highland Kenya, 
the trial found that combining targeted MSAT, IRS, bed nets, and larviciding in hotspots 
reduced parasite prevalence within but not outside hotspots and did not interrupt 
transmission (Bousema et al., 2016). More recently, evidence has emerged from a three-arm, 
cluster-randomized trial in a highly seasonal, low transmission setting in central Senegal. In 
that trial, two different hotspot strategies reduced malaria incidence substantially both in the 
hotspot villages in which they were implemented and in non-hotspot villages in which they 
were not implemented (Diallo et al., 2020). Nonetheless, the incidence reductions – which 
averaged 43% (95% CI: 35%, 50%) for MSAT with IRS and 48% (95% CI: 40%, 54%) for MDA with 
IRS across the hotspot and non-hotspot villages – did not achieve the original aim of “virtual 
elimination”. The trial team concluded that hotspot strategies may have the potential to 
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contribute to elimination if implemented more intensively than in the trial, with more rounds 
of MDA, possibly in combination with MSAT and IRS. 
Maximizing the impact of resources to tackle malaria requires understanding the efficiency of 
alternative policy choices; however, no empirical evidence on the efficiency or costs of a 
hotspot strategy involving MDA or MSAT has previously been published. Even empirical 
evidence on the costs of MDA and MSAT delivered as blanket strategies is scarce. When WHO 
reviewed the costs of (targeted and blanket) MDA for malaria, cost data were identified in only 
one published study (regarding 720 people in Vanuatu) and two unpublished studies 
(regarding Sierra Leone during the Ebola emergency and the Comoros islands) (WHO Evidence 
Review Group, 2015b). Cost estimates for related interventions, including seasonal malaria 
chemoprevention (effectively MDA restricted to children under 10) in central Senegal (Pitt et 
al., 2017) and MDA for various neglected tropical diseases in India (Krishnamoorthy et al., 
2002), Sudan (Kolaczinski et al., 2011), and Kenya (Pullan et al., 2019), vary widely. For MSAT 
for malaria, three dry-season rounds in a moderate transmission area in Zambia were 
estimated to cost $804 (2012 USD) per disability-adjusted life-year (DALY) averted, which the 
authors judged “highly cost-effective” (Silumbe et al., 2015). Evidence on the costs and cost-
effectiveness of IRS is more extensive (Conteh et al., 2004, Goodman et al., 2001, Guyatt et al., 
2002, Faraj et al., 2016, Yukich et al., 2008), but does not address IRS’s added value when 
combined with MDA or MSAT and older studies do not address the higher costs of next 
generation insecticides.  
While empirical evidence is scarce, a modelling study predicted how the efficiency of different 
combinations of malaria interventions, including MDA, MSAT and IRS, may vary across Africa, 
and the savings that could be achieved by targeting intervention packages to provinces or 
5km2 land areas (Walker et al., 2016). Other researchers have proposed a geographic resource 
allocation framework based on cost-effectiveness (Drake et al., 2017). And IRS (Protopopoff et 
al., 2007), like larviciding (Worrall and Fillinger, 2011) and many other malaria interventions 
(Carter et al., 2000), is usually targeted to areas considered at higher risk, so economic 
evaluations of such vector control strategies nearly always assess geographically targeted 
interventions. None of these malaria studies, however, nor others we are aware of, have 
described or accounted for how the average cost per person reached may vary with the type 
and extent of targeting. Studies of the efficiency of targeting social interventions (Dutrey, 
2007), vitamin A supplementation (Loevinsohn et al., 1997), and HIV prevention (Wilson et al., 
2005) emphasize the costs of the targeting process itself, as well as the imperfect sensitivity 
Chapter 5.    Local geographic targeting of malaria hotspot strategies  -  Page 80 of 216 
and specificity of targeting. The reductions in scale of targeted relative to blanket interventions 
also mean that intervention costs incurred at regional, district, and health facility level may be 
divided across fewer recipients than a blanket intervention. This combination of additional 
costs of identifying the target and diseconomies of reduced scale mean that there are likely to 
be diseconomies of targeting malaria interventions, that is, higher average costs per person 
reached than blanket strategies. These diseconomies of targeting may have important 
implications for understanding the efficiency of targeted and blanket strategies, especially 
when considering targeting interventions at increasingly fine spatial scales (Stresman et al., 
2019, Kabaghe et al., 2018).  
To address some of these research gaps and inform malaria policy, we conducted an economic 
evaluation alongside the hotspot trial in Senegal. For our economic evaluation, we first sought 
to inform the design and planning for other geographically targeted intervention packages by 
developing a flexible cost model, populated with data from the trial and secondary sources, to 
estimate how the costs of geographically targeted MSAT, MDA, and IRS could be expected to 
vary with implementation choices and context. Secondly, given the substantial relative 
incidence reductions achieved, we sought to determine whether the intervention packages 
implemented in the trial could be considered cost-effective as disease-burden reduction 





The trial population comprised the ~587,000 people (in 2014) living in the catchment areas of 
the 46 rural health posts in Mbour, Fatick, Bambey and Niakhar districts. When baseline data 
were collected in 2012, parasitaemia prevalence (1.9% by microscopy) and annual malaria 
incidence (11 cases per thousand person-years at risk) were low, having fallen dramatically in 
the preceding decade, and malaria was also highly seasonal, with 86% of cases occurring from 
September to December each year (Diallo et al., 2020). From 2008 to 2012, 80% of all malaria 
cases were concentrated in <40% of villages each year, indicating substantial geographical 
heterogeneity in local malaria transmission (Diallo et al., 2020).  
Health posts are the key primary health care facilities throughout Senegal; they are led by a 
head nurse, who also supervises a network of community health workers (CHWs), and reports 
to a district health management team. Both testing and treatment with artemisinin 
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combination therapy are meant to be free of charge in public facilities; however, the initial 
consultation costs ~$0.17 (100 XOF) for children or $0.34 (200 XOF) for adults, with fee waivers 
intended for the poorest. Standard malaria control measures in central Senegal at the time of 
the trial included requiring parasitological confirmation in health facilities before treatment 
with artemisinin combination therapy (artemether-lumefantrine as first-line treatment), 
intermittent preventive treatment of malaria in pregnancy, mass LLIN distribution campaigns 
(in Fatick, Bambey, and Niakhar in 2011 and in Mbour in 2013), free LLIN top-ups for pregnant 
women at antenatal clinics, and subsidised LLINs available for purchase at health facilities 
(JHBSPH, 2015). In the 2012 baseline survey, 61% of the study population surveyed had slept 
under a bed net the previous night (Diallo et al., 2020). Senegal’s life expectancy at birth was 
estimated at 67 years for 2016 (WHO, 2019b). With a gross domestic product of $1,522 per 
capita in 2018, Senegal is a lower-middle-income country (World Bank, 2019) whose malaria 
budget is financed primarily by the United States’ President’s Malaria Initiative and the Global 
Fund (WHO, 2018d).  
Study design and comparators 
The trial was designed to compare two multi-component, village-based targeting strategies 
(n=15 clusters each) and a reference strategy (n=10 clusters), over two malaria seasons (2013-
14) (Figure 3) (Diallo et al., 2020). Clusters had a mean population (in 2014) of 14,682 people. 
Most clusters comprised a single health post catchment area, but 6 health posts with smaller 
catchment populations were merged with an adjacent catchment area to form clusters. As 
villages varied widely in population size, clusters comprised between 6 and 69 villages. 
In the reference strategy, which closely resembled standard practice, in addition to standard 
malaria control measures described above, radio messages encouraged care-seeking for fever 
and the small number of people confirmed to have malaria in public health facilities was 
provided with a long-lasting insecticide-treated bed net (LLIN) to top up coverage. Intervention 
strategies comprised all elements of the reference strategy plus additional activities.  
Hotspot villages were identified by tallying by village the number of RDT-confirmed malaria 
cases passively detected in health facilities in the previous malaria season. To ensure balance 
between hotspot and non-hotspot villages within each cluster for research purposes, clusters 
were stratified by incidence. Geospatial analysis was used to develop an algorithm by which 
hotspots were defined as villages with 3 or more cases in the previous June-September (for 
villages associated with health posts in the slightly higher incidence stratum), or 4 or more 
cases in the previous June-December (for villages associated with health posts in the lower 
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incidence stratum). Researchers reviewed the health facility records to identify hotspots in the 
trial; however, the algorithm was designed to be straightforward to implement by head nurses 
in collaboration with district staff based on data in existing clinical registers. In 2013 and 2014, 
55% and 56% of study area residents, respectively, lived in villages declared “hotspots”.  
Figure 3 Trial structure 
Population figures and numbers of villages are estimates for 2014, the second year of the trial. The classification of 
hotspot and non-hotspot villages was redone each year, so the number of hotspot and non-hotspot villages within 
each arm (and their associated populations) were different in 2013. Case management in the trial encompassed 
both standard diagnosis with parasitological confirmation, and also additional radio messages to encourage care 
seeking and provision of a LLIN if needed for anyone diagnosed with malaria. LLIN: Long-lasting insecticide-treated 
bed net; IPTp: Intermittent preventive treatment of malaria in pregnancy; MDA: Mass drug administration; MSAT: 




In July and August each year, residents of hotspot villages were meant to receive IRS with 
Actellic 300CS, a non-pyrethroid “next generation” insecticide. In September and October, 
CHWs conducted two rounds of door-to-door visits in hotspot villages to offer either MSAT or 
MDA depending upon the trial arm. In MSAT clusters, the CHWs offered RDTs to all persons 
aged over three months and treated anyone with a positive test result with DP, except for 
pregnant women and those with a known allergy, who were referred to a health facility. In 
MDA clusters, the CHWs offered DP to all persons aged over three months except pregnant 
women and those who were ill, taking other medications, or known to be allergic to 
antimalarials. The trial was thus designed to compare the effects in both hotspot and non-
hotspot villages of implementing IRS+MDA in hotspots, IRS+MSAT in hotspots, and the 
reference strategy, without determining the added value of IRS as part of the intervention 
strategies. In 2013, however, logistical problems in obtaining the insecticide meant that only 
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23% of households in the hotspot villages received IRS (i.e. 12% of all households in the 
intervention clusters), and the quality of spraying was low, with a 24-hour mosquito mortality 
rate of just 37% after four months (Diallo et al., 2020); we refer to this as “LowIRS”. In 2014, 
IRS reached 66% of households in hotspot villages in the two intervention arms, and additional 
training improved the quality of spraying, resulting in mosquito mortality rates of 82% after 
four months.   
For our cost-effectiveness analysis, we assumed that policy makers would want to consider 
implementing either MSAT in hotspots or MDA in hotspots, either with IRS at the 66% 
coverage that was achieved in our study (“IRS”) or without any IRS (“NoIRS”). While we assume 
policy makers would not choose to implement LowIRS, we include it in our analysis because 
the trial produced robust estimates of the effectiveness of this combination of interventions, 
whereas “NoIRS” strategies had to be modelled from trial data on implementation of LowIRS 
and IRS. Inclusion of LowIRS strategies also provides valuable information on the consequences 
of failure to achieve good IRS coverage and of the relative contribution of IRS to the 
effectiveness achieved by IRS+MSAT and IRS+MDA. We therefore compared seven alternative 
hotspot intervention strategies: the reference strategy (i.e. none of the intensive hotspot 
interventions, close to standard practice), IRS+MSAT, IRS+MDA, LowIRS+MSAT, LowIRS+MDA, 
NoIRS+MSAT, and NoIRS+MDA (Figure 4Error! Reference source not found.). 
Figure 4 Decision tree 
For simplicity, the full decision tree is only shown for the reference strategy. The pathway is identical for each of the 





















Chapter 5.    Local geographic targeting of malaria hotspot strategies  -  Page 84 of 216 
 
Costs 
We first estimated costs to the provider of each intervention (hotspot identification, IRS, 
MSAT, and MDA) and the societal costs (i.e. costs to the provider and to households) of 
passively detected cases. We assumed that receipt of interventions (at home or nearby) would 
not incur meaningful household costs. We then combined the intervention costs to estimate 
the societal costs of each of the seven strategies (Figure 4Error! Reference source not found.). 
We focus on economic costs, which reflect the full value (opportunity cost) of resources used, 
even if they did not require direct payment, such as donated drugs or the time of existing 
health workers; however, we also estimate financial costs to the provider, which represent 
expenditure and are useful for budgeting and assessing affordability.  
The costs of identifying hotspots and of implementing targeted IRS, MSAT, and MDA were 
estimated through prospective micro-costing of the activities in 2014. We gathered data on 
resource use, costs, and outputs from project accounts, project administrative records, 
Ministry of Health records, international reference price lists, and a series of questionnaires. 
These questionnaires were administered after the single IRS round and each round of MSAT 
and MDA to districts, health posts, and IRS coordinators; data were entered in MS Access and 
analysed in Excel. For internationally traded goods (Hutton and Baltussen, 2005), notably 
insecticide, RDTs, antimalarials, and LLINs, international market prices were used, even where 
goods were donated for research purposes or subsidized. 
Research costs were excluded. We included the costs of health worker time needed to identify 
hotspots but excluded the development and validation of the algorithm as a research cost. 
While data on the previous year’s malaria cases were gathered and analysed in the entire 
study area to identify hotspots, the costs of hotspot identification in the reference arm were 
excluded as a research cost. Where research staff contributed directly to the implementation 
of interventions, such as supervision or participation in planning meetings, the value of their 
time has been included; similar external support would be expected outside a trial context. 
Separately, we also report on the incentive payments made to health service staff, which were 
intended to support research but likely contributed to more assiduous implementation of the 
interventions. 
We developed a simple, flexible, and transparent mechanistic cost model to predict how 
provider costs for the four interventions could be expected to vary with changes to 
intervention characteristics and context, as well as input prices. This model reflected the cost 
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data collected and our understanding of how the interventions were implemented in the trial 
and could be implemented in future. We disaggregated costs by round and by the level of the 
health system (country, district, health post, CHW) or output (persons reached per round) with 
which those costs would be expected to vary approximately linearly (see Section 5.2). As a 
base case, we modelled the costs of implementing each intervention in the entire study area 
(which comprises all rural catchment areas of the 4 districts). This modelling remained close to 
what was observed in the trial, but reduced differences in costs between strategies that were 
driven by differences in contextual factors and removed the inherent inefficiencies of 
implementation in a trial context. For the base case, we also estimated the costs of “LowIRS”.  
In further scenarios, we used a somewhat stylised version of our population to model how 
costs of implementing the interventions could be expected to vary with the degree of targeting 
(proportion of the study area population targeted: 100%, 50%, 20%), with the level of the 
targeting unit (village-based targeting as implemented in the trial or district-based targeting), 
and with the number of consecutive implementation rounds (2, 4). Such modifications to the 
intervention could be considered to respond to different epidemiological contexts, to reduce 
costs, and/or to increase effectiveness relative to the strategies implemented in our trial.  
In the cost-effectiveness analysis, the societal cost of illness and case management was 
estimated by combining primary and secondary data on the cost per case (based on local 
protocols and practice) with the number of uncomplicated and severe cases estimated in the 
cost-effectiveness model (Table 2). We assumed that the cost per case treated, whether 
uncomplicated (requiring only outpatient treatment) or severe (requiring hospitalisation), 
would be the same across study arms.  
Costs were inflated to 2018 values using the consumer price index for the relevant currency 
(Kumaranayake, 2000) and converted to United States dollars (USD) using the average 2018 
exchange rate (World Bank, 2019, Hutton and Baltussen, 2005). Economic costs to the provider 
in the base case scenario are presented for each intervention by activity and by cost driver, 
and for each strategy by intervention. Total economic and financial costs of each intervention 
in the base case, actual implementation in the trial, and ten further scenarios are presented 
per 10,000 population – including both residents of hotspot and non-hotspot villages and 
those who did and did not receive the interventions – to provide a more useful basis of 
comparison than the total study population. For each intervention, average economic costs 
per recipient of that intervention per round are also presented in the base case, actual 
implementation, and ten further scenarios to explore diseconomies of targeting. To indicate 
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potential budget impact, we compared total financial costs per capita with average per capita 
public expenditure on malaria (WHO, 2018d) and on health in Senegal (WHO, 2019a). 
Cost-effectiveness analysis 
We developed a decision analytic model to combine trial and secondary data to estimate 
economic costs and effects of each of the seven strategies for the entire study area from a 
societal perspective. We modelled implementation over a 1-year period and included the 
consequences of any malaria episodes in that year over a lifetime horizon. This short-term 
approach was considered appropriate because the pre-elimination strategies evaluated are 
not intended as a policy to be implemented indefinitely (and are not expected to be 
considered socially or politically acceptable if continued long-term), but rather as interim 
measures to reduce incidence sufficiently for case investigation and reactive interventions to 
become feasible. Further, they were not found to involve any “start-up” costs; all activities 
would need to be repeated each year. Our analysis was conducted and reported in accordance 
with the CHEERS checklist (Husereau et al., 2013) and reference cases for economic evaluation 
(Wilkinson et al., 2016) and for costing (Vassall et al., 2017). 
We plotted the costs and effects of each of the seven strategies on the cost-effectiveness 
plane, identified the cost-effectiveness frontier and expansion path, and calculated 
incremental cost-effectiveness ratios (ICERs) between adjacent points on this path. The cost-
effectiveness frontier is defined by the set of economically efficient strategies; it excludes 
inefficient strategies, which are said to be “dominated” because they are less effective and 
more costly than a single alternative strategy (“strict dominance”) or a combination of 
alternative strategies (“extended dominance”). The expansion path connects strategies on the 
cost-effectiveness frontier from least to most effective and costly. The expansion path 
therefore indicates the order in which strategies should be considered for adoption given 
increasing availability of resources. To facilitate interpretation, we present all findings per 
10,000 population.  
To explore the robustness of our finding to uncertainty and heterogeneity, including plausible 
variation in other relevant contexts, we conducted both deterministic and probabilistic 
analyses. One-way deterministic sensitivity analyses are presented on separate cost-
effectiveness planes for each parameter explored. Unlike tornado diagrams, which can only 
compare two strategies, use of cost-effectiveness planes allow illustration of the sensitivity or 
robustness of the expansion path – i.e. the order in which strategies should be considered for 
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We used Monte Carlo simulation to reflect the combined impact of uncertainty in stochastic 
parameters on our ICER estimates. Distributions were selected to be consistent with our 
understanding of the logical bounds and shape of each parameter: beta distributions for 
proportions; gamma distributions for durations and costs, which are non-negative and right-
skewed; and normal distributions for rates, rate ratios, and discounted YLLs. While the latter 
parameters cannot take on negative values, which a normal distribution may allow, the very low 
standard deviations made negative draws very unlikely in practice and normal distributions have 
the benefit of reflecting the symmetrical shape of the distributions and the potential to take on 
values >1. We calculated mean costs and effects for each of the seven strategies across 10,000 
iterations and used percentiles to generate 95% confidence intervals for each ICER estimate. To 
centre our plot on the cost-effectiveness plane at the origin and reflect uncertainty relative to the 
reference strategy, we calculated the incremental costs and effects of each intervention strategy 
relative to the reference strategy for each of the 10,000 iterations and generated scatter plots. 
We present cost-effectiveness acceptability curves (Fenwick et al., 2001) to indicate the 
probability of each strategy being cost-effective at plausible and widely used cost-effectiveness 
thresholds (Ochalek et al., 2018, Marseille et al., 2015) (also see Section 6.1.7. Annex 2). Analyses 
were conducted in Microsoft Excel with Visual Basic for Applications.  
Effects 
Our primary cost-effectiveness analysis is of the incremental cost per DALY averted, which allows 
our findings to be compared with alternative uses of these resources to address any health 
condition. We also estimate the incremental cost per malaria case averted to permit comparison 
with existing malaria literature and with epidemiological data, in which incidence is a common 
endpoint and subject to less uncertainty than DALY estimates.  
The number of malaria cases expected under each strategy is estimated as the product of the 
simulated population size, the incidence in the reference arm of the trial, and the incidence rate 
ratio of the relevant intervention arm relative to the reference arm. Because incidence data were 
not available for 2015, incidence measures were restricted to the 4-month malaria seasons 
(September – December) in 2013 and 2014. This restriction assumed that the interventions did 
not affect incidence in the following 8 months, which may slightly underestimate the number of 
cases averted. The approach also assumes that the incidence rate ratios of each intervention 
strategy relative to the reference strategy were independent of the incidence in the reference 
arm, within the range seen in our study of 14.3 (in 2014, used as base case) to 29.4 (in 2013, used 
in sensitivity analysis) cases per thousand person-years at risk within the malaria season. In 
reality, lower relative impact would be expected at higher transmission intensity. To estimate the 
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incidence rate ratios for NoIRS+MSAT and NoIRS+MDA relative to the reference strategy, which 
were not measured in the trial, we took a simple but conservative approach, which assumed that 
they would be less effective than LowIRS+MSAT and LowIRS+MDA, respectively. We assumed that 
this loss of effectiveness would be a linear function of the product of efficacy and coverage based 
on data for 2013 and 2014, as detailed in Annex 1 (Section 5.1.6.).    
Every one hundred malaria cases were assumed to generate the same number of DALYs, on 
average, regardless of study arm (Table 1, Section 5.1.6.). Total years of life lost (YLLs) and years 
of life with disability (YLDs) were summed to generate the DALY estimate for each strategy. The 
number of confirmed malaria cases, severe cases, and malaria-related deaths were obtained from 
passive surveillance data from all health facilities and CHWs providing malaria treatment across 
the study area. The proportion of all confirmed cases that became severe and the proportion of 
all severe cases that result in death were estimated across the entire study area because of the 
small numbers involved. For each of the 15 people who died from malaria in our study area across 
both years, we used life tables and age at death to estimate the individual’s remaining life 
expectancy, which we discounted at 3% (in the base case) with no age weighting to generate the 
discounted YLLs for each death. We then used the mean and s.d. of discounted YLLs per death to 
generate a distribution for the number of YLLs associated with each death in our model. 
Remaining life expectancy at death was taken from life tables for Senegal, which represent the 
real opportunity cost in this context, and sensitivity analysis presented results based on Japanese 
life expectancy, which represents a theoretical maximum (WHO, 2019b). As is standard for 
malaria interventions, YLDs comprised only 1.3% of DALYs in our model. They were calculated 
separately for uncomplicated and severe cases as the product of the number of cases of malaria 
in each arm, the probability of becoming severe, the average duration of a case, and the disability 
weight (Salomon et al., 2015) for infectious disease (moderate or severe). Long-term sequelae 
were not included but were not expected to substantially alter overall DALY estimates.  
In deterministic sensitivity analysis, we considered how including in DALY estimates the adverse 
events associated with receipt of MSAT and MDA by persons who were not ill affected relative 
effectiveness and cost-effectiveness. Adverse events included widespread minor complaints, such 
as dizziness (MDA) and finger pain (MSAT), and a child’s death following MDA in 2013 (Section 
6.1.7. Annex 2). 
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Our probabilistic base case cost-effectiveness model indicated that the reference strategy would 
result in the most malaria cases, 48 per 10,000 residents in the malaria season (95% CI, 46 to 50), 
followed in descending order by NoIRS+MSAT (39, 35 to 42), LowIRS+MSAT (35, 31 to 39), 
NoIRS+MDA (32, 29 to 35), LowIRS+MDA (30, 26 to 33), IRS+MSAT (27, 23 to 31), and IRS+MDA 
(25, 21 to 29), the most effective strategy (Table 3Error! Reference source not found.). As disease 
progression parameters were assumed constant across intervention strategies, the numbers of 
cases and DALYs averted displayed the same relationships across the seven strategies (Table 
3Error! Reference source not found.).  
Table 3 Deterministic and probabilistic estimates of total effects and total costs of the 7 strategies 
DA: Deterministic analysis. Mean probabilistic estimates and deterministic estimates are virtually identical 
 








Strategy Mean 95% CI Mean 95% CI Mean 95% CI 
Reference 48 48 (46, 50) 2.79 2.78 (0.9, 4.7)     1,185  1,186 (958, 1,448) 
NoIRS+MSAT 39 39 (35, 42) 2.26 2.25 (0.74, 3.84)     6,404  6,401 (5,122, 7,833) 
LowIRS+MSAT 35 35 (31, 39) 2.05 2.05 (0.67, 3.49)     9,287  9,286 (7,826, 10,886) 
IRS+MSAT 27 27 (23, 31) 1.59 1.58 (0.52, 2.72)   13,253  13,254 (11,093, 15,566) 
NoIRS+MDA 32 32 (29, 35) 1.88 1.87 (0.61, 3.19)   10,920  10,928 (8,588, 13,593) 
LowIRS+MDA 30 30 (26, 33) 1.75 1.74 (0.57, 2.98)   13,837  13,846 (11,392, 16,563) 
IRS+MDA 25 25 (21, 29) 1.46 1.46 (0.47, 2.5)   17,878  17,889 (14,965, 21,060) 
 
Costs  
Costs of implementing geographically targeted interventions 
Our base case mechanistic modelling of intervention costs throughout the study area indicated 
that the total economic costs of MDA were the highest of the geographically targeted 
interventions at $10,048 (constant 2018 USD) per 10,000 residents, followed by IRS at $7,135, 
MSAT at $5,368, LowIRS at $2,972, and the identification of hotspots at just $75 per 10,000 
residents (Figure 5, Table 4). The average costs of MDA and MSAT were $1.57 and $0.82 per 
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recipient per round, respectively, while IRS and LowIRS cost $1.99 and $2.39, respectively, per 
person living in a household that was sprayed (Table 4). 
Figure 5 Total intervention costs by activity and driver 
Total economic costs per 10,000 population are presented for the base case scenario. Costs of case management reflect 
incidence in the reference arm. IRS: Indoor residual spraying; MDA: Mass drug administration; MSAT: Mass screening 
and treatment. 
 
Table 4 Total economic costs of Hotspot ID, IRS, MSAT, and MDA: as implemented in trial and base case analysis 
In the trial, 36% of intervention arm residents received IRS, 33% of MSAT arm residents received MSAT, and 32% 
received MDA, which is reflected in the “Implementation in trial” and base case. The 10 cost scenarios indicate the 
proportion of people targeted, and the proportion of people targeted who are reached matches the trial: 66% IRS, 55% 
MSAT, and 66% MDA. HP: Health post.  
  HOTSPOT INTERVENTIONS 
Total economic costs per 10,000 population Hotspot ID IRS MSAT MDA 
Implementation in trial $73 $7,326 $5,935 $11,183 
CEA BASE CASE: 2 rounds targeted MSAT/MDA across all health posts $75 $7,135 $5,368 $10,048 
CEA BASE CASE (LowIRS): As above except lower IRS coverage $75 $2,972 $5,368 $10,048 
Average economic cost per recipient per round Hotspot ID IRS MSAT MDA 
Implementation in trial NA $2.05 $0.91 $1.75 
CEA BASE CASE: 2 rounds targeted MSAT/MDA across all health posts NA $1.99 $0.82 $1.57 
CEA BASE CASE (LowIRS): As above except lower IRS coverage NA $2.39 $0.82 $1.57 
Mean number of intervention recipients (per 10,000 
populatio) per round 
Hotspot ID IRS MSAT MDA 
Implementation in trial NA 159,135 70,231 73,236 
CEA BASE CASE: 2 rounds targeted MSAT/MDA across all health posts NA 210,247 191,692 187,532 
CEA BASE CASE (LowIRS): As above except lower IRS coverage NA 72,930 191,692 187,532 
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Differences in MDA and MSAT costs were driven primarily by differences in the costs of RDTs, DP, 
and CHWs (Figure 5). The DP tablets ($8,619) accounted for 86% of MDA costs, while RDTs 
($2,118) and DP ($112) together accounted for 42% of MSAT costs. Total payments to CHWs were 
3.3 times greater for MSAT ($1,800) than for MDA ($551) primarily because far more CHW-days 
were required; pairs of CHWs provided MDA to a mean of 132 people per day, compared with 48 
people per day for MSAT. CHWs providing MSAT were also paid 17% more per day than CHWs 
providing MDA to account for their more complex tasks. MSAT took substantially longer to deliver 
because of the additional time necessary to administer and wait for the results of each person’s 
test and then treat positive cases, and because people had greater concerns about MSAT and 
therefore required more time for discussion. Coverage of MSAT (55% of people targeted) was also 
lower than of MDA (66%), which reduced the total costs of consumables. The insecticide, Actellic 
300CS ($4,441), accounted for 62% of IRS costs, while other resources used in door-to-door 
delivery, including spray teams and local transport, accounted for 25% ($1,793).  
Scenario analyses with our cost model (Figure 6) indicated that reducing the proportion of the 
population targeted would decrease total costs of IRS, MSAT, and MDA, but increase the average 
cost per person reached. Under the district-based targeting, the increase in average costs per 
person reached when moving from 50% to 20% of the population targeted was almost 
imperceptible; however, for the finer scale, village-based targeting strategy, the increase in 
average costs per person reached was substantial. For a given intervention and number of rounds, 
village-based targeting always costs more than district-based targeting in total and on average; 
however, the differences become wider as the proportion of the population targeted decreases. 
Furthermore, in devising an intervention strategy, the costs of identifying hotspot villages – 
though very low in our context – would need to be added to any village-based targeting strategy, 
whereas no additional resources would be needed in our context to identify higher incidence 
districts for a district-based targeting strategy, because these data are already routinely collected 
and analysed. Increasing the number of implementation rounds would increase total costs, but 
slightly reduce the cost per person reached because subsequent implementation rounds cost less 
than the first, which requires additional meetings and trainings. The difference in costs between 
village-based and district-based targeting was smaller for MDA than for either MSAT or IRS 
because a greater proportion of the costs of MDA varied with the number of people reached, 
meaning that MDA showed lesser economies of scale, and thus lesser diseconomies of targeting. 
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Figure 6 Total and average economic costs of Hotspot ID, IRS, MSAT, and MDA: modelled scenarios 
The figures illustrate that village-based targeting is always more expensive than district-based targeting and the 
differences widen as the proportion of the population targeted narrows. The proportion of people targeted in the 10 
cost scenarios are shown on the x-axis in both figures. The proportion of people targeted who are reached matches the 
trial: 66% IRS, 55% MSAT, and 66% MDA. Costs of identifying hotspot villages would need to be added to any village-
based targeting strategy (except where 100% of the population is targeted). District-based targeting would not occur 
any incremental costs in this context because the necessary information is already collected and analysed sufficiently. In 
the lower figure, “village” and “district” indicate whether village-based or district-based targeting are assumed. Colour-
coding on both figures are identical. Hotspot village identification is not shown on the lower figure because there are no 
direct “recipients” of this information-gathering activity. 
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The financial costs to Senegal’s health service of implementing these four interventions are 
estimated to be $63 per 10,000 population for hotspot identification (if head nurses and district 
staff complete the task without additional per diems), $6,418 for IRS, $4,842 for MSAT, and 
$9,745 for MDA (Table 5). These financial costs would represent 0%, 24%, 18%, and 37%, 
respectively, of average combined domestic government and external expenditure on malaria per 
10,000 population across Senegal, and 0%, 3%, 2%, and 5%, respectively, of Senegal’s average 
general government expenditure on health per 10,000 population. While these targeted intensive 
strategies would not be expected to be implemented in the entire country, these ratios give a 
broad indication of the magnitude of costs relative to existing expenditures. 
Table 5 Total financial costs and budget impact of Hotspot ID, IRS, MSAT, and MDA: as implemented in trial and base 
case analysis 
“public malaria expenditure”: domestic government expenditure and external donor expenditure combined; GGHE: 
General government expenditure on health (from all financing sources). 
  INTERVENTIONS 
Total financial costs per 10,000 population Hotspot ID IRS MSAT MDA 
Implementation in trial $63 $6,538 $5,310 $10,825 
CEA BASE CASE: 2 rounds MSAT/MDA across all health posts $63 $6,418 $4,842 $9,745 
CEA BASE CASE (LowIRS): As above except lower IRS coverage $63 $2,495 $4,842 $9,745 
Financial costs as % public malaria expenditure Hotspot ID IRS MSAT MDA 
Implementation in trial 0% 25% 20% 41% 
CEA BASE CASE: 2 rounds MSAT/MDA across all health posts 0% 24% 18% 37% 
CEA BASE CASE (LowIRS): As above except lower IRS coverage 0% 9% 18% 37% 
Financial costs as % GGHE Hotspot ID IRS MSAT MDA 
Implementation in trial 0% 3% 3% 5% 
CEA BASE CASE: 2 rounds MSAT/MDA across all health posts 0% 3% 2% 5% 
CEA BASE CASE (LowIRS): As above except lower IRS coverage 0% 1% 2% 5% 
 
Treatment costs 
The economic cost to providers of each uncomplicated or severe malaria case was estimated to 
be $4 or $46, respectively, on average. Including the opportunity cost to households of illness 
increased estimated costs to $21 and $85, respectively, per case. When combined with the 
proportion of all malaria cases detected by the health service that resulted in hospitalisation, we 
found that severe cases accounted for 22% of the economic costs to the provider of case 
management and 43% of the societal cost of malaria cases. In the deterministic analysis (which, 
unlike the probabilistic analysis, allowed breakdown of each strategy’s costs by intervention), 
treatment of malaria cases cost $1,185 per 10,000 population with the reference strategy, and 
$620 with IRS+MDA (), the most effective strategy, resulting in a maximum savings of $565 in 
treatment costs averted per 10,000 population (Figure 7). 
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Figure 7 Total economic cost of strategies by intervention component 
Total economic costs per 10,000 population are presented for the base case scenario. Research participation incentives 
are included in this graph (and not in any other graphs or tables) to indicate their magnitude, as they may have 
contributed to more assiduous implementation; however, they cannot be attributed to individual interventions, and as 
they were paid in all strategies, they do not represent incremental costs in any of the intensive strategies relative to the 
control. IRS: Indoor residual spraying; MDA: Mass drug administration; MSAT: Mass screening and treatment.  
 
 
Combined costs of each multi-component strategy 
When the base case estimates of individual intervention costs were combined in the probabilistic 
sensitivity analysis with estimates of the number of cases occurring with each strategy, the 
reference strategy was the least expensive at $1,186 ($958 to $1,448) per 10,000 population, 
followed by NoIRS+MSAT ($6,401, $5,122 to $7,833), LowIRS+MSAT ($9,286, $7,826 to $10,886), 
NoIRS+MDA ($10,928, $8,588 to $13,593), IRS+MSAT ($13,254, $11,093 to $15,566), 
LowIRS+MDA ($13,846, $11,392 to $16,563), and IRS+MDA ($17,889, $14,965 to $21,060), the 
most expensive strategy (Table 3Error! Reference source not found.).  
In addition, research participation incentives of $562 per 10,000 population were provided to 
health post, district, and regional staff under all strategies (Error! Reference source not found.). 
While intended to support research, these payments likely encouraged more assiduous 
implementation; however, they were not specific to any of the four interventions and did not 
generate incremental costs for any of the intervention strategies relative to the reference 
strategy. They are therefore shown in Error! Reference source not found., but not in other 
results. 
Cost-effectiveness 
In the base case analysis, LowIRS+MSAT, LowIRS+MDA, and NoIRS+MDA were dominated, 
meaning that they were both less effective and more costly than alternatives (Figure 8). Relative 
to the control, the first strategy on the expansion path, NoIRS+MSAT, cost an additional $9,839 
(95% CI: $4,939 to $34,054) per DALY averted and was both the least costly and least effective of 
the targeted strategies. Relative to NoIRS+MSAT, the next strategy on the expansion path, 
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IRS+MSAT, cost an additional $10,221 ($5,597 to $32,423) per DALY averted. Relative to 
IRS+MSAT, IRS+MDA cost an additional $36,203 ($13,084 to $121,785) per DALY averted and was 
both the most effective and most costly strategy. At all plausible cost-effectiveness thresholds, 
the reference strategy was most likely to be the most cost-effective (but least effective) strategy 
based on the short-term disease burden reductions achieved (Figure 9).  
 
 
Figure 8 Probabilistic sensitivity analysis on the cost-effectiveness plane 
Points on the expansion path are labelled in black with black borders. Dominated strategies are labelled in 
grey. DALY: Disability-adjusted life-year; IRS: Indoor residual spraying; MDA: Mass drug administration; 
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Figure 9 Cost-effectiveness acceptability curves 
Thresholds are described further in Section 6.1.7. DALY: Disability-adjusted life-year; IRS: Indoor residual spraying; LICs: 
Low-income countries; MDA: Mass drug administration; MICs: Middle-income countries; MSAT: Mass screening and 






In a series of one-way sensitivity analyses, the expansion path changed to include NoIRS+MDA 
when DP costs decreased; if DP costs were 50% lower than in our base case, all MSAT strategies 
and LowIRS+MDA would be dominated and the expansion path would include only the reference 
strategy, NoIRS+MDA and IRS+MDA (Figure 10). When RDT costs or CHW per diem costs 
increased, NoIRS+MDA became the first point on the expansion path, followed by IRS+MSAT and 
IRS+MDA. When insecticide costs decreased by half and when the effectiveness of each of the 
strategies were at the upper bound of their confidence intervals, all MDA strategies and 
NoIRS+MSAT were dominated, and the expansion path extended directly from the reference 
strategy to IRS+MSAT and then IRS+MDA (Figure 10). If the effectiveness of MDA strategies were 
at the upper bounds of their 95% confidence intervals and the effectiveness of MSAT strategies at 
their lower bounds, the expansion path would extend from the reference strategy to NoIRS+MDA 
and IRS+MDA. In the reverse situation, with MDA strategies at their lower bounds of plausible 
effectiveness and MSAT strategies at their upper bounds, the expansion path would extend from 
the reference strategy to NoIRS+MSAT and IRS+MSAT.   
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The expansion path would also exclude the MDA strategies if DALY estimates were adjusted for 
adverse events associated with MDA and MSAT. The brief finger pain reported by 42% of MSAT 
recipients only added 0.004 DALYs per 10,000 population to the MSAT strategies. Accounting for 
the smaller proportion (19%) of MDA recipients who experienced non-serious side effects, such as 
headache and dizziness, added 0.3 DALYs to MDA strategies, while accounting for the child who 
died following MDA administration added 0.5 DALYs per 10,000 population. The non-serious 
adverse events alone would have caused IRS+MDA to be dominated, while inclusion of the single 
death (out of nearly 300,000 courses of MDA in the 2-year trial) more than halved the DALYs 
averted by IRS+MDA relative to control and nearly eliminated the DALYs averted by NoIRS+MDA 
relative to control. 
Plausible variation in incidence (within our very low incidence context), the proportion of cases 
becoming severe, and the discount rate all led to substantial changes in ICERs, but did not alter 
the expansion path from the base case. The incremental cost per DALY averted of NoIRS+MSAT 
relative to the reference strategy fell substantially in these three analyses to $4,559 (higher 
incidence), $4,902 (higher proportion progressing to severe), and $6,320 (lower discount rate); 
however, these values remain far above all plausible cost-effectiveness thresholds. While they are 
near three times Senegal’s per capita GDP ($4,566), this threshold is now recognized to be 
unaffordably high (Ochalek et al., 2018, Marseille et al., 2015). Using Japanese instead of 
Senegalese life expectancy values only slightly decreased ICERs and did not change the expansion 
path. 
  
Chapter 5.    Local geographic targeting of malaria hotspot strategies  -  Page 101 of 216 
Figure 10 Deterministic sensitivity analysis on the cost-effectiveness plane 
The deterministic base case is shown with 11 deterministic sensitivity analyses, ordered (approximately) 
from largest to smallest impact on the expansion path and ICERs. Solid colour points and black lines show 
the base case and associated cost-effectiveness frontier, respectively, and are identical on all 12 panels. The 
slope of each line is the incremental cost-effectiveness ratio. Points not on a line are dominated by more 
cost-effective alternatives. Hollow points and light blue dashed lines show strategies at the lower 
parameter value. Points with black centres and purple dotted lines show strategies at the higher parameter 
value. Where the expansion path differs from the base case, strategies on the expansion path are labelled 
in light blue boxes (for lower parameter value) or purple boxes (for higher parameter values). Square points 
show MSAT-based strategies and triangular points show MDA-based strategies. DALY: Disability-adjusted 
life-year; DP: Dihydroartemisinin-piperaquine; IRS: Indoor residual spraying; MDA: Mass drug 
administration; MSAT: Mass screening and treatment; USD: United States Dollars. 
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5.1.5. Discussion 
 
In the trial setting, the hotspot strategies evaluated successfully reduced both incidence and 
transmission, but did not achieve “virtual elimination” as intended. Our cost analysis is valuable in 
showing how the costs of geographically targeted MDA, MSAT, and IRS could be expected to vary 
with changes in context or input prices, or with strategy modifications which decision-makers may 
want to consider. We demonstrate the diseconomies of village-based targeting relative to district-
based targeting or blanket intervention. That is, the average costs per recipient increases as the 
proportion of the population targeted in a village-based targeting strategy falls. The costs of 
identifying hotspot villages were very low in our study relative to the costs of the interventions 
themselves; however, such information costs may be much higher in contexts with weaker health 
systems. In our study, the diseconomies of targeting were primarily driven by diseconomies of 
reduced scale as costs incurred at health post, district, and higher levels were divided across a 
decreasing proportion of the population. Targeting interventions to a fraction of the population 
can substantially decrease total costs, but these cost reductions are not linear. For a given degree 
of targeting (e.g. 20% of the population), employing district-based targeting rather than the 
village-based targeting evaluated in our trial would reduce total costs, especially if <50% of the 
population are targeted. Increasing the number of consecutive monthly rounds would 
substantially increase total costs, while slightly decreasing the cost per recipient per round of 
MSAT and, to a lesser extent, MDA. If implemented in a large proportion of the country, these 
interventions would require substantial relative increases in donor and/or domestic government 
expenditure, which would likely displace other activities, whether for malaria or other health 
priorities in Senegal or elsewhere. Nonetheless, targeting interventions at villages rather than 
higher-level units, such as districts, may prove more economically efficient in contexts where high 
sensitivity and specificity of targeting at fine spatial scale can be achieved. 
In contexts with comparably low incidence and case fatality rates and similar costs, neither two 
rounds of targeted MDA nor two rounds of targeted MSAT, with or without the addition of 
targeted IRS, can be considered cost-effective for short-term reductions in disease burden 
because the same value of resources could avert substantially more DALYs if used for alternative 
interventions in Senegal or other low- or lower-middle-income countries. These strategies would 
become more cost-effective in contexts with higher incidence or rates of progression to severe 
disease (e.g. where immunity and/or access to care were lower) than observed in our trial setting, 
or if the costs of tests, drugs, and insecticides were substantially lower. The relative efficiency of 
MDA and MSAT strategies was sensitive to the costs of DP, RDTs, and CHWs, and to uncertainty in 
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effectiveness estimates. While these targeted strategies are inherently equitable in that they 
preferentially benefit people at greatest malaria risk within the implementation area (even if they 
do not personally receive the interventions), they could also be viewed as an inequitable 
prioritisation of malaria control amongst people at low overall risk when the same resources 
could generate more substantial health benefits if used towards other health areas or populations 
at greater risk. 
Our development of a flexible and transparent cost model based on detailed primary data 
collection is a particular strength of our research. It allowed us to generate findings of wider use 
beyond the study setting to inform future intervention design and analysis. In particular, it 
showed how to account for economies of scale and diseconomies of targeting, and how these 
differed between IRS, MDA, and MSAT. Whereas Larson and colleagues’ approach recommended 
calculating the average unit cost for each activity (e.g. cost per training) comprising an 
intervention (Larson et al., 2016) and PMI’s approach involved identifying fixed costs of IRS at a 
national level and considering all other costs variable (with the number of structures sprayed) 
(Cico and Johns, 2018), our analysis recognized that some costs vary with the output level, but 
other costs vary with the number of CHWs, health posts, or districts involved in the intervention. 
Understanding this cost structure is particularly important in analysing geographically targeted 
strategies, and also explains some of the variation in average costs across different health system 
contexts.  
The trial’s design allowed it to capture both the direct and indirect effects of intervention 
strategies within and outside the targeted hotspot villages, and thus measure the impact on 
transmission directly. It was not, however, designed to assess the incremental costs and effects of 
adding targeted IRS to targeted MDA or MSAT, nor the effectiveness of targeted IRS alone. We 
exploited the unintended variation in strength of IRS implementation between the first and 
second implementation years to explore the value of adding targeted IRS to either targeted MSAT 
or MDA. This exploration indicated that targeted IRS produced only small incremental gains when 
added to targeted MDA, but that targeted IRS+MSAT produced more than twice the health 
benefits of targeted NoIRS+MSAT, possibly because the imperfect sensitivity of RDTs and higher 
rates of MSAT refusal meant that MSAT alone missed cases that could have been averted by 
either IRS or MDA. The many assumptions underpinning this modelling, however, mean that 
these findings warrant further evaluation in field trials robustly designed for this purpose.  
We did not model potential changes in effectiveness that could be expected from other possible 
modifications to the strategies (i.e. changes in the degree and/or level of targeting or number of 
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implementation rounds) because doing so would require highly complex and uncertain 
transmission modelling, beyond the scope of existing models (Stresman et al., 2019). We 
considered a range of discount rates; however, because PMI funds most of Senegal’s (and many 
other countries’) NMCP activities, with additional support from other donors, a discount rate 
representing donors’ opportunity costs (3%), rather than Senegal’s, seemed most appropriate for 
the base case. The DALY weights used to calculate the years of life lived with disability for malaria 
have many limitations; however, more accurate weights and accounting for long-term sequelae 
are unlikely to substantially alter overall DALY estimates, which are driven almost entirely by the 
years of life lost from deaths. The reference strategy comprised standard practice plus some 
additional malaria control measures and research participation incentives paid to health workers, 
which were also paid in the intervention strategies. The fact that the reference strategy did not 
perfectly match usual practice may have either underestimated the effectiveness of the hotspot 
strategies (by reducing scope for impact) or overestimated their effectiveness (if the extra nets 
provided in the reference strategy had a synergistic effect with the hotspot strategies, as 
predicted in transmission models, or if the incentives encouraged more assiduous implementation 
of the interventions). Any such impact is, however, unlikely to have affected our overall 
conclusions. By comparing financial costs per capita for each intervention scenario with relevant 
national per capita budgets, we provided a useful indication of the scale of expenditure required 
for implementation; however, we did not conduct a full budget impact analysis, which would 
require identification of all districts in Senegal for which intensive strategies were recommended 
and adaptation of the cost model to these districts. While we populated our decision analytic 
model with best available evidence, including carefully collected primary cost and outcome data, 
and selected plausible parameter distributions, our estimates may have been biased by missing 
data, misclassification, and incorrect parameter distributions, and there is structural uncertainty 
in our models.  
This paper contributes to scant literature on the economics of MDA, MSAT, next generation IRS, 
and geographical targeting of public health interventions. Our estimates of the financial costs of 
delivering MDA ($0.21 per person-round excluding DP costs) were lower than the three 
experiences of (blanket) MDA for malaria for which WHO collected retrospective financial data in 
2015 ($0.36 per person-round in Sierra Leone, $11.05 in Comoros, and $0.53 in Vanuatu excluding 
drug costs, constant 2015 USD) (WHO Evidence Review Group, 2015b). Two of these studies were 
implemented on a relatively small scale on remote islands, which may partially explain their 
higher costs. The enormous scale of delivery of malaria MDA to 2.5m people in Sierra Leone 
during the Ebola emergency likely led to some economies of scale; however, the extremely 
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challenging health system context may explain why we estimated lower costs in the stable, 
relatively well-functioning health system context of central Senegal, where formal health workers, 
CHWs, and families were already familiar with MDA for children under 10 (i.e. SMC). In virtually 
the same context as our study, the economic costs of blanket (i.e. not geographically targeted) 
SMC was estimated around $0.50 (constant 2010 USD) per child per round (Pitt et al., 2017), 
which, given the low cost of the sulphadoxine-pyrimethamine and amodiaquine used (~$0.11) 
reflects somewhat higher delivery costs than in our study. This is unsurprising, as while 
geographical targeting and only having two administration rounds slightly increases the cost per 
person per round, including all people in the household in drug distribution would be expected to 
decrease average costs per recipient.  
We only identified one previous empirical MSAT cost estimate; three dry-season rounds in Zambia 
cost $4.39 (range: $1.62-13.96, constant 2012 USD) per person-round (Silumbe et al., 2015), 
substantially more than our estimate of $0.91 per person-round. This difference may reflect the 
far higher test positivity rate (13% vs. 1% in our study), higher coverage rates achieved, higher 
transport costs, and inclusion of substantial overhead costs in the Zambian setting, as well as 
other factors (Silumbe et al., 2015). While Silumbe and colleagues described MSAT as “highly cost-
effective” relative to WHO thresholds in their study’s moderate transmission setting, their 
estimate of an incremental cost of $804 per DALY averted would not be considered cost-effective 
relative to thresholds more recently proposed (Ochalek et al., 2018). An earlier modelling exercise 
projected substantially higher MSAT costs than in our study, of $5 to $11 (constant 2007 USD) per 
person-round plus the costs of treatment (Crowell et al., 2013), largely because it assumed that 
CHWs could administer MSAT to far fewer people per day and that the costs of CHW per diems 
and RDTs were more than twice as high as we observed in practice.  
More recent modelling (Walker et al., 2016) used many of the same parameter estimates as 
Crowell and colleagues and, like them, only considered outcomes as cases, and not deaths or 
DALYs. For IRS, Walker et al used a median cost of $8.80 per person protected in 2012 across 
countries receiving PMI IRS funding. This median was substantially higher than PMI’s estimate for 
Senegal in 2017 of $6.57 (Cico and Johns, 2018), and more than four times our own estimate of 
$1.99 per person protected in 2015. Our IRS cost estimates may have been lower than PMI’s 
because we did not include the fixed national-level costs associated with the existence of an IRS 
programme, and because our study was conducted in an easier-to-reach area than the four 
southern Senegalese districts in PMI’s IRS programme. Further, Walker and colleagues’ model did 
not account for the effects of interventions on neighbouring areas or account for economies of 
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scale or the level at which interventions are targeted. Despite these differences, our findings 
concur with modelling indicating that MSAT is unlikely to be cost-effective in low transmission 
settings (Crowell et al., 2013) and questioning the added value of IRS in central Senegal if MSAT or 
MDA are implemented (Walker et al., 2016). That our estimates may underestimate the costs of 
these interventions further underscores our overall conclusion that these interventions, as 
implemented in our study, cannot be considered cost-effective in comparable contexts.  
Future research should explore the effects of strategies involving different combinations of 
interventions, degrees and levels of targeting, and numbers of rounds of intensive interventions 
in different contexts, and their associated costs. While additional field research is important, the 
choice of which strategies to test in which contexts should be guided by analysis using both 
transmission models and the cost model developed here. Further economic research should be 
conducted to improve understanding of how cost data on new interventions from trials such as 
this one can be used to develop models that accurately inform wider decision-making across 
contexts.  
Our findings are particularly relevant for policy making in low transmission settings and other 
contexts where MDA, MSAT, and IRS are considered. While the NMCPs of Senegal and other 
countries, as well as WHO, the Gates Foundation, and many other institutions and individuals 
vociferously champion malaria elimination, the question of whether malaria elimination can be 
achieved and is an equitable goal in the medium term remains highly contested (Lines et al., 2008, 
Shah, 2010, McNeil Jr., 2008). The challenges in malaria elimination are not only technical and 
economic, but social (Hausmann-Muela and Eckl, 2015), political, and ecological (Little, 2013). 
One concern is that the push towards elimination, like the Global Malaria Eradication Plan of the 
1950s to 1960s, may prove unsuccessful, in which case any resources used will carry a high 
opportunity cost in terms of lives that could have been saved if the resources had been focused 
on those areas with the greatest disease burdens. Others argue that malaria programme efforts 
should focus on disease control (rather than elimination), with greater efforts focused on social 
and economic development, including housing improvements, which could lead to sustainable 
elimination and wider social benefits (Tusting et al., 2013). Elimination advocates counter that 
elimination cannot wait, and must be achieved before drug and insecticide resistance and waning 
global commitment lead to a deadly global resurgence, and that continuous, effective control is 
not possible. Our findings provide important empirical evidence on the affordability, efficiency, 
and trade-offs involved in several interventions expected to play a role in elimination efforts, and 
thus make an important contribution to the elimination debate. 
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5.1.6. Annex 1: Additional information on the effectiveness analysis 
 
Projecting potential effectiveness of MSAT or MDA in hotspots without IRS 
To estimate the incidence rate ratios for NoIRS+MSAT and NoIRS+MDA relative to control, we 
used the data collected in the trial to model the rate ratio for an intervention strategy relative to 
the control as a linear function of the effective coverage of IRS, as follows: 
!!"#$%#&'( = ) *+,--./012.342.567.89" : ; 
Where RRStrategy denotes the incidence rate ratio for either the MDA or MSAT strategy relative to 
control, m and b are constants, and EffectiveCoverageIRS is the product of the proportion of 
targeted households that received IRS (IRS coverage) and the efficacy of that spraying (IRS 
efficacy), expressed as the % of mosquitoes that die in a 24-hour knockdown test, performed 4 
months after the spraying.  
As the effectiveness of the MDA strategy was only slightly lower when combined with LowIRS 
(RR=0.68) rather than IRS (RR=0.62), the model predicted only a slight further diminution in 
effectiveness if MDA were to be combined with NoIRS (RR=0.71) (Table 6). For MSAT, however, 
the effectiveness when combined with IRS (RR=0.65) was substantially higher than when 
combined with LowIRS (RR=0.78), and so the model predicted a larger diminution in effectiveness 
if MSAT were combined with NoIRS (RR=0.84). This analysis suggests that in the IRS+MSAT 
strategy, roughly 54% of the malaria cases, deaths, and DALYs averted were attributable to the 
use of IRS, whereas 46% were attributable to MSAT.    
 
Table 6 Modelled estimates of the effectiveness of MDA and MSAT strategies with No IRS 
  IRS coverage scenario 








 IRS coverage 0.74 0.23 0 
 IRS efficacy 0.82 0.37 0 
 EffectiveCoverageIRS 0.74 0.23 0.00 
Effectiveness (rate ratio 
relative to control) 
MDA strategy (RRMDA) 0.52 0.63 0.67 
 MSAT strategy (RRMSAT) 0.57 0.74 0.81 
Standard error (SE) for 
effectiveness estimate 
MDA strategy (SEMDA) 0.037 0.034 0.034 
 MSAT strategy (SEMSAT) 0.037 0.037 0.037 
 
Chapter 5.    Local geographic targeting of malaria hotspot strategies  -  Page 108 of 216 
All four standard errors for the rate ratios that were empirically estimated based on IRS and 
LowIRS combined with MDA or MSAT were very similar with one another. We therefore assumed 
that the standard error for NoIRS combined with either MSAT or MDA would match the standard 
error for either strategy combined with LowIRS.  
DALY calculations 
We estimated DALYs as follows: 
<>?@A = @?<A : @??A 
To estimate YLDs for each strategy, the number of severe and uncomplicated cases of malaria 
were estimated and multiplied by the average duration of each case and a disability weight 
reflecting the severity of the case, as follows:   
@?< = B36A.AC&D&$& * <E56014FC&D&$& *+<1A6;1G10HI.17J0C&D&$&K +: B36A.ALMNOPQRSN%#&T
* <E56014FLMNOPQRSN%#&T *+<1A6;1G10HI.17J0LMNOPQRSN%#&TK 
The number of malaria cases for each strategy in our model was estimated as the product of the 
hypothetical population, the incidence in the reference arm, and the rate ratio of malaria 
incidence in the relevant arm with respect to the reference arm:  
36A.A = U4VEG6014F * WF/1X.F/.YOM#$OR * !60.!6014 
To estimate YLLs for each strategy, we multiplied the number of deaths expected in each strategy 
and an estimate of the number of years of life lost with each death. The number of deaths 
expected was estimated as the product of the number of severe cases and the probability that a 
severe case would result in death based on analysis of the passive surveillance data. 
We estimated the number of YLLs associated with each of the 15 malaria-related deaths observed 
in the entire study area in the 2-year period.    
@?? = 36A.AC&D&$& * U54;T&%#Z * @??A 
We also used additional analyses of passive surveillance data from all health facilities and CHWs 
providing malaria treatment across the study area to determine the proportion of severe malaria 
cases that resulted in death and the age and sex of people who died of malaria. Across the entire 
study area and two-year intervention period, only 15 malaria-related deaths were recorded. As 
the number of YLLs associated with each death depends upon the person’s remaining life 
expectancy, which in turn depends on their age at death and sex, we estimated the YLLs 
associated with each death separately, using discounting but no age weighting. The discounting 
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used reflected the overall discount rate for costs and effects used in our model, which was 3% in 
the base case and varied in our sensitivity analyses. Based on the discounted YLLs estimated for 
each of our 15 observations, we estimated the mean and standard deviation (s.d.) for the number 
of YLLs per death in our setting, which were then used in probabilistic sensitivity analysis.   
DALYs associated with side effects  
In the deterministic sensitivity analysis, we examined the impact on effectiveness and cost-
effectiveness estimates of including DALYs associated with side effects, which are not usually 
accounted for in malaria (or other) models (Table 7). 
Table 7 Additional parameters: DALYs associated with side effects of MDA and MSAT 
ADDITIONAL EFFECTS PARAMETERS Base case Source 
Side effects of MSAT (only included in deterministic 
sensitivity analysis)     
Probability of finger pain 0.419 Trial estimates from Day 4 survey 
Duration of symptoms (days) 0.083 Assumption 
DALY weight pain (open wound, short term) 0.006 Salomon et al, 2015  
Side effects of MDA (only included in deterministic 
sensitivity analysis)     
Risk of death per year from MDA across the 
population (hotspot and non-hotspot) 2.2E-06 
Trial estimate from 1 death in MDA 
arm across 2 administration years 
Probability of non-fatal side effects from MDA 0.187 Trial estimates from Day 4 survey 
Duration of symptoms (days) 2.000 Assumption 
Probability headache 0.225 Trial estimates from Day 4 survey 
Probability dizziness 0.250 Trial estimates from Day 4 survey 
Probability diarrhea 0.168 Trial estimates from Day 4 survey 
Probability fever 0.170 Trial estimates from Day 4 survey 
Probability abdominal pain 0.115 Trial estimates from Day 4 survey 
Probability nausea 0.107 Trial estimates from Day 4 survey 
Probability vomiting 0.137 Trial estimates from Day 4 survey 
DALY weight headache (tension-type) 0.037 Salomon et al, 2015  
DALY weight dizziness (infectious disease moderate) 0.051 Salomon et al, 2015  
DALY weight diarrhea (mild) 0.074 Salomon et al, 2015  
DALY weight fever (infectious disease mild) 0.006 Salomon et al, 2015  
DALY weight abdominal pain (mild) 0.011 Salomon et al, 2015  
DALY weight nausea (mild) 0.011 Salomon et al, 2015  
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5.1.7. Annex 2: Additional information on thresholds used 
 
As neither Senegal nor other countries that might want to consider these strategies have explicit 
cost-effectiveness thresholds, two sets of thresholds were used because they were either widely 
used or considered plausible.  
The first set of thresholds, based on multiples of per capita gross domestic product (GDP) per 
DALY averted, have long been referred to as “the WHO thresholds”, although they are no longer 
supported by WHO and accepted to be too high (Marseille et al., 2015, Bertram et al., 2016). 
Based on these thresholds, interventions costing less than per capita GDP per DALY averted were 
considered “highly cost-effective”, while those costing less than three times per capita GDP per 
DALY averted were considered “cost-effective.” This approach was applied using estimates of per 
capita GDP in 2018 for Senegal, low-income countries, and lower-middle-income countries. 
The second set of thresholds were based on work by Ochalek and colleagues (2018) to define 
empirically supply-side cost-per-DALY thresholds for countries globally. They generated four 
alternative estimates for each country based on different sets of assumptions. To update the 
estimates for Senegal to 2018 values, we used the published estimates of the threshold as a 
proportion of GDP in 2015, and then applied these same proportions to Senegal’s GDP in 2018. 
While the proportions should be expected to vary with the per capita GDP level, this approach 
appeared a sufficient approximation, especially as the ICERs generated were very distant from 
these estimated thresholds. While these thresholds are relevant for provider costs and our ICERs 
reflect societal costs, the societal perspective produces lower ICERs than a provider perspective 
for our interventions, making it more likely that they would fall below the threshold. However, 
even with this advantage, the societal ICERs we produced remained far above the supply-side 
thresholds.   
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Table 8 Economic costs of Hotspot ID, IRS, MSAT, and MDA: as implemented in trial and for modelled scenarios 
In the trial, 36% of intervention arm residents received IRS, 33% of MSAT arm residents received MSAT, and 32% 
received MDA, which is reflected in the “Implementation in trial” and base case. The 10 cost scenarios indicate the 
proportion of people targeted, and the proportion of people targeted who are reached matches the trial: 66% IRS, 55% 
MSAT, and 66% MDA. HP: Health post; S: Scenario. *Identifying hotspot health posts is assumed not to incur 
incremental costs because incidence by health post is already reported to Dakar. 
  INTERVENTIONS 
Total economic costs per 10,000 population Hotspot ID IRS MSAT MDA 
Implementation in trial $73 $7,326 $5,935 $11,183 
CEA BASE CASE: 2 rounds MSAT/MDA across all health posts $75 $7,135 $5,368 $10,048 
CEA BASE CASE (LowIRS): As above except lower IRS coverage $75 $2,972 $5,368 $10,048 
S1: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted $0 $12,566 $8,286 $20,035 
S2: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) $75 $6,664 $4,664 $10,411 
S3: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) $75 $3,122 $2,491 $4,637 
S4: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted (by village) $0 $12,566 $15,828 $39,767 
S5: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) $75 $6,664 $8,696 $20,416 
S6: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) $75 $3,122 $4,416 $8,805 
S7: 2 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) $0* $6,294 $4,143 $10,018 
S8: 2 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) $0* $2,544 $1,662 $4,013 
S9: 4 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) $0* $6,294 $7,914 $19,884 
S10: 4 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) $0* $2,544 $3,168 $7,958 
Cost per recipient per round Hotspot ID IRS MSAT MDA 
Implementation in trial NA $2.05 $0.91 $1.75 
CEA BASE CASE: 2 rounds MSAT/MDA across all health posts NA $1.99 $0.82 $1.57 
CEA BASE CASE (LowIRS): As above except lower IRS coverage NA $2.39 $0.82 $1.57 
S1: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted NA $1.90 $0.76 $1.51 
S2: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) NA $2.01 $0.85 $1.57 
S3: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) NA $2.35 $1.14 $1.75 
S4: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted (by village) NA $1.90 $0.72 $1.50 
S5: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) NA $2.01 $0.80 $1.54 
S6: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) NA $2.35 $1.01 $1.66 
S7: 2 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) NA $1.90 $0.76 $1.51 
S8: 2 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) NA $1.92 $0.76 $1.51 
S9: 4 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) NA $1.90 $0.72 $1.50 
S10: 4 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) NA $1.92 $0.72 $1.50 
Mean number of intervention recipients per round Hotspot ID IRS MSAT MDA 
Implementation in trial NA 159,135 70,231 73,236 
CEA BASE CASE: 2 rounds MSAT/MDA across all health posts NA 210,247 191,692 187,532 
CEA BASE CASE (LowIRS): As above except lower IRS coverage NA 72,930 191,692 187,532 
S1: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted NA 389,403 320,953 389,797 
S2: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) NA 194,702 160,477 194,899 
S3: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) NA 77,881 64,191 77,959 
S4: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted (by village) NA 389,403 320,953 389,797 
S5: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) NA 194,702 160,477 194,899 
S6: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) NA 77,881 64,191 77,959 
S7: 2 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) NA 194,702 160,477 194,899 
S8: 2 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) NA 77,881 64,191 77,959 
S9: 4 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) NA 194,702 160,477 194,899 
S10: 4 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) NA 77,881 64,191 77,959 
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Table 9 Financial costs and budget impact of Hotspot ID, IRS, MSAT, and MDA: as implemented in trial and for modelled 
scenarios 
“public malaria expenditure”: domestic government expenditure and external donor expenditure combined; GGHE: General 
government expenditure on health (from all financing sources). 
  INTERVENTIONS 
Total financial costs per 10,000 population Hotspot ID IRS MSAT MDA 
Implementation in trial $63 $6,538 $5,310 $10,825 
CEA BASE CASE: 2 rounds MSAT/MDA across all health posts $63 $6,418 $4,842 $9,745 
CEA BASE CASE (LowIRS): As above except lower IRS coverage $63 $2,495 $4,842 $9,745 
S1: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted $0 $11,536 $7,759 $19,733 
S2: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) $63 $5,974 $4,137 $10,109 
S3: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) $63 $2,637 $1,964 $4,334 
S4: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted (by village) $0 $11,536 $14,881 $39,250 
S5: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) $63 $5,974 $7,749 $19,898 
S6: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) $63 $2,637 $3,469 $8,287 
S7: 2 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) $0 $5,774 $3,880 $9,866 
S8: 2 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) $0 $2,322 $1,556 $3,952 
S9: 4 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) $0 $5,774 $7,441 $19,625 
S10: 4 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) $0 $2,322 $2,980 $7,855 
Financial costs as % public malaria expenditure Hotspot ID IRS MSAT MDA 
Implementation in trial 0% 25% 20% 41% 
CEA BASE CASE: 2 rounds MSAT/MDA across all health posts 0% 24% 18% 37% 
CEA BASE CASE (LowIRS): As above except lower IRS coverage 0% 9% 18% 37% 
S1: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted 0% 43% 29% 74% 
S2: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) 0% 22% 16% 38% 
S3: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) 0% 10% 7% 16% 
S4: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted (by village) 0% 43% 56% 148% 
S5: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) 0% 22% 29% 75% 
S6: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) 0% 10% 13% 31% 
S7: 2 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) 0% 22% 15% 37% 
S8: 2 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) 0% 9% 6% 15% 
S9: 4 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) 0% 22% 28% 74% 
S10: 4 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) 0% 9% 11% 30% 
Financial costs as % GGHE Hotspot ID IRS MSAT MDA 
Implementation in trial 0% 3% 3% 5% 
CEA BASE CASE: 2 rounds MSAT/MDA across all health posts 0% 3% 2% 5% 
CEA BASE CASE (LowIRS): As above except lower IRS coverage 0% 1% 2% 5% 
S1: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted 0% 5% 4% 9% 
S2: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) 0% 3% 2% 5% 
S3: 2 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) 0% 1% 1% 2% 
S4: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 100% targeted (by village) 0% 5% 7% 19% 
S5: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 50% targeted (by village) 0% 3% 4% 9% 
S6: 4 rounds MSAT/MDA across all 4 districts, 46 HPs; 20% targeted (by village) 0% 1% 2% 4% 
S7: 2 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) 0% 3% 2% 5% 
S8: 2 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) 0% 1% 1% 2% 
S9: 4 rounds MSAT/MDA across 2 districts, 23 HPs; 50% targeted (by district and HP) 0% 3% 4% 9% 
S10: 4 rounds MSAT/MDA across 1 district, 9 HPs; 20% targeted (by district and HP) 0% 1% 1% 4% 
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5.2. Mechanistic cost modelling of intensive malaria strategies 
 
5.2.1. Mechanistic cost model: Approach  
The mechanistic cost model we developed generated estimates of how the costs of implementing 
each intervention (IRS, MSAT, MDA, hotspot identification) would vary with specific aspects of the 
implementation context and modifications to the interventions, as well as changes in input prices, 
resource use, and epidemiology.  
The model disaggregates the total costs of each intervention in the trial context in 2014 by 
implementation round and by what we refer to as “variation unit”. We define “variation units” as 
the level of the health system or output with which the costs would be expected to vary linearly. 
This approach facilitates modelling of costs in another context based on relatively easily 
obtainable data, while accounting for potential economies and diseconomies of scale and 
targeting strategy. Costs were disaggregated by whether they were expected to vary with the 
number of countries, districts, health posts, or CHWs involved in the intervention, or with the 
output quantity. Output metrics differed between the interventions; for IRS, costs were identified 
that were expected to vary with the number of households sprayed, while for MDA and MSAT, 
costs were identified that were expected to vary with the number of people receiving the 
interventions. In addition, for MSAT, costs were also identified which were expected to vary with 
the number of people who tested positive, which is a function of the number of people screened 
and the screening positivity rate (a function of local epidemiology and the test’s sensitivity and 
specificity).  
For each implementation round for each intervention in our trial setting, we generated the 
average cost per variation unit for each of the variation units we identified (i.e. countries, 
districts, health posts, CHWs, households or persons receiving the intervention). For example, we 
divided the costs of implementing the first round of MSAT that were expected to vary with the 
number of health posts ($14,237) by the number of health posts in our trial context (n=18), to 
generate an average cost per health post of implementation costs associated with the number of 
health posts ($791). Rather than model this average cost as a constant, we structured our model 
so that these average costs AC per health system or output level i and implementation round j, 
were a function of input prices p, resource use q, and local epidemiology e, to permit further 
modelling:  
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We assumed that these average costs for each variation unit could be used to estimate the total 
costs of implementing the given intervention in a different context, with a somewhat different 
targeting strategy, and/or with a different number of implementation rounds. That is, we 
assumed that for each intervention, the total costs could be modelled as: 






Where TC is total costs of implementation, i is a factor variable denoting x different variation units 
involved in implementation, j is a factor variable denoting the y implementation rounds, AC is the 
average cost of implementation per round per variation unit, and n is the number of variation 
units i for round j in which the intervention is implemented. Drawing in part on the analysis of the 
costs of three monthly rounds of SMC (Pitt et al., 2017), we assume that estimates of the costs of 
subsequent implementation rounds can be modelled based on the costs of implementing the 
second implementation round in the trial context. 
This approach of disaggregating costs by variation unit is different from disaggregating costs by 
the level at which they are incurred. For example, in our model, the costs of training health post 
nurses at their district headquarters were broken down into those costs that could be expected to 
vary with the number of districts, such as the costs of facilitators and room rental, and those costs 
that could be expected to vary with the number of health posts, namely the costs of per diems, 
food, travel, and time associated with attending the training for each health post’s head nurse. 
This approach assumed that, for example, there would be one district-level training in each 
district if and only if the intervention were implemented in at least one area in that district, but 
that a nurse would only participate in the training if his or her health post were implementing the 
intervention.  
To model expansion of the interventions from one or two trial arms to the entire study area, 
which we used for the base case, we changed the value nij for each variation unit i and 
implementation round j, as necessary. While the number of countries (n=1) and districts (n=4) 
remained the same as in implementation in the trial context, the number of health posts 
increased to 46 and the population increased to 587,285. For the base case, we assumed that the 
proportion of the total population (hotspot and non-hotspot villages) who received each of the 
interventions remained the same as in the trial: 36% of intervention arm residents received IRS, 
33% of MSAT arm residents received MSAT, and 32% of MDA arm residents received MDA. To 
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estimate the required number of CHWs for each intervention, we assumed that the number of 
households reached per CHW would remain the same as in the trial implementation. Populating 
this model thus required only additional estimates of the number of districts, health posts, and 
population across the area of interest.  
In further analyses, we modelled the costs of potential changes to the interventions across our 
study area. We modelled the costs of implementing the interventions with a more narrowly 
targeted approach and compared the costs of targeted strategies with the costs of a blanket 
approach (i.e. without geographical targeting) across our study area. We also predicted the costs 
of extending to 3 or 4 rounds of MDA or MSAT and of targeting by district and health post instead 
of by village. For these analyses, we defined a proportion of the population that was targeted 
(100%, 50%, 20%), and then applied the coverage rates achieved in the trial (IRS: 66%, MSAT: 
55%, and MDA: 66%) to estimate the number of people who would receive each intervention 
under the given scenario.  
While we explored the sensitivity of our cost-effectiveness model to plausible variation in key 
parameters, we did not model explicitly how costs might vary outside our study area. Our model 
is designed to facilitate such estimates with limited additional data in future, notably on the 
numbers of each variation unit across which the interventions would be implemented, and any 
changes in prices (e.g. salary levels), epidemiology (broadly, as the screening positivity rate is not 
a major cost driver at low incidence levels), or aspects of intervention delivery that would be 
expected to differ substantially in the new context.  
In our scenario analyses, we assumed that coverage i.e. the proportion of people targeted to 
receive the intervention who actually received it, remained constant and the same as observed in 
the trial. The model is set up to allow the coverage rate to be varied; however, it only accounts for 
the additional costs associated with greater outputs. For example, if the interventions were 
implemented in a context in which the same approach to intervention delivery resulted in 95% 
coverage, our model would account for the additional costs associated with the additional people 
reached. Any additional efforts necessary to achieve higher coverage – such as additional 
communication activities or extra visits to reach missed households or individuals – would need to 
be costed separately.     
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5.2.2. Mechanistic cost model: Implementation in Excel   
In Figure 12, we illustrate the structure of the Excel workbook we developed to implement this 
approach. In the left-hand two-thirds of the diagram, we illustrate (in blue) the cost model, and 
on the right (in green), we show the additional elements necessary to implement the cost-
effectiveness model.  Most of the worksheets are used to organize inputs and are illustrated in 
the top third of the diagram. Cost model inputs are linked to a single cost model analysis 
worksheet at the centre of the diagram. On the righthand side of the diagram, the numerous 
worksheets required for the cost-effectiveness analysis (including probabilistic sensitivity analysis) 
are illustrated. Products of the analysis (illustrated at the bottom of the diagram) are a set of 
tables and figures with cost estimates, a table of parameters, and a set of tables and figures to 
communicate the cost-effectiveness findings.  
Four types of inputs are required for the cost model. Firstly, as a starting point, we generated a 
set of resource descriptions to think through the model structure and information needs in the 
trial and scenarios we modelled. We began by listing each intervention, for each intervention 
listing the activities, and then breaking down each activity into cost categories. For each cost 
category, we then identified the specific resources involved and formulated precise price and 
quantity variable descriptions and identified sources for this information. This process was 
iterative, beginning with an initial brainstorm, and refined over the course of the research.  
Quantities of resources used were recorded in sheets organized to match the data collection 
process. For example, we separated sheets by activity and in some cases by data source to match 
our data collection tools, which, in turn, matched the source, timing, and topic for our data 
collection, largely from the respondent’s perspective. For example, we administered 
questionnaires at the district, health post, and CHW levels and did so separately for IRS and for 
each round of MDA and MSAT. Within these sheets, we ensured that data were disaggregated 
sufficiently to be categorized according to the model structure. In some cases, only expenditure 
data were available and so expenditure data were used instead.  
Prices and assumptions were collated in a single sheet with multiple tables, generated from 
primary and secondary sources. Within these tables, prices were converted into United States 
dollars, and to a variety of appropriate units, such as the cost per hour and cost per minute of 
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The intervention structure and outputs in both the trial context and scenarios of interest were 
described in a set of sheets with quantitative data on each level of the (hierarchical) structure 
involved in intervention delivery. These sheets included simple data, such as the number of 
districts and health posts involved in each intervention in the trial, as well as more complex 
data on the numbers of villages, households, and individuals who actually received each 
intervention. For additional modelling to other contexts, further information could be added. 
These data served as an important starting point for identifying the variation units used to 
structure the model.  
In Figure 13, we explain the cost data summary and modelled cost scenarios sheet in greater 
depth. Six of the seven variables used to define the model structure were categorical, while 
the resource description required free text. Each row of the worksheet reflected a resource, 
sufficiently disaggregated that it could be categorized according to all the dimensions of the 
model structure. While resources may be disaggregated in greater depth than required by the 
model structure, this approach highlights how far disaggregation is actually necessary for the 
intended analyses, which may avoid time spent in collecting data in unnecessary detail.  
In the “observed in trial” section, two columns contain formulae linked to input worksheets 
with data on the quantity and price of each resource. In a third column, price and quantity are 
multiplied to generate a cost of that resource. This “long form” structuring of the data 
facilitates flexible analysis along multiple dimensions through the use of pivot tables. The total 
cost of a given intervention – the key product of the cost model – was generated by using pivot 
tables to sum the “cost” column and to filter, stratify, and cross-tabulate the analysis by the 
given intervention, activity, or other variables.  
For each resource, the variation unit with which it was associated was indicated in the 
“structure” section and the number of units at this variation level over which costs were 
spread in the trial was indicated in the “observed in trial” section. For example, the cumulative 
quantity of time of all head nurses to receive training was expected to vary with the number of 
health posts (as indicated in the “structure” section). In the “observed costs in trial” section, 
the total costs of this resource in the trial were therefore divided by the 18 health posts in 
which MDA was implemented to generate an average cost per health post of head nurse time 
receiving training. This variable, in turn, was an input in subsequent scenario analyses.   
Additional sets of columns were used to generate scenario analyses in the cost analysis and 
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of additional columns required for each scenario analysis depended on the complexity of the 
changes made. At a minimum, each scenario analysis included three columns: one in which a 
change is made to prices, quantities, or the number of variation units across which the 
intervention is implemented; one indicating the sources and assumptions behind any such 
changes; and one recalculating the total cost of that resource in the new scenario. All values in 
the scenario and sensitivity analyses use formulae to link to other columns in the same 
worksheet or in the input worksheets; values are not input directly into the “cost data 
summary and modelled cost scenarios” sheet. 
In our cost analysis, we evaluated all costs deterministically; probabilistic analysis was only 
implemented in our cost-effectiveness analysis. It would, however, be possible to conduct a 
probabilistic sensitivity analysis within the structure of this workbook by defining price, 
quantity, or cost variables as distributions rather than fixed values.     
 
5.2.3. Mechanistic cost model: Insights for understanding the costs of scale-up 
and alternative approaches to targeting 
This approach to cost modelling offers several insights for understanding the costs of “scale 
up” and the costs of alternative targeting strategies. The term “scale-up” can mean many 
things (Mangham and Hanson, 2010). Our model gives some insights into what economies may 
be reasonable to expect, and how this may differ based on the cost structure of the particular 
interventions. The degree to which economies of scale are likely depends on the proportion of 
total intervention costs that are associated with variation levels higher than the output level, 
which in turn depends on the degree and level of targeting and the number of implementation 
rounds.  
Our analysis shows that the total and average costs per person targeted or reached depend on 
both the proportion of a total population targeted, i.e. the degree of targeting, and also the 
structure of that targeting, i.e. the level at which the targeting takes place. In Figure 14, we 
show how alternative approaches for reaching the same proportion of the population would 
result in different costs. They involve different numbers of CHWs, health posts, and districts to 
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Chapter 6.    Designing economic evaluations for transferability: A 
critical review and practical guide  
 
6.1. Preface to Chapter 6 
 
Many important methodological questions emerge from the two economic evaluations, which 
are worth exploring in greater depth. In this sixth chapter, I focus on how to improve the 
transferability of economic evaluation evidence from trials and pilots beyond the particular 
context of the trial or pilot itself. I focus on transferability – that is, the degree to which 
evidence from one context may be appropriately used to inform decision-making in another 
context - because of its broad relevance and importance to all economic evaluations and 
especially to those conducted in LLMICs. Transferability emerged as a key challenge from the 
bibliometric analysis presented in Chapter 2, which demonstrated the acute scarcity of 
economic evaluation evidence, especially in LLMICs. The first economic evaluation in this 
thesis, presented in Chapter 4, was conducted in accordance with standard guidance on 
improving the generalizability or transferability of economic evaluations; however, 
shortcomings were identified in the recommended statistical approach to improving 
transferability. In both economic evaluations presented in Chapters 4 and 5, some progress 
was made in addressing the shortcomings in methodological guidance by demonstrating how 
mechanistic cost modelling can usefully inform understanding of how costs may be expected 
to vary outside the trial context or with specific changes to the interventions.    
This chapter aims to begin to respond more holistically to some of the shortcomings in current 
methodological guidance on how to improve the transferability of economic evaluation 
evidence, focusing especially on LLMICs. First, I conduct a critical review to identify insights 
from wide-ranging literature, including research not framed as pertinent to transferability or to 
economic evaluation. I then draw on both this literature review and my own experience 
conducting economic evaluations to propose some initial methodological guidance regarding 
how to make economic evaluations more transferable in future.  
The critical review was conducted alongside and after the economic evaluations presented in 
this thesis; it therefore informed some of the analyses previously presented, but could not 
inform their study designs, which instead reflected standard guidance at the time when they 
were done. The designing for transferability guide was developed after both the economic 
evaluations and critical review were conducted, and so represents a proposal for how future 
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economic evaluations should be conducted. As this guidance has not yet been tested, post-
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6.2. Abstract  
 
The costs, effects, and cost-effectiveness of interventions vary across contexts. Understanding 
when and how to transfer evidence appropriately across geographies or jurisdictions and from 
small-scale trial or pilots to much larger, real-world decision contexts is therefore challenging. 
Nonetheless, such transfers are crucial for optimizing the efficiency of policy choices and the 
value of evidence. This article aims to promote more efficient priority setting by increasing the 
transferability of economic evaluation evidence generated from trials and pilots. A wide-
ranging critical review identified ten literature streams which contribute to understanding how 
to make economic evaluations more transferable. Drawing on this review and experience 
conducting economic evaluations, I propose guidance on how to design economic evaluations 
alongside trials or pilots in ways that promote transferability. I argue that transferability is a 
complex question requiring a complexity perspective, even for seemingly simple interventions. 
Making economic evaluation evidence more transferable requires understanding and 
communicating what an intervention is and the mechanisms of action through which it 
interacts with context to produce changes in costs and effects. Model-based economic 
evaluations alongside trials or pilots can facilitate the transfer of findings generated within 
trials and pilots to relevant decision context(s). Questions are presented to guide researchers 
through four iterative stages: I) Framing the economic evaluation, II) Model identification 
and/or development, III) Data needs identification, and IV) Analysis and reporting. Identifying 
and closing – where possible – the transferability gap between planned implementation in the 
study context and anticipated implementation in one or more decision contexts are important 
first steps. Future research should pilot and further refine this guidance.  
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6.3. Introduction  
 
Policy makers at every level face constant decisions about whether to maintain the status quo 
or to adopt a new course of action. Only rarely, however, can they draw on robust evidence 
from an empirical economic evaluation conducted to inform the exact decision problem they 
face in their own decision context (Drummond et al., 2015, Kalo et al., 2016, Pichon-Riviere et 
al., 2012). While they may sometimes commission empirical research, such investment is not 
feasible for every decision in every context and takes time. Instead, especially for new 
interventions, any potentially relevant evidence is often drawn from small-scale pilots or trials 
of interventions that may not precisely reflect the ones under consideration and may have 
been carried out in in contexts that do not precisely match the decision context.  
Judgments about the relevance of evidence to a particular decision context are challenging 
because the effectiveness, costs, and cost-effectiveness of interventions vary across contexts. 
Both overly wide and overly narrow definitions of “relevant evidence” risk sub-optimal policy 
choices (Drummond et al., 2009). While maximizing the usefulness of empirical evidence is 
important in any setting, the particularly acute scarcity of data in low- and lower-middle-
income countries (LLMICs) intensifies the need to ensure that opportunities for data collection 
afforded by trials and pilots are fully exploited.  
This article aims to promote more efficient priority setting by increasing the transferability – 
and thus usefulness – of economic evaluation evidence generated from trials and pilots, 
especially in LLMICs. In the following sections, I first define transferability and the associated 
challenges. Second, I critically review wide-ranging literature pertinent to improving the 
transferability of economic evaluation evidence. Third, I present initial guidance on how to 
make economic evaluations conducted alongside trials and pilots more transferable, before 
concluding with some final reflections.  
    
6.4. Defining transferability and its challenges 
 
I use the term “transferability” to refer to the degree to which evidence regarding 
interventions in one context may be appropriately used to inform decisions regarding another 
context, with or without modifications to the analysis or interpretation. Transferability is 
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related to the term “generalizability” and sometimes (erroneously) used interchangeably. 
Barbieri and colleagues usefully distinguish between the terms:  
Studies may be considered generalizable if they can be applied . . . without any 
adjustment needed for interpretation. In addition, some studies may be transferable if 
they can be adapted to apply to other settings. Finally, some may be so specific to a 
given jurisdiction that they are simply not transferable to any other jurisdiction. . . It is 
probably best to think of the transferability of data as being represented by a 
spectrum, with ‘generalizable’ being at one end and ‘not transferable’ at the other. 
(Barbieri et al., 2010) 
In this sense, which I adopt, the concept of generalisability is nested within a wider concept of 
transferability.  
I apply the term “transferability” both to the transfer of findings across geographies or 
jurisdictions, as referenced above, as well as to the transfer of findings from small-scale trials 
or pilots to much larger, real-world contexts. These two dimensions of evidence transfer often 
occur simultaneously, as findings from a trial or pilot in one country may be used to inform 
national policies in another country. While the transfer to real-world contexts is often 
discussed in terms of “external validity” (Mantopoulos et al., 2015, Ramsey et al., 2015, Van 
Staa et al., 2009) and “scale up” (Colbourn et al., 2015, Johns et al., 2005, Kumaranayake, 
2008), I argue that using the term “transferability” usefully highlights the common challenges 
faced in both dimensions of evidence transfer. 
When transferring evidence across contexts, other “contexts” may include other geographical 
areas, either within the same country or in another country, or they may include different 
population groups, types of contact points, degrees of researcher involvement, or policy, 
political, economic, or social contexts. For example, policy makers may seek to use an 
evaluation of an intervention implemented nationally in hospitals to inform decisions about 
whether to roll out a similar intervention in primary care or amongst a different patient group.  
Secular trends, exogenous shocks, and policy changes may also change a local context, so that 
an evaluation of past implementation may not reflect the future context even in the same 
geographical location. 
Both effects and costs may vary across contexts and thus change the incremental cost-
effectiveness ratio and the optimal adoption decision. Transferring evidence across 
geographies even within the same jurisdiction raises numerous challenges, such as accounting 
for differences in health service structures, epidemiology, population characteristics, or price 
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levels. Transferring evidence across jurisdictions may raise additional challenges, such as 
adapting to different decision-making processes, currencies, or laws.  
The effects or benefits of an intervention as measured in trials, pilots, and small-scale studies 
are often substantially greater than the benefits achieved in subsequent expansion, such as in 
national roll-out (Blonde et al., 2018, Carls et al., 2017, Glasgow et al., 1999). This dilution of 
effectiveness at scale occurs even when the initial evaluations are framed as “effectiveness” 
rather than “efficacy” studies and may reflect a reduction in implementation effort, resource 
inputs, fit of the intervention to the new context, and other factors.  
Average costs in trial or pilot settings may also differ from the “real world” (Batura et al., 2014, 
Johns et al., 2005, Kumaranayake, 2008, Ramsey et al., 2015). They may be higher than in the 
“real world” because of diseconomies of small-scale production (e.g. of medicines) for a trial, 
the involvement of more highly paid consultants and researchers, the smaller number of 
recipients over which fixed costs may be spread, inefficiencies in implementation caused by 
the research context, and the fact that evaluations are often conducted in the early stages of 
implementation, before implementation has been optimized. Conversely, average costs from 
trials and small-scale pilots may appear lower than at scale if national-level costs have not 
been included or if the standard of care to which a new intervention is compared is 
substantially different from standard practice.  
Despite all these challenges in appropriately transferring cost, effectiveness, and cost-
effectiveness evidence across contexts, transfers happen whenever research evidence is used 
to inform prospective decision-making. To help ensure that such transfers are appropriate and 
to maximize the value generated from individual studies, primary studies must be designed 
with the need to inform new contexts in mind.  
 
6.5. A Critical review of transferability literatures 
 
6.5.1. Critical review methods 
 
To examine contributions to improving the transferability of economic evaluation evidence 
from a far wider scope of literature than a systematic review would allow, a critical review was 
conducted. In their typology of reviews, Grant and Booth write:  
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“An effective critical review presents, analyses and synthesizes material from diverse 
sources . . . . A critical review provides an opportunity to ‘take stock’ and evaluate what 
is of value from the previous body of work. . . . [There] is no formal requirement to 
present methods of the search, synthesis and analysis explicitly. The emphasis is on the 
conceptual contribution of each item of included literature, not on formal quality 
assessment. While such a review does serve to aggregate the literature on a topic, the 
interpretative elements are necessarily subjective and the resulting product is the 
starting point for further evaluation, not an endpoint in itself.”  
I identified relevant literature through an iterative process of searches in databases, including 
Web of Science, Scopus, Pubmed, and Google; review and selection of relevant publications; 
review of publications cited by and citing each of these relevant publications; and suggestions 
from reviewers. Initial searches combined the following terms: (“transferability” OR 
“generalizability”) AND (“health economic evaluation” OR “cost-effectiveness analysis”). 
Subsequent searches combined (“transferability” OR “generalizability”) with alternative terms 
(“health intervention” OR “health system”), and then employed new terms (e.g. “scale-up 
cost”, “external validity”, “health system constraints”) to identify literature on themes relevant 
to the research question, which were known to me or emerged as potentially relevant and had 
not yet been captured. I therefore include work which omits the words “transferability” or 
“generalizability” if I believe it contributes to answering the research question. The advantage 
of this approach is that allows for a more holistic, multidisciplinary review of conceptual 
contributions to the research question without restriction on the study design, type of 
publication, or focus of the publication.  
I include research from countries of all income levels about all types of health interventions, 
but focus particularly on the degree to which findings are relevant to LLMICs and facilitate 
comparison of a broad range of clinical and non-clinical interventions designed to improve or 
maintain health. I focus on the transferability of findings, rather than on methodological 
requirements or preferences of decision-makers, which vary between contexts. For example, 
while some decision-makers specify a societal perspective and others a provider perspective, I 
do not focus here on the need to adapt an analysis to meet such differences in decision-
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6.5.2. Critical review findings 
 
Many literature streams have made relevant contributions to understanding how to make 
economic evaluations alongside trials and pilots more transferable, but these literature 
streams have tended to run in parallel, with different vocabularies and framings and little 
communication between them. I identified ten such literature streams emerging from four 
wider (and somewhat overlapping) research areas (10, Figure 14). In the following sections, I 
critically review the main contributions and limitations of each of these literature streams in 
turn, with a focus on relevance for LLMICs, before summarizing findings and key research gaps. 
 
1) Increasing the generalisability of economic evaluations alongside trials 
The first literature stream is framed around making economic evaluations conducted alongside 
trials more “generalisable”, especially to real-world settings. This literature underscores the 
value of conducting economic evaluations alongside naturalistic, rather than highly artificial 
trials (Ramsey et al, 2015); statistically analysing within-trial heterogeneity to allow adjustment 
of findings for contexts outside the trial (Grieve et al., 2005, Sculpher et al., 2004, Manca et al., 
2005); separate reporting of resource use and unit costs (Ramsey et al, 2015); description of 
the study setting (Drummond, 2005); and, using data from trials within decision analytic 
models, which appropriately reflect the decision context, rather than conducting entirely trial-
based economic evaluations, which are restricted to the costs and outcomes measured in the 
trial (Sculpher et al., 2006, Sculpher, 2015).  
As this literature focused on clinical interventions in high-income countries, authors assume 
that cost and outcome data are collected from individual patients through case report forms, 
which may not be possible for public health interventions delivered at a community, rather 
than individual level. Recommendations to improve generalisability through more 
representative study sites (Gheorghe et al., 2013) may not be feasible, especially for public 
health interventions, which may need to be conducted in a single geographic area to identify 
and measure community (herd) effects and to evaluate the feasibility of delivery before 
deciding to implement in multiple locations or on a very large scale. The analysis of the costs of 
SMC presented in Chapter 4 used statistical methods to examine within-study heterogeneity, 
as recommended; however, while this analysis yielded some useful findings regarding 
economies of scale, it also revealed limitations to such an approach, which did not exploit 
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2) Transferability of economic evaluations across jurisdictions 
A second literature stream focuses retrospectively on the transfer of existing economic 
evaluation evidence. I identify three stages: assessment, comparison, and transfer. First, 
economic evaluations may be assessed for their “potential transferability” (Nixon et al., 2009, 
Boulenger et al., 2005) to determine whether they have employed adequate methods and 
reported enough information for transferability to another context to be assessed. Many 
economic evaluations fall at this first hurdle (Mandrik et al., 2015, Augustovski et al., 2009). 
Second, relevance to another specific decision context may be assessed. Welte and colleagues 
(Welte et al., 2004) provide the seminal guidance on these first two stages, describing three 
“general knock-out criteria” (lack of comparability of intervention or comparator or insufficient 
methodological quality) and 14 transferability factors on which the study and target decision 
contexts should be compared (Goeree et al., 2011). Third, adjustments may be made to permit 
evidence transfer. The ISPOR report on transferability across jurisdictions (Drummond et al., 
2009) recommended (in their order of preference): no adjustments; simple adjustments, such 
as use of purchasing power parities to adjust prices, where appropriate; re-analysis of patient-
level data where multi-country studies have included the jurisdiction of interest; or adjustment 
through decision analytic modelling.  
This literature stream makes the important point that researchers should not to be too 
restrictive in what evidence is considered transferable, nor too demanding in how much data 
and effort is considered necessary to adjust existing evaluations to a sufficient degree to use 
their evidence to inform decision-making (Essers et al., 2010). Limitations of this literature 
stream include its narrow focus on clinical interventions – often “pricing and/or 
reimbursement of health technologies” (Drummond et al., 2009) – and on Western Europe and 
North America. There is little consideration of how the organization of the health system or 
wider population characteristics may affect transferability, except as described by “practice 
patterns” or “case mix” – large and complex concepts, which are not unpacked. While several 
recommendations advocate the use of “expert opinion” in determining whether evidence is 
transferable or which data or estimates to use, they do not specify what particular expertise is 
necessary or how experts should assess the evidence. This gap is particularly problematic for 
LLMICs, where economic evaluation expertise is scarce and economic evaluation experts may 
lack knowledge of the specific aspects of the local health system most critical for the particular 
decision. While considerable attention is paid to whether the “decision problem” is 
transferable, little attention is given to understanding the intervention itself and how it may 
interact with context to produce changes in health outcomes. Some (especially large) UMICs 
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are discussed (Alshreef et al., 2018, Mandrik et al., 2015, Augustovski et al., 2009, Barbieri et 
al., 2010, Drummond et al., 2009), but virtually no mention is made of LLMICs.   
 
3) Synthesis of economic evaluation evidence across all LMICs 
A third literature stream consists of initiatives addressing the transferability challenge in LMICs 
by synthesizing – or facilitating synthesis of – economic evaluation evidence across all LMICs. 
This literature underscores the scarcity of economic evaluation evidence in LMICs; the trade-
offs between precise contextualization and time, resources, and broad applicability; and the 
importance of methodological quality, standardization, and aggregation of evidence in 
promoting transferability.  
Arguing that “one major factor limiting the transferability of [standard, incremental] . . . CEA 
results from one population to another . . . [is the] different current mixes of interventions” 
(Tan-Torres Edejer et al., 2003), WHO developed generalised cost-effectiveness analysis 
(GCEA) (Murray et al., 2000), in which intervention packages are compared to a null set 
representing the natural course of illness without preventive or curative interventions. By 
decontextualizing analyses and requiring comparison of all options for a given disease or sub-
sector, however, GCEA is ill-suited for analysing evidence on new interventions and may lack 
face validity for decision-makers seeking context-specific advice.  
A second set of initiatives compiled and – to varying degrees – synthesized evidence. For 
example, the Gates Foundation funded development of cost-per-DALY (CEVR, 2019) and 
intervention cost databases (GHCC, 2019). The Disease Control Priorities project synthesized 
evidence, including cost-effectiveness analyses; generated league tables; and combined league 
tables with other evidence and expert opinion to recommend benefits packages (Jamison and 
Mosley, 1991, Jamison et al., 2018, Horton, 2017). WHO-CHOICE used econometric analyses to 
estimate outpatient consultation and inpatient bed-day costs for all LMICs (Stenberg et al., 
2018). Numerous United Nations agencies collaborated to develop the OneHealth Tool, which 
models the costs and health impacts of various combinations of interventions in any LMIC 
(WHO, 2019c). While recognizing the importance of context, this second set of approaches is 
retrospective, relying on limited existing data, which constrain the accuracy and context-
specificity of their findings. Data underpinning WHO-CHOICE estimates, for example, are 
drawn from only 30 countries, are of questionable quality and comparability, and are at least a 
decade old (Stenberg et al., 2018).  
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A third set of initiatives developed general reference cases for conducting economic 
evaluations in LMICs (Wilkinson et al., 2016, Vassall et al., 2017), and guidance in specific areas 
(Walker et al., 2010a) in order to improve comparability, quality, and reporting, but do not 
address other aspects of how to make interventions more transferable. 
 
4) Value of implementation 
A small literature on “value of implementation” (Fenwick et al., 2008) does not use the term 
“transferability”, but focuses on how to replicate the effectiveness achieved in clinical trials in 
real-world implementation, or how to transfer findings from clinical trials to real-world settings 
in ways that take into account the reduced uptake of a new technology outside a trial setting 
(Kim and Basu, 2017). In doing so, it speaks to the scope of the alternative courses of action 
that should be evaluated and potentially transferred. Specifically, it demonstrates the 
importance of an integral (rather than sequential) assessment of the cost-effectiveness of a 
new technology and “implementation activities” aiming to instigate and maintain its use 
(Hoomans et al., 2009, Kim and Basu, 2017). In the sequential evaluation, which reflects 
standard practice in HTA, interventions that appear less cost-effective under idealised 
conditions of “perfect” implementation (Andronis and Barton, 2016b, Andronis and Barton, 
2016a) may be eliminated from consideration at an initial stage, even where they are more 
readily implementable and therefore potentially more cost-effective in practice than those 
interventions that remain under consideration at a later stage (Hoomans et al., 2009).   
Yet, the value of implementation literature (Fenwick et al., 2008, Willan and Eckermann, 2010, 
Whyte et al., 2016, Faria et al., 2017, Kim and Basu, 2017, Hoomans et al., 2009) remains 
narrowly focused on clinical interventions in Western Europe and North America and does not 
engage meaningfully with implementation as a potentially complex process of behaviour 
change whose effectiveness and costs require research. This gap is important because 
incorporating implementation activities into integral cost-effectiveness estimates may raise 
substantial challenges for transferability, as variations in human behaviour between contexts 
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5) Intervention reporting 
A fifth literature stream grappled with identifying the essential features defining an 
intervention, the interconnections between interventions and their context, and the potential 
for interventions to require “tailoring” to work in similar ways in new contexts. Despite evident 
relevance, few publications in this stream refer to “transferability” explicitly and none engage 
meaningfully with questions of costs or cost-effectiveness. Hoffman and colleagues’ (2014) 
“template for intervention description and replication (TIDieR) checklist and guide” extended 
reporting guidelines for randomized trials (Schulz et al., 2010) and protocols (Chan et al., 
2013), but was “intended to apply across all evaluative study designs”, “with the objective of 
improving the completeness of reporting, and ultimately the replicability, of interventions”. It 
clarified that an intervention cannot be defined solely by “a label or the ingredients list” – as is 
common in HTA – and must include the “why, what (materials), what (procedure), who 
provided, how, where, when and how much”, as well as information on planned tailoring and 
unplanned modifications to the intervention, which “can all influence efficacy and replicability 
but are often missing or poorly described” (Hoffmann et al., 2014). While their 11 checklist 
items are designed to apply both to an intervention and comparator and both to “apparently 
simple drug interventions” and to all components of more complex interventions, they focus 
on clinical decision-making.   
While narrowly framed, two extensions to TIDieR appear useful for all interventions. One 
extension makes an important contribution in arguing that “providing the underlying rationale 
of the intervention enables readers to understand its essential components” (Campbell et al., 
2018). Another usefully promotes reflexivity by asking who filled out the checklist (Cotterill et 
al., 2018).  
Alternatives to TIDieR (Kagesten et al., 2017, Mohler et al., 2015, WHO, 2017b) emphasize the 
usefulness of clear reporting at the early stages of intervention development as a means of 
improving intervention design and implementation. One of these checklists features the only 
reporting item focused on transferability, seeking somewhat simplistic “[reflections] on the 
context-dependence of the programme and on the degree of effort that would be needed to 
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6) Transferability of complex interventions 
A sixth literature stream is framed around complex interventions. The key insight from this 
literature is that understanding transferability requires understanding the mechanisms of 
action through which an intervention interacts with context to produce changes in outcomes 
(Grant et al., 2013, Moore et al., 2015, Bunce et al., 2014, Oakley et al., 2006). Theories of 
change are important tools for understanding mechanisms of action; they can inform and, in 
turn, be refined by process evaluations and “[provide] a comprehensive set of indicators to 
evaluate all stages of the causal pathway through which an intervention achieves impact.” (De 
Silva et al., 2014) Many authors justify including process evaluations in wider evaluations on 
the basis that they achieve “deep understanding of the ‘how’ and the ‘why’ behind 
intervention outcomes” (Bunce et al., 2014) or “greater explanatory power” (Oakley et al., 
2006), which are “crucial to understanding . . . how these effects might be replicated by similar 
future interventions” (Moore et al., 2015); that is, process evaluations “[improve] the 
credibility and transferability of study findings” (Bunce et al., 2014). Pawson and Tilley (2004), 
leading proponents of one type of theory-based evaluation, explain that “[realist] evaluations 
asks not, ‘What works?’ or, ‘Does this program work?’ but asks instead, ‘What works for whom 
in what circumstances and in what respects, and how?’”  
Whereas other literature streams tend to mention context vaguely, the complex intervention 
literature specifies that the most important contextual features depend on the mechanisms of 
action of the particular intervention. Context is “those features of the conditions in which 
programmes are introduced that are relevant to the operation of the programme 
mechanisms” (Pawson and Tilley, 2004) or “anything external to the intervention that may act 
as a barrier or facilitator to its implementation, or its effects” (Moore et al., 2015).  
The literature stream also emphasizes that complex interventions may require “tailoring” or 
“adaptation” to work in similar ways in new contexts. Villeval and colleagues (2019) argue that 
the key functions (or mechanisms) of a complex intervention may be transferable, but their 
“specific form (i.e. concrete activities implemented)” must be adapted to local contexts by 
“local actors [who] will decide on the form of the replicated intervention according to the 
specificities of and the knowledge they have about the features of their context”.  This insight 
is important; however, the implications of changes in the “form” of an intervention for costs 
are not mentioned (Villeval et al., 2019).   
In fact, most of the complex intervention literature stream ignored costs (Villeval et al., 2019, 
Burchett et al., 2018) or treated economic questions superficially, referring to costs, for 
Chapter 6. Designing economic evaluations for transferability - Page 141 of 216 
 
example, as a characteristic of an intervention (Schloemer and Schroder-Back, 2018) or of the 
context, rather than a dynamic product of the interaction between the intervention 
components (which themselves require resource inputs) and the context. Authors therefore 
failed to consider that an intervention that may be effective in or adaptable to another context 
should not necessarily be implemented if it is not also an efficient use of resources in that 
context. 
The complex intervention literature largely frames its contributions as not relevant to “simple” 
interventions, such as “drugs or surgical procedures” (Lewin et al., 2017, Rogers, 2008, Oakley 
et al., 2006), although some authors recognized that “[few] interventions are truly simple” 
(MRC, 2008) and that even simple interventions may have complex interactions with context 
(Moore et al., 2015).  Petticrew (2011) argued that interventions are not inherently complex or 
simple, but rather, that researchers may choose to view an intervention as simple or complex, 
depending on the research questions and purpose of the analysis. This insight has important 
implications for understanding the manifestly complex question of transferability. 
 
7) Economic evaluation of complex interventions 
A seventh, very small literature stream argues that articulating theories of change with specific 
reference to resources can improve the transferability of economic evaluation evidence. In 
particular, Anderson and Hardwick extended their prior work – including Walker et al. (2010b) 
– and drew on Pawson and Tilley (2004), Byford and Sefton (2003), and others to propose 
“explanatory economic evaluation” drawing on realist principles (Anderson and Hardwick, 
2016). They argued that “most economic evaluations . . . are archetypal ‘black box’ 
evaluations, with minimal interest in how and why a particular configuration of resources (an 
intervention) changes outcomes” and that this approach “has important [negative] 
consequences for the generalisability and use of their findings”. They proposed that the main 
evaluation team “could more explicitly theorise and capture the resource requirements and 
consequences of hypothesised programme mechanisms, outcomes and contexts”. In addition 
to better incorporating resources within the main programme theory, Anderson and Hardwick 
also promoted development of “programme theories which explicitly seek to explain cost-
effectiveness or altered costs”. They illustrated their proposal for a “cost-effectiveness-specific 
programme theory” with a realist review of economic evaluations of “shared care” for chronic 
conditions in HICs.  
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While these authors repeatedly argued that “context matters”, however, they did not 
elaborate on which aspects of context mattered (Walker et al., 2010b) and did not include 
context in their example of a “cost-effectiveness-specific programme theory” (Anderson and 
Hardwick, 2016). As with the previous literature stream, authors also tended to frame their 
recommendations as relevant for complex but not “simple” interventions. Most crucially, they 
did not discuss how “explanatory economic evaluation” principles might be enacted in primary 
economic evaluations (rather than reviews) (Anderson and Hardwick, 2016). They also 
focussed exclusively on the transferability of the economic evaluation evidence relating to an 
intervention’s function, without considering how evidence on the costs of a particular “form” 
of an intervention could be transferred. 
 
8) Health system constraints 
An eighth literature stream framed around health system constraints offers an explicitly 
economic framing of context within economic evaluations, which is wider and more relevant 
for guiding policy choices in LMICs than Welte’s framework (2004). Mikkelsen and colleagues 
(2017) used WHO’s health system building blocks as a framework to describe supply 
constraints and identified demand constraints such as “stigma, limited knowledge about HIV, 
fatalism, out-of-pocket payments, and waiting times”. Vassall and colleagues (of which I was 
one) (2016a) presented a conceptual model of distal and proximal demand and supply 
constraints which may affect the “care pathway”, and some of the relationships between 
interventions, the supply and demand context, and population health outcomes.  
The constraints literature deals with both the transfer of trial and small-scale evidence to real-
world implementation and the extension of findings across geographies in ways that recognize 
heterogeneity between contexts. While most do not focus on “transferability” as such, authors 
in this stream articulate a tension between generating evidence to support “generic advice to 
a wide range of countries” (Hauck et al., 2016) and “[taking] into account the local health 
system” (Mikkelsen et al., 2017).  
Throughout this literature stream, however, conceptualization of what interventions are and 
how they interact with context to produce changes in outcomes – i.e. the mechanisms of 
action – remain poorly defined. Descriptions of the cost-effectiveness of a technology and of 
“enabling interventions” (2016a) – and indeed, the very notion of a “constraint” to optimizing 
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utility – mirror the dichotomized conceptualization within the value of implementation 
literature of a technology divorced from actors or actions to instigate its use.  
 
9) DALYs, QALYs, and 10) Benefits  
The final two literature streams emerge from different research traditions, but both deal with 
the appropriate measure of effect to use in economic evaluations. Both QALYs (Sassi, 2006) 
and the benefits in CBAs (Robinson et al., 2019) are designed to reflect a specific society’s 
preferences, and are thus considered appropriate measures of utility or societal welfare . Most 
LLMICs have not conducted valuation surveys for QALYs (Kularatna et al., 2013, Welie et al., 
2020) or willingness-to-pay for a change mortality or morbidity risk, however, which inhibits 
adjustment of QALYs or benefits to most contexts in LLMICs. Further, the contingent valuation 
methods used in CBA to value changes in health outcomes or health risks do not reference the 
available health budget, so risk displacing more health benefits than they gain (Culyer and 
Chalkidou, 2019, Ochalek et al., 2018). A literature stream framed around “benefits transfer” 
deals with the transfer of the valuation of non-market goods – originally, environmental goods, 
and more recently, preference-based health outcomes – across contexts for use in CBAs. This 
literature emphasizes the tension between a preference-based approach, which is necessarily 
about local, context-specific preferences, and efforts to promote transferability. Brower and 
colleagues showed that simple transfers are more appropriate for “similar” contexts, while 
more complex transfers are required for “dissimilar” contexts, but do not provide any 
generalizable insights into how “similar” and “dissimilar” contexts should be defined for any 
given intervention (Brouwer and Bateman, 2005). Finally, the validity of contingent valuation 
methods and asking people in LLMICs to value health risks is unproven.  
While criticized for many shortcomings, including their focus on health rather than welfare and 
their exclusion of context-specific factors affecting a person’s lived experience of a condition 
(e.g. educational opportunities or public transport) (Nord, 2015, Chen et al., 2015), DALYs are 
explicitly designed to be universal (Sassi, 2006), which facilitates their transfer across contexts. 
As most full health economic evaluations to date in LLMICs have used DALYs, cost-per-DALY 
estimates can also be compared with existing literature. 
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6.5.3. Summary: Transferability literatures 
 
Insights into how to make economic evaluations more transferable have emerged from many 
different literature streams. I have sought to delineate these literature streams in meaningful 
ways; however, each stream includes publications that overlap with one or more other 
streams, and some of these literature streams, which vary tremendously in size, could have 
been grouped differently.   
From this review, I conclude that transferability is a complex question requiring a complexity 
perspective, even for seemingly simple interventions. As well as adherence to standard 
economic evaluation guidelines, making economic evaluation evidence more transferable 
requires understanding and communicating what an intervention is and the mechanisms of 
action through which an intervention interacts with context to produce changes in costs and 
effects. The key contextual features are those implicated in the mechanisms of action through 
which the intervention produces costs and effects. Interventions may require adaptation to 
work in similar ways in new contexts, and such changes are likely to affect the costs of the 
interventions. By contrast, similar forms of interventions may be deployed to serve very 
different functions, creating additional opportunities to maximize the use of scarce primary 
cost data. Articulation of theories of change with respect to both costs and effects in primary 
economic evaluations seems to offer a promising avenue for further research. Despite their 
widely-discussed limitations, DALYs facilitate evidence transfer and should therefore be used 
whenever possible, potentially alongside additional effect measures. 
 
6.6. Designing for transferability guide  
 
Drawing on my critical review and experience conducting economic evaluations, I propose 
some initial guidance on the design of economic evaluations alongside trials or pilots in ways 
that promote transferability. This guidance is intended to apply to all types of interventions 
and strategies in all settings when implemented in the context of trials or pilots, but responds 
particularly to the context of LLMICs, where so few economic evaluations are conducted that 
each economic evaluation must seek to inform a wide range of decisions, for which the 
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decision-makers are many and not necessarily known. The proposed approach encourages 
development of an in-depth understanding of how an intervention or strategy works in a 
particular context as a means of exploring how its costs and effects may be expected to vary in 
another context. An assumption underlying this approach is that understanding if and how 
cost-effectiveness evidence can be transferred across contexts is a complex research question, 
requiring a complexity lens (Petticrew, 2011).  
The purpose of this approach is to help economic evaluations do more than report 
retrospectively on the cost-effectiveness of precisely what was done in a trial or pilot, and 
instead to inform prospective decision-making – in a plausible and transparent way – both for 
the local context and, to the extent possible and appropriate, for different contexts and 
modified versions of the interventions studied. To achieve this aim, the invaluable opportunity 
to collect data alongside a trial or pilot should be conceived of as a means of developing and 
populating flexible and transparent mechanistic cost models and a decision analytic model 
alongside the trial or pilot. While decision analytic models are often used in economic 
evaluations alongside trials in LLMICs, this practice is not reflected in standard guidelines 
(Husereau et al., 2013), and mechanistic cost models are uncommon. This approach responds 
to Sculpher’s criticisms of “trial-based economic evaluations” (Sculpher et al., 2006, Sculpher, 
2015), which only analyse data within a trial, and uses the opportunity afforded by the trial or 
pilot to gain in-depth understanding of the alternative strategies, how they work, and how 
they incur costs and produce effects in a given context. It also responds to Anderson and 
Hardwick’s (2016) exhortations for explanatory economic evaluation, while focusing on the 
design and conduct of primary economic evaluations.  
The guidance that follows proposes a reversal in the order in which activities are commonly 
undertaken. Instead of treating transferability as an afterthought, transferability becomes the 
guiding principle of the economic evaluation; the focus remains throughout on generating 
evidence to inform prospective decision-making outside of the trial or pilot. The four main 
stages of this model-based economic evaluation alongside a trial or pilot are: I) Framing the 
economic evaluation, II) Model identification and/or development, III) Data needs  
identification, and IV) Analysis and reporting (Figure 15, Box 1). These stages share many 
commonalities with existing guidelines, but also differ in several important ways, notably: i) 
the order in which activities are conducted, ii) the use of theory of change and process 
evaluation for all intervention types, iii) the development of mechanistic provider cost models 
(as well as a decision analytic model), iv) a more targeted, model-driven approach to data 
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collection, and v) an explicitly iterative approach. The following guidance therefore necessarily 
covers some of the same ground as existing guidance, referring to such guidance as 
appropriate, but focuses on where this approach diverges from standard guidance.  
Figure 15 Designing for transferability: A flowchart of questions to consider in designing and conducting an 
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Box 1 Designing for transferability: Questions to guide the design of economic 
evaluations alongside a trial or pilot  
 
These questions are intended to guide initial design of an economic evaluation and to be 
revisited throughout the study, incorporating emerging findings and reflecting changing 
policy contexts, to maximize the transferability – and thus usefulness – of the economic 
evaluation produced. The four stages (I-IV) and seven steps (A-G) are explained below 
and illustrated in Figure 15. All references to “interventions” should be understood to 
refer both to a new intervention and to a comparator. Implementation of interventions in 
the study (i.e. trial or pilot) context is distinguished from intervention implementation in 
the decision context. 
I. Framing 
Framing is an iterative process – broken into three steps here – of A) understanding what 
is planned for intervention implementation in the study, B) considering what decisions an 
economic evaluation based on study implementation plans could or should inform, and 
C) assessing the transferability gap, that is, how planned implementation in the study 
and the associated costs and effects may differ from implementation in the decision 
contexts that the evaluators seek to inform. Understanding of the transferability gap 
should inform revisions to plans for the study in (A) and to the decision problems to 
address in (B), as well as model development in stage II. While (A) is shown as the 
starting point – as is often the case, from the perspective of economic evaluators, when 
they join a study for which initial plans have already been developed – (B) would be the 
ideal starting point. To answer the questions posed at this stage, evaluators will need to 
consult documents (academic literature and policy documents) and various people (e.g. 
policy experts, decision-makers, practitioners, and academics) at local, national, and 
potentially international levels. Detailed guidance available elsewhere on intervention 
reporting (Hoffmann et al., 2014, Mohler et al., 2015, Kagesten et al., 2017, WHO, 
2017b, Campbell et al., 2018, Cotterill et al., 2018) may be used to structure descriptions 
and discussions regarding planned intervention implementation in the study context and 
anticipated implementation in the decision context, as well as eventual reporting of what 
was done. 
 
A) INTERVENTION IMPLEMENTATION AND MECHANISMS OF ACTION: How will the 
interventions be implemented in the study? How are they expected to influence 
costs and effects?   
1. How are the proposed intervention activities expected to interact with the existing 
context to produce changes in health outcomes (i.e. what is the theory of change 
and what are the key aspects of the local context that the intervention will modify)?  
2. What are expected to be the resources used for: i) the activities to instigate change, 
including the intervention itself (e.g. policy change, training, radio campaigns, 
materials, drugs) and ii) downstream consequences of the interventions (e.g. 
changes in case management following introduction of a preventive intervention, 
reductions in complications or onward transmission following introduction of an 
improved case management intervention)?  
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RELEVANT DECISIONS: What policy decisions could/should this economic evaluation 
seek to inform? 
3. In which contexts outside of the specific research context might the same or 
similar interventions be relevant for consideration?  
4. How likely is it that additional economic evaluations of the same or similar 
interventions will be undertaken in the same, similar, or different contexts and on 
what time scale? For example, if few or none are expected in the near future, then 
this economic evaluation should consider seeking to inform a wider range of 
decisions than if many other related economic evaluations are expected 
imminently. 
5. Is the form of the intervention – e.g. door-to-door visits by CHWs – potentially 
relevant for informing decisions regarding similar interventions for other health 
areas?  
6. Are there other interventions relevant to the decision context, which are not 
planned for implementation in the study context?  
 
B) TRANSFERABILITY GAP: What is the transferability gap between planned 
implementation in the study and decision contexts?  
7. How may aspects of the research context affect the costs and effects measured 
relative to implementation outside a research context? For example, will research 
staff be involved in implementation or will their research activities influence the 
effects measured? Will the people implementing or receiving the interventions 
receive more (or fewer) resources than they would if the intervention were 
implemented outside a study context?  Is it possible to avoid or mitigate the 
influence of the research activities on the costs and health outcomes measured so 
as to approximate a real-world context more closely?  
8. What changes to implementation (and associated resource use) in the research 
context, if any, may need to be made (and by whom) to . . . 
a. . . . ensure feasibility and/or affordability in the decision context (e.g. lower the 
cadre/qualifications of implementing staff)?  
b. . . .maintain or increase effectiveness in the decision context (e.g. additional 
community meetings in more sceptical communities, or doubling the frequency 
of patient contacts)?  
9. What changes to effects and associated downstream costs would be expected in 
any new context considered and for each of the changes above? e.g. might lesser 
access to care outside the research context decrease incremental treatment costs 
and increase incremental health benefits for a preventive intervention? Might 
lowering the cadre of staff implementing the intervention also lead to reduced 
health benefits? 
10. Who has participated in discussions regarding the preceding questions? Should 
others also be consulted, e.g. people who may play substantial roles in intervention 
implementation in the study, in the policy decision process, or in eventual 
implementation in the anticipated decision contexts?  
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II. Models 
Based on an understanding of the decision problem and the transferability gap, the 
evaluator can develop an appropriate model structure or identify an existing model 
structure to use. Detailed guidance on how to conceptualize a cost-effectiveness model 
(Roberts et al., 2012)  and specific issues pertaining to different model types are provided 
elsewhere (Karnon et al., 2012, Pitman et al., 2012, Siebert et al., 2012, Squires et al., 
2016) and therefore not repeated here. 
C) PROVIDER COST MODEL: What is an appropriate model structure? 
11. Are there any existing cost models for similar interventions? 
12. What activities and resources are involved in each intervention? 
13. Which administrative or implementation levels (i.e. countries, provinces, districts, 
health facilities), and outputs (e.g. persons reached, cases treated) are involved in 
the process of intervention delivery and downstream costs? Do these variation 
units provide an appropriate structure for the cost model, or are there additional 
factors which may need to be incorporated, such as the number of delivery rounds 
or the proportion of cases that are severe, to generate a plausible cost model using 
readily available data?   
14. Are prices expected to vary with the scale of implementation of this particular 
intervention? If so, has this relationship been incorporated into the cost model? 
15. For each resource, with which implementation level or output can the quantity 
used be expected to vary? For example, the quantity of a specific drug used may 
vary with the number of patients reached or the number of illness episodes, and 
the quantity of nursing hours spent in receiving training may vary with the number 
of facilities involved in the intervention (if a fixed number of nurses per facility are 
trained).  
 
D) COST-EFFECTIVENESS MODEL: What is an appropriate model structure? 
16. To what extent and how can changes in effectiveness be modelled across the 
decision contexts? e.g. would dynamic transmission modelling be required or might 
a decision tree assuming equal efficacy and different coverage be sufficient? Could 
coverage data for similar types of interventions in the decision context be used? 
17. How do the cost model and cost-effectiveness model interact? Are there feedback 
loops, or can cost model outputs be used as inputs in the cost-effectiveness model? 
 
III. Data  
After framing the evaluation and identifying appropriate model structures, the evaluator 
should consider what data may be needed to populate the model, and the extent to 
which relevant data may be obtained from the study, or from additional sources such as 
routine health information systems, secondary data, or existing models such as WHO-
CHOICE (2011). Initial sensitivity analysis should be used to prioritise parameters for 
which obtaining accurate and precise estimates will have the greatest impact on 
improving the overall model’s precision and accuracy.    
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E) DATA: What data are needed and obtainable to populate the models?   
18. What resource use data are needed to populate the model? What level of detail 
will be needed to ensure that resource use data can be disaggregated according to 
the model structure? For example, will the total time nurses spend on the 
intervention need to be separated into time spent with patients (which may vary 
with the number of patients) and time spent in training (which may be fixed per 
nurse)? For each resource and scenario, will quantities reflect the research context 
or estimates for or observations from another context? 
19. Will the prices of resources used in the study implementation differ from likely 
prices in the decision-making context(s)? Do any price differences reflect 
differences in the quality of the resource (e.g. substitution with lower cadre of 
staff)? Which prices are consistent with the effect measures used? Which are 
relevant for decision-making? Are these prices expected to vary with location 
and/or with other factors (e.g. technological improvements over time lowering 
prices of tests, economic improvements increasing wages)? 
20. What data on effects are needed and obtainable? How are they expected to differ 
between the study context and the decision context?  
21. What data – qualitative or quantitative – are necessary to check the assumptions in 
the model structure and parameters? Have they been incorporated into data 
collection? 
22. Are resources available within this study to collect data in any or all of the decision 
contexts to which the findings may be transferred? For example, would it be 
possible to collect data on the numbers of units at each administrative level for the 
entire country?  
 
IV. Analysis  
The evaluator should ensure that the analysis is conducted and reported in accordance 
with relevant guidelines for high-quality economic evaluation research. During this stage, 
evaluators should revisit the previous stages of the evaluation to consider whether the 
framing of the analysis should change (perhaps in response to policy changes over the 
course of the study), if any aspects of model structure warrant revisiting, and if any 
further data would be useful and obtainable within the current study to maximize the 
usefulness of the results presented.  
F) ANALYSIS: Will analysis and reporting meet relevant quality benchmarks?  
23. Will the economic evaluation meet the iDSI reference case (Wilkinson et al., 2016), 
CHEERS checklist (Husereau et al., 2013), and other relevant quality benchmarks for 
study conduct and reporting? These may include guidelines for the 
country/countries of the study and any other countries in which the intervention(s) 
may be considered, as well as the World Health Organization, potential funders, 
and any other relevant decision-makers. 
24. Will the costs incurred in implementing the intervention(s) in the research context 
and any modelled costs be presented separately and transparently?  
25. Has the structure of the model(s) been presented?
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6.7. Conclusion  
 
Drawing on a wide-ranging critical review of 10 different literature streams and my own 
experience conducting economic evaluations, this article proposes preliminary guidance on 
how to make economic evaluations conducted alongside trials and pilots more transferable. 
Rather than remaining an afterthought, promoting transferability of economic evaluation 
evidence should become the guiding principle of intervention research. Promoting 
transferability requires efforts from the earliest phases of intervention design to identify and 
close – where possible – the transferability gap between planned implementation in the study 
context and anticipated implementation in one or more decision contexts. I argue that 
transferability is a complex question requiring a complexity perspective, even for seemingly 
simple interventions. Making economic evaluation evidence more transferable requires 
understanding and communicating what an intervention is and the mechanisms of action 
through which it interacts with context to produce changes in costs and effects. The key 
contextual features are those implicated in the mechanisms of action. I identify four stages for 
a model-based economic evaluation alongside a trial or pilot: I) Framing the economic 
evaluation, II) Model identification and/or development, III) Data needs identification, and IV) 
Analysis and reporting. For each stage, I articulate key questions to guide analysts to close the 
transferability gap. Future research should pilot and further refine the “Designing for 
transferability” guide as part of wider efforts to improve the transferability of economic 
evaluation evidence and maximize the value for money of empirical research. 
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Chapter 7.    Discussion 
 
In this final chapter, I summarize my empirical and methodological findings and relate them to 
the first four objectives of the thesis. I then discuss key strengths and limitations of the thesis 
and conclude.   
 
7.1. Empirical findings (Objectives 1, 2, and 3) 
 
Objective 1  
In Chapter 2, I met the first objective of the thesis, which was to examine the size, scope, and 
distribution of the recent, applied, economic evaluation literature. This uniquely 
comprehensive analysis provided an important snapshot of the economic evaluation literature, 
and in so doing, has provided a valuable, quantitative basis for debates around research 
prioritization, research capacity, and research methods. The analysis showed that more than 
1200 economic evaluations were published annually in the 28-month period we studied in 
2012-14. Of these, just 4% addressed LICs, 4% addressed lower-middle-income countries, and 
14% addressed UMICs, while francophone Africa and West Africa emerged as regions in which 
economic evaluations were particularly scarce. Moreover, 33 (18%) of the 184 economic 
evaluations identified as having studied at least one LLMIC examined more than 10 countries, 
further underscoring the importance of addressing the transferability challenge in LLMICs and 
in francophone and West Africa especially.   
The careful way in which I searched, screened, and communicated my search strategy and 
findings also provided valuable information for anyone reviewing the economic evaluation 
literature, which is especially useful now that NHS EED has ceased to be updated and the Wiley 
Health Economics Database is no longer available. While the Tufts Cost-Effectiveness Registry 
now offers a valuable database of cost-per-DALY studies (CEVR, 2019), my bibliometric analysis 
showed that less than half of full economic evaluations in LLMICs used DALYs, and thus 
quantified the limitations of relying exclusively on this registry in reviewing the economic 
evaluation literature. While the iDSI reference case now specifies that economic evaluations 
should report costs per DALY averted, my analysis demonstrates the scale of the changes in 
research practices necessary to meet this new requirement.  
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The experience of conducting this review also afforded me the opportunity to engage with 
systematic review and bibliometric methods, and, in the process of individually screening 
15,057 publications, to gain insights into the field of economic evaluation as a whole. These 
observations informed my critical review of transferability literatures and designing for 
transferability guide, which I presented in Chapter 6. 
Objective 2  
The second and third objectives of the thesis were met in Chapters 4 and 5, respectively, 
where I presented two economic evaluations of malaria interventions in central Senegal. The 
second objective was to explore the costs of delivering SMC to children under 10 on a large 
scale in central Senegal. As recommended (Sculpher et al., 2004), this evaluation explored 
heterogeneity in costs within the trial as a means of better understanding transferability 
beyond the trial. The Global Health Cost Consortium has also highlighted the importance of 
exploring cost heterogeneity (Vassall et al., 2017). My analysis demonstrated substantial 
economies of scale in the size of the health post catchment areas used to deliver the 
interventions. This finding indicated that the average cost of delivery across the intervention 
area should not be generalised to any setting, and that instead, costs should be understood as 
a function of the size of the catchment populations. The identification of an L-shaped average 
cost curve was consistent with the very limited literature on economies of scale in health care 
provision, but inconsistent with economic theory, which predicts a U-shape. This finding has 
important implications for efforts to improve the efficiency of health service provision, and 
suggests that the scale at which average costs begin to increase is greater than that observed 
in any of the facilities in our study area. Some other analyses of the costs of public health 
interventions have not explored uncertainty or heterogeneity in costs because they only 
collected costs of the overall programme without disaggregation; however, my analysis of SMC 
demonstrated that in-depth cost data collection and analysis of public health interventions is 
feasible and informative. 
The analysis of SMC also demonstrated the limits of an econometric approach to 
understanding cost variation. While many potential explanatory variables, such as 
geographical features, the number of years of experience with the intervention, and coverage 
rates, were hypothesized to be associated with the cost per course administered, the analysis 
was unable to identify robust statistical relationships with these variables. This absence of 
evidence may reflect a genuine absence of relationship; more likely, however, it reflects a 
degree of homogeneity within our study area, which may partly reflect the area itself and also 
perhaps the influence of the trial in standardizing procedures. It may also reflect the sample 
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size (n=46 facilities), which, while large for facility-based costings, remains small in statistical 
terms when exploring associations between multiple variables.  
The economic evaluation of SMC has already informed major changes in global malaria policy 
at WHO, which has led to the adoption of SMC as national policy in 12 countries and delivery 
of SMC to 19 million children under five in 2018 (WHO, 2019d). In addition, in the south of 
Senegal, SMC has been delivered to children under ten since shortly after the conclusion of our 
trial. While the economic evaluation of SMC responded directly to policy makers’ stated 
questions at the time, it was a partial rather than full economic evaluation as it did not 
incorporate a cost-effectiveness analysis. The economic evaluation of SMC presented in this 
thesis remains the only cost analysis in children up to age 10 and so may play an important 
role in informing deliberations about the potential expansion of current WHO guidance to 
recommend SMC for a wider age range. Direct comparisons of the costs and effects of 
delivering SMC to different age ranges would be ideal; however, in the absence of such head-
to-head field trials, mechanistic cost modelling, as used in the hotspot trial, could be extended 
to examine potential economies of scale in expanding the age range for SMC. In-depth 
comparison of the costs of delivering SMC to children under 10 in central Senegal as reported 
in this thesis with the costs of delivery of SMC to children under 5 across other countries of 
West Africa would be a valuable opportunity to better understand cost variation and 
transferability.  
Objective 3 
The third objective of the thesis was to assess the costs and cost-effectiveness of various 
combinations of MSAT, MDA, and IRS, which were geographically targeted at “hotspot” 
villages. This evaluation was conducted alongside a cluster-randomized trial, which was 
implemented in approximately the same geographical area of central Senegal as the first trial, 
but restricted to the rural areas (and thus excluding the semi-urban areas). The analysis 
provided important insights into how the efficiency of these interventions can be expected to 
vary with intervention choices, including the degree and level of targeting and number of 
rounds of implementation, as well as with contextual factors, including local epidemiology, 
prices, and health system structure. It showed that, despite the substantial relative reductions 
in malaria incidence achieved, the targeted interventions could not be considered cost-
effective in reducing the short-term disease burden in this context.  
The WHO’s latest approach, “High burden to high impact”, launched in 2018 (WHO, 2018c), 
reflects a desire to rebalance global efforts towards both improved control in high burden 
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areas and elimination in others. This renewed focus on tackling malaria in the highest burden 
areas may be a response to criticism that the focus of both attention and financial investment 
on malaria elimination was both inequitable and inefficient and resonates with the empirical 
findings presented in my economic evaluation of targeted MSAT, MDA, and IRS.    
Future research could combine the cost models I developed with transmission dynamic models 
to consider how the cost-effectiveness of alternative combinations of interventions, with 
varying degrees of geographical targeting, may vary across contexts. As current transmission 
dynamic models in the malaria field tend to integrate costs only as a fixed cost per person 
reached, with no consideration of how costs may vary with context, scale, or targeting (Drake 
et al., 2016), such integration of cost functions would be valuable. Future research could also 
further explore the concept of “diseconomies of targeting” and seek to understand the 
broader implications for malaria and other health areas. 
Together, these two economic evaluations of malaria interventions make important 
contributions to a very limited evidence base on malaria interventions delivered door-to-door 
by CHWs. This scarcity of evidence is particularly remarkable in light of the large global and 
national investments in malaria control and elimination. Both these analyses also offer 
important insights for the analysis of public health interventions beyond the field of malaria. 
Many large-scale programmes for the control and elimination of neglected tropical diseases 
(NTDs), for example, are based around similar, mass drug administration campaigns and face 
questions of if and how to target these efforts by age and geography (Pullan et al., 2019). A 
major multi-country study in Africa is now exploring community-based distribution of self-
testing kits for HIV (Neuman et al., 2018), which shares many features with MSAT for malaria, 
which we explored in the cost-effectiveness analysis alongside the hotspot trial. My analyses 
offer useful empirical findings to inform decision-making in these other areas, as well as 
methodological insights into how to collect and analyse data on these types of public health 
interventions, which are discussed further in the next section. 
 
7.2. Methodological findings (Objective 4) 
The fourth objective of the thesis was to develop and apply methods for the analysis of cost 
data in ways that promote transferability and to develop more general guidance on how to 
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design economic evaluations for transferability. In this section, I summarize how I met the first 
part of this objective in Chapter 5 and how I met the second part of this objective in Chapter 6.  
Analysing cost data in ways that promote transferability  
Estimates of intervention costs are critical for budgeting and priority setting. They must, 
however, reflect how costs vary within countries, between countries, and with scale. Where 
large-scale costing studies have been possible and large numbers of data points are available 
which reflect sufficient variation across relevant characteristics (including scale), econometric 
analyses have the potential to offer insights into cost variation (Lépine et al., 2016, Lépine et 
al., 2015, Meyer-Rath and Over, 2012). Econometric analyses can then be used to inform 
decision-making about continuation, modification, and/or expansion of the intervention of 
interest. These analyses are only possible, however, when the intervention has already been 
implemented at a very large scale, across sufficiently diverse contexts, and where good quality 
cost data relevant to the intervention is available, making them essentially “ex post” 
evaluations, meaning that they occur after very substantial scale-up has already occurred.  
While ex-post evaluations are undoubtedly important and underutilized, earlier stage 
economic evaluations are needed to inform decisions about whether such large-scale 
implementation should be undertaken at all. When new interventions are implemented 
initially, whether in small-scale pilots or trials, economic evaluations can generate initial cost 
estimates. To use findings from such small-scale studies to inform decision-making for real-
world implementation, however, analytical adjustments may be needed. These adjustments 
may need to reflect the cost implications of changes in the scale of delivery and extension or 
transfer to other geographical areas. Further, all possible variants of an intervention cannot be 
piloted in all settings, so those data that do exist need to be used to explore how modifications 
to an intervention may affect costs. 
In the cost analysis of SMC, I disaggregated the costs of delivering SMC across the three 
monthly implementation rounds and the levels of the health system with which each cost 
component would be expected to vary. I explained and provided examples of how this simple 
disaggregation of costs could be used to estimate the costs of implementation of SMC in the 
entire study area, including the control areas, and thus adjust for the inherent inefficiencies in 
trial-based implementation, in which meetings and trainings, for example, must be held at 
regional and district level, but not all health post catchment areas within the given districts and 
regions implement the intervention. I also discussed how costs could be expected to vary if the 
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intervention strategy were extended to include four or more monthly implementation rounds, 
which have been implemented and considered for implementation elsewhere.   
In the subsequent evaluation of the hotspot strategies, I substantially developed and extended 
the approach initiated in the cost analysis of SMC. I began by disaggregating the costs of each 
of the interventions – hotspot identification, IRS, MDA, and MSAT – in the same way as in the 
SMC analysis, that is, by implementation round and by the health system or output level with 
which each cost component would be expected to vary, as well as by activity and cost driver. I 
then developed a simple mechanistic model to estimate how costs could be expected to vary if 
the number of rounds of implementation or the number of units at any level of the health 
system or output were changed. This approach allowed me to estimate the costs of 
implementation if each of the interventions were implemented throughout the study area, 
thereby adjusting for the inherent diseconomies of trial-based implementation. In addition, 
this adjustment also accounted for variation in population, epidemiology, and catchment sizes 
between arms. Failure to account for such imbalances may lead to differences in cost 
estimates which reflect differences in economies of scale between the different populations in 
which the alternative strategies were implemented, rather than meaningful differences in the 
costs of implementing the interventions in the same areas. Further, the cost models allowed 
me to explore how costs may be expected to vary with changes to how the interventions are 
implemented, including different levels and degrees of targeting, in order to increase the 
usefulness of the analysis across a wide range of contexts and interventions.  
The hotspot evaluation thus illustrated how in-depth prospective data collection alongside a 
trial can be used to develop a simple, transparent, and flexible mechanistic cost model, which 
can predict how costs may vary with specific changes to context, scale, and scope of the 
interventions. This model could be adapted to estimate the costs of delivering similar 
interventions for other diseases, and provides a useful framework for costing public health 
interventions implemented through a cascade of activities.  
Designing economic evaluations for transferability 
In Chapter 6, I completed the fourth objective of the thesis by developing more general 
guidance on how to design economic evaluations for transferability. The need for such 
guidance emerged from my experience conducting the bibliometric analysis in Chapter 2 and 
the two economic evaluations in Chapters 4 and 5. The bibliometric analysis demonstrated the 
stark need to transfer economic evaluation evidence, especially across LLMICs. My experience 
conducting the SMC cost analysis in Chapter 4 then demonstrated some of the shortcomings of 
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standard guidance on how to improve the transferability of economic evaluations. Drawing on 
initial work in Chapter 4, I developed in Chapter 5 a mechanistic cost model, which usefully 
indicated how costs of several interventions could be expected to vary with contexts and some 
modifications to the interventions. While a very valuable contribution, the development of this 
cost model was a post-hoc analysis focused on better analysis of provider cost data.  
In Chapter 6, I sought to generate more general guidance on how to improve the 
transferability of economic evaluations conducted alongside trials or pilots in ways that would 
be relevant to all intervention types and contexts. Nonetheless, I paid particular attention to 
ensuring the usefulness and relevance of the guidance to LLMICs. As the need for such 
guidance emerged from the experience of conducting the economic evaluations in Chapters 4 
and 5, the critical review of transferability literatures presented in Chapter 6 was conducted 
alongside and after the economic evaluations. The critical review therefore informed some of 
the analyses conducted in the preceding chapters, but could not inform their study designs, 
which instead reflected standard guidance at the time when they were done. The designing for 
transferability guide in Chapter 6 was developed after both the economic evaluations and 
critical review were complete.  
In the designing for transferability guide, I draw on both my experience conducting economic 
evaluations and also a wide-ranging critical review of literature streams, which offer insights 
for improving the transferability of economic evaluations conducted alongside trials or pilots. I 
argue that promoting transferability requires efforts from the earliest phases of intervention 
design and that transferability is a complex question requiring a complexity perspective, even 
for seemingly simple interventions. I identify four stages for a model-based economic 
evaluation alongside a trial or pilot: I) Framing the economic evaluation, II) Model 
identification and/or development, III) Data needs identification, and IV) Analysis and 
reporting. For each stage, I articulate key questions to guide analysts to close the 
transferability gap.  
Future research could pilot the guidance and seek to: understand how it has been used; 
explore perceptions of its usefulness and contributions to the research process and to eventual 
influence of the research on decision-making; and solicit recommendations for its 
improvement. For such purposes, it would be valuable to pilot the guidance with research 
teams working on both trials and pilot studies, for different types of health conditions, and 
different types of delivery platforms, and in contexts where researchers have different pre-
existing relationships with decision-makers. Given that the guidance emerged from the 
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experience of conducting the two economic evaluations presented in this thesis, it would be 
particularly valuable to pilot the tool in interventions for communicable diseases other than 
malaria, as well as non-communicable diseases, especially in a hospital setting and for curative 
interventions. It would also be valuable to pilot the tool in a range of LLMICs, as well as in 
upper-middle and high-income countries to understand the perceived relevance of the 
framework and questions in diverse country contexts. Reporting examples of how the 
guidance has been used, especially where theories of change have been developed with 
specific reference to costs and effects, would likely facilitate wider use of the guidance, along 
with critical reflections on areas for improvement. 
 
7.3. Strengths and limitations 
 
As the individual chapters within this thesis already include discussion of their individual 
strengths and limitations, I reflect here on some of the strengths and limitations of the thesis 
as a whole.  
A key feature of this thesis is that it offers both policy-relevant findings in the field of malaria 
control and methodological findings relevant for the conduct of economic evaluations. This 
dual aim was valuable in bringing methodological considerations and rigour to the empirical 
work and in ensuring that the methodological innovations drew on and could feasibly inform 
practical experience in this applied, policy-focused field. Nonetheless, it could be argued that 
pursuit of this dual aim has been at the expense of greater depth, which could have been 
achieved if only one aspect or the other had been the sole focus.   
This thesis also combines wide-ranging literature reviews and in-depth analyses. Engagement 
with a very wide range of literature provided valuable perspective on the “big picture”. In 
reviewing the applied economic evaluation literature, I examined a comprehensive cross-
section of the literature and conducted a range of quantitative analyses, which provided 
insights into the economic evaluation field as a whole. In examining the literature related to 
transferability, I again took a wide, multi-disciplinary approach, which allowed me to draw 
valuable insights. By contrast, in conducting two economic evaluations, I collected and 
analysed primary data in depth in a single geographical area and in doing so made substantial 
contributions to areas of public health importance. I believe that this combination of breadth 
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and depth has produced valuable insights, but it inevitably also leaves numerous gaps that 
could be explored further in future. 
The research setting in Senegal was both a strength and a limitation of the thesis. The research 
benefitted from strong existing research collaborations between the London School of Hygiene 
& Tropical Medicine, the Department of Parasitology at Université Cheikh Anta Diop, and the 
Institut de Recherche pour le Développement, which greatly facilitated the inclusion of 
economic evaluation components alongside the trials. Conducting the second economic 
evaluation in the same locations and with the same institutional collaborators as the first 
reduced the time required to familiarize myself with the local context and research partners 
and to adapt data collection tools and made understanding and interpretation of the data 
easier. The common setting for both studies also facilitated the direct application and further 
development in the second evaluation of ideas generated in the first evaluation regarding the 
role of health system structure and monthly implementation rounds in driving costs.     
That the research only took place in a single setting was also a limitation. As the need for new 
methods for making economic evaluations more transferable emerged from the economic 
evaluations presented in the thesis, these economic evaluations and the PhD as a whole were 
not originally designed with the aim of improving transferability. Exploration of transferability 
could have benefitted from a multi-country study. The context in which the trials were 
conducted seemed prima facie broadly representative of and potentially relevant to a large 
number of people living with ostensibly similar epidemiological and socio-economic contexts; 
however, the extent to which this assumption holds has not yet been examined, because this 
thesis research was confined to a single setting. Comparing predictions generated by the cost 
model for another context with the actual costs of implementation in that other context would 
be a useful opportunity for model validation and possible refinement. Such an opportunity 
may exist for SMC, which has now been implemented across much of the Sahel. A consultancy 
report on SMC implementation in 7 countries in 2015 has been produced (Gilmartin and 
Collins, 2017); however, meaningful comparison of model projections with these findings 
would require engagement from and with individuals involved in implementation and cost 
estimation in those countries and the usefulness of such an exercise would depend on the 
availability of more detailed data (e.g. on resource use and prices) than currently reported. The 
proposed guidance on designing for transferability has yet to be applied, and feedback from 
practical experience of implementing this guidance – especially alongside pilots or trials of very 
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different types of interventions, for different health areas, and in other contexts – would be 
likely to contribute usefully to its further development. 
The two economic evaluations were not originally undertaken with a focus on transferability; 
rather, the importance of transferability emerged from the experience of conducting these 
evaluations, the bibliometric analysis, and wider experience of leading the supplementary 
issue in Health Economics. In part, the focus on transferability also reflects the explosion of 
literature around transferability in the last few years. The ways in which transferability was 
addressed were therefore constrained by the data that had already been collected.  
This thesis recommends understanding the mechanisms of action through which costs are 
incurred and outcomes produced as a means of improving transferability. While both trials 
contained process evaluations, which helped to generate such understanding, these process 
evaluations were not theory-driven and could have been more extensive, especially for the 
hotspot trial. In one sense, this absence of explicit programme theory (represented in a 
diagram) is understandable, as the central mechanisms of action for the interventions in both 
trials involved medicines and diagnostic tests, and therefore could be viewed as “simple”, just 
as many pharmaceutical interventions are described (Oakley et al., 2006). While the hotspot 
trial involved many components, some might argue that the strategies evaluated were 
“complicated”, rather than “complex” (Rogers, 2008). Yet, each intervention also involved 
hundreds of community health workers travelling door-to-door to administer medicines, 
diagnostic tests, and insecticide to large numbers of people, who were not ill, but who 
nonetheless largely accepted these interventions. The interventions involved a cascade of 
training and planning across levels of the health system and effects were generated both at 
the individual and community levels, through indirect effects. As Petticrew (2011) observed, 
“on close examination most interventions, including medical interventions, reveal themselves 
to be complex.“ Petticrew argued that the choice to view an intervention as complex or simple 
should reflect the research questions, and not just the intervention. Producing an initial theory 
of change, incorporating both costs and effects, and refining this theory of change through a 
process evaluation is recommended for future evaluations; however, the practicalities of how 
to do this usefully are unclear. Anderson and Hardwick’s “explanatory economic evaluation” 
drawing on realist principles (Anderson and Hardwick, 2016) provided one example of how 
resources could be included within a theory of change, but this example was drawn from a 
retrospective literature review, rather than a prospective evaluation.  
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I focused on methods for modelling transfer of costs and did not simultaneously model how 
costs of implementation and effectiveness may covary. Incremental effects of preventive 
malaria interventions are a function of underlying incidence, intervention coverage, 
intervention efficacy, and care pathways and outcomes for malaria cases, all of which may vary 
across contexts and with changes to the intervention. Understanding how costs and coverage 
may covary across contexts is particularly challenging; a conservative approach is to model 
coverage achieved through comparable delivery platforms in a given context and to model the 
costs of achieving that level of coverage through a simple model, like the one developed in this 
thesis. Achieving a higher level of coverage would require additional activities, which are 
themselves interventions, whose effectiveness and costs would need to be measured. For SMC 
and especially the hotspot strategies, the indirect effects of the interventions are a complex 
function of intervention coverage and underlying incidence. Further work to model the 
transfer of both costs and effectiveness across contexts would be valuable and would require 
collaboration between health economists and infectious disease modellers to ensure that both 




This thesis provides evidence generated alongside two trials in central Senegal on the 
efficiency of SMC and packages of intensive malaria interventions geographically targeted at a 
local level. The analysis of SMC showed that it was potentially affordable, even in highly 
constrained contexts, but that the cost per child receiving the intervention varied substantially 
across health post catchment areas, and, to a lesser extent, across the three monthly rounds of 
administration. SMC has now been administered to tens of millions of children across the 
Sahel. The second analysis revealed that relative to existing malaria budgets, targeted MSAT 
and targeted MDA each incurred substantial costs, which were considerably increased when 
combined with targeted IRS. As implemented in a low transmission context in central Senegal, 
these geographically targeted strategies were found not to be cost-effective in reducing the 
short-term disease burden.   
This thesis also provides systematic evidence of the scarcity of economic evaluation research, 
especially in LMICs, and therefore the imperative to make each economic evaluation as useful 
as possible across a wide range of contexts. To improve the transfer of economic evaluation 
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evidence from trials and pilots across contexts, transferability should become the guiding 
principle throughout all stages of an economic evaluation. In particular, evaluators must clearly 
conceptualize and articulate what an intervention is, and use understanding of the 
mechanisms of action through which an intervention incurs costs and produces effects to gain 
insights into the transferability of findings. From the outset of the evaluation, evaluators 
should seek to identify and (where possible) narrow the “transferability gap” between planned 
implementation within the trial or pilot and the intended decision contexts. Data collected 
within the trial or pilot can and should be used to develop and populate simple, mechanistic 
provider cost models to estimate how costs might be expected to vary with particular changes 
to context or the intervention, thereby increasing the transferability of the findings. Future 
research should explore, refine, and extend these approaches to promoting transferability so 
that opportunities for data collection alongside trials or pilots can be fully exploited and used 
to inform priority setting decisions across a broader set of contexts. 
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